



US 20250257101A1

(19) United States

(12) Patent Application Publication

Weiner et al.

(10) Pub. No.: US 2025/0257101 A1

(43) Pub. Date: Aug. 14, 2025

(54) FILOVIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME

(71) Applicants: The Trustees of the University of Pennsylvania, Philadelphia, PA (US); THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US); Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)

(72) Inventors: David B. Weiner, Merion, PA (US); Ami Patel, Philadelphia, PA (US); Jian Yan, Wallingford, PA (US)

(21) Appl. No.: 19/068,349

(22) Filed: Mar. 3, 2025

#### Related U.S. Application Data

- (63) Continuation of application No. 17/404,143, filed on Aug. 17, 2021, now Pat. No. 12,240,872, which is a continuation of application No. 16/098,912, filed on Nov. 5, 2018, filed as application No. PCT/US2017/031215 on May 5, 2017, now Pat. No. 11,091,518.  
(60) Provisional application No. 62/332,372, filed on May 5, 2016, provisional application No. 62/402,519, filed on Sep. 30, 2016, provisional application No. 62/483,979, filed on Apr. 11, 2017.

#### Publication Classification

- (51) Int. Cl.  
*C07K 14/005* (2006.01)  
*A61K 9/00* (2006.01)  
*A61K 38/00* (2006.01)  
*A61K 39/00* (2006.01)  
*A61K 39/12* (2006.01)  
*A61K 39/39* (2006.01)  
*A61P 31/12* (2006.01)  
*C07K 14/54* (2006.01)
- (52) U.S. Cl.  
CPC ..... *C07K 14/005* (2013.01); *A61K 9/0009* (2013.01); *A61K 39/12* (2013.01); *A61K 39/39* (2013.01); *A61P 31/12* (2018.01); *C07K 14/54* (2013.01); *C07K 14/5443* (2013.01); *C07K 14/5443* (2013.01); *A61K 38/00* (2013.01); *A61K 2039/53* (2013.01); *A61K 2039/54* (2013.01); *A61K 2039/545* (2013.01); *A61K 2039/55527* (2013.01); *A61K 2039/55538* (2013.01); *A61K 2039/58* (2013.01); *A61K 2039/70* (2013.01); *C07K 2319/02* (2013.01); *C12N 2760/14122* (2013.01); *C12N 2760/14134* (2013.01)


(57)

#### ABSTRACT


Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Ebolavirus glycoprotein immunogens are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against Ebolavirus are disclosed. Method of preventing Ebolavirus and methods of treating individuals infected with Ebolavirus are disclosed. Consensus Ebolavirus proteins are disclosed.

Specification includes a Sequence Listing.


1A.




**1A.**



**1B.**



**1C.**



Figures 1A-1C






Figure 2A-2H

**3A.**



**3B.**



**3C.**







Figure 3A-3C



**4B.**



**4C.**



**4D.**




Figure 4A-4D




Figure 5A-5D




Figure 6





Figure 7A-7B





Figure 8A-8B

## Experimental vaccines against Ebola



The Ebola viral glycoprotein (GP) is the major antigenic target for vaccines: Antibody & T cell target

### Vaccines currently in clinical trials

- rSVAG/ZEBOV/GP
- ChAd3 prime + MVA boost
- MVA pan-filovirus

Advantages: immunogenic, protective in NHPs,  
single dose protection


### Drawbacks:

- development of anti-vector immunity
- duration of memory response uncertain
- adverse reactions in human clinical trials
- may not be suitable for all populations


An additional platform with a cleaner safety profile that can induce strong immune responses against heterologous Zaire Ebola viruses would be very beneficial

Figure 9

## Developing an EBOV GP DNA vaccine formulation




## A single immunization of DNA vaccine is immunogenic in mice




Polyfunctional CD4+ and CD8+ T cells secreting IFNy, IL2, and TNFa were similar for all vaccines and formulations.

Figure 11

**A single immunization is fully protective in mice against lethal mouse-adapted Ebola virus challenge**



## Individual GP DNA vaccine constructs induce robust memory responses in mice




Robust immune responses are detectable months after last injection

Figure 13

## Efficacy of GP DNA vaccines in non-human primates

Administered I.M. followed by EP

Efficient Formulation	Efficient formulation
1. ConEBOvGP#1	1. ConEBOvGP#1
2. Outbreak-matched GP	2. Outbreak-matched GP
+ Adjuvant: Opt. Rhesus pIL12	3. ConEBOvGP#2 + Adjuvant: Opt. Rhesus pIL12



Cynomolgus macaques are a model for Ebola vaccine efficacy and lethal challenge

Evaluated different injection regimens in order to understand immunogenicity





Figure 14

## GP DNA vaccine formulations are immunogenic in NHPs




DNA formulations vaccines induce robust anti-Ebola GP antibody responses (GMT >10<sup>3</sup>) & anti-GP T-cell responses.

Immune responses are boosted following each injection.

Figure 15

## GP DNA formulation vaccines protect against lethal Zaire Ebola virus (Makona) challenge

Challenge dose = 1000 TCID<sub>50</sub> Guinea-Makona 2014 C07 virus  
(7-U reference strain), 28 days post-final DNA immunization



Animals were monitored for 28 days post-challenge.

Surviving animals did not have any significant signs of disease.  
They also maintained normal CBC and enzyme levels

Figure 16

## EBOV-001 phase I clinical (NCT02464670)

### Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Primary outcome: safety assessment

Secondary outcome: immunological assessment

Other: intradermal (ID) delivery vs intramuscular (IM) delivery

Group	Sequence	Allocation	Intervention	Target Sample Size (n)
1	ConEBOVGP#1	0-4-12 weeks	IM	2
2	Guinea-GP	0-4-12 weeks	IM	2
3	ConEBOVGP#1	0-4-12 weeks	ID	2
4	ConEBOVGP#1 + Guinea-GP	0-4-12 weeks	IM	4
5	ConEBOVGP#1 + Guinea-GP + plasmid IL12	0-4-12 weeks	IM	4+1

Figure 17

## EBOV-001 seroconversion





Figure 18

## EBOV 001: Induction of Ebola GP Specific T-Cell Responses (ELISpot): Representative Patients



- ELISpot analysis: baseline, week 2, week 6, week 14.
- 4 peptide pools used for stimulation were GP pool 1, GP pool 2, GP pool 3, GP pool 4.

Figure 19

# Comparison with other Ebola vaccine platforms currently in clinical trials

	ChAd3/MVA-GP	rVSV/ZEBOVGP	GP DNA Vaccine
Transgene	NIAID VRRC/GSK 1976 GP	PHAC/Newlink/Merck 1995 GP	Inovio Consensus GP 2014 GP
Route of administration	I.M.	I.M.	I.M. or I.D.
Regimen	ChAd3 prime (60-80% sero), MVA boost	Single injection	2 injection (100% sero, ID) 3 injection (100% sero, IM)
Side Effects	Fever, Fatigue, Arthralgia Lymphopenia	Fever, Fatigue, Arthralgia	None
Injection Site Pain	Yes	Yes	Yes
Antibody titers	>10 <sup>3</sup>	>10 <sup>3</sup>	10 <sup>3</sup> -10 <sup>6</sup>
T cell responses	Yes	N/A	Yes
Cold-chain	-20C	-20C	4C
Other notes	Need MVA boost to generate long-term memory	Ring-vaccine trial, long- term memory not confirmed	Can be re-administered Memory study ongoing

\*\*Rampling et al 2015, Legerwood et al 2014, Agnandji et al 2015, Henao-Restrepo et al 2015, Tapia et al 2015

Some of the side effects of rVSV/ZEBOVGP and ChAd3/MVAGP overlap with symptoms of Ebola

Figure 20

- 69 subjects from all cohorts (1-5) are included in analysis.
- ELISA analysis from baseline, week 2, week 6, week 14.
  - Protein used was Ebola Zaire

#### Cohort descriptions

Cohort	Vaccine	Plasmids included in vaccine	Schedule	Route	Dose (mg)
1	INO-4201	pGX4201	0-4-12 weeks	IM	2
2	INO-4202	pGX4202	0-4-12 weeks	IM	2
3	INO-4201	pGX4201	0-4-12 weeks	ID	2
4	INO-4212	pGX4201 and pGX4202	0-4-12 weeks	IM	4
5	INO-4212 +INO-9012	pGX4201, pGX4202, and pGX6001	0-4-12 weeks	IM	4+1

Ethnicity	Race					West African Origin
	Hispanic	Not Hispanic	Black	White	Asian	
Number subjects	74	8	66	34	37	2
Male	25	4	21	9	15	0
Female	49	4	45	25	22	1
						Subject 4201-007, Cohort 1
						Sierra Leone

Figure 21

## ELISA Titers by Cohort and Timepoint





Figure 22

## ELISA Titers by Cohort and Timepoint



Cohort	Reciprocal EBOV Geometric Mean Titers				
	1	2	3	4	5
Week 2 GMT (range)	1 (1-1)	3.50 (1-36,450)	3.91 (1-12,150)	1 (1-1)	1 (1-1)
Week 6 GMT (range)	163.88 (1-36,450)	882.49 (1-109,350)	39,664.20 (4050-109,350)	77.06 (1-109,350)	12,689.48 (1-109,350)
Week 14 GMT (range)	2,049.04 (1-108,350)	13,500.60 (1-108,350)	46,968.00 (4050-108,350)	15,914.10 (1-108,350)	46,968.00 (1-108,350)

Figure 23

## ELISA Summary

- Summary:
  - Little to no reactivity after the first dose
  - Dose 2 begins to drive seroconversion, with Cohorts 3 and 5 seeing the largest frequency
  - Dose three drives >90% seroconversion in 4/5 cohorts. Cohorts 3 and 5 show 100% seroconversion at this timepoint




Figure 24

## EBOV001 ELISpot

- 75 subjects from all cohorts (1-5) are included in analysis.
- ELISpot analysis from baseline, week 2, week 6, week 14.

- 4 peptide pools (Zaire) used for stimulation:
  - Pool 1 (pp1-28)
  - Pool 2 (pp29-56)
  - Pool 3 (pp57-84)
  - Pool 4 (pp85-112)

Cohort	Vaccine	Plasmids included in vaccine	Schedule	Route	Dose (mg)
1	INO-4201	pGX4201	0-4-12 weeks	IM	2
2	INO-4202	pGX4202	0-4-12 weeks	IM	2
3	INO-4201	pGX4201	0-4-12 weeks	ID	2
4	INO-4212	pGX4201 and pGX4202	0-4-12 weeks	IM	4
5	INO-4212 +INO-9012	pGX4201, pGX4202, and pGX6001	0-4-12 weeks	IM	4+1

Figure 25

### Cohort 1 : Subject responses by peptide pool (all subjects, n = 15)




Figure 26

**Cohort 2 : Subject responses by peptide pool (all subjects, n = 15)**




Figure 27

### Cohort 3 : Subject responses by peptide pool (all subjects, n = 15)




Figure 28

**Cohort 4 : Subject responses by peptide pool (all subjects, n = 14)**




Figure 29

**Cohort 5 : Subject responses by peptide pool (all subjects, n = 15)**




Figure 30

## ELISpot Summary by Cohort




Figure 31

## ELISpot Summary by Cohort




Figure 32

## Responder Analysis

### Vaccine Responders – All Subjects

All Subjects			% Responders				
Responder	Total	% Responders	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5
EBOV	4	75	5.3%	0/15	1/15	1/15	0/15
GP Pool 1	31	75	41.3%	6/15	8/15	4/15	6/15
GP Pool 2	22	75	29.3%	5/15	4/15	3/15	5/15
GP Pool 3	5	75	6.7%	0/15	1/15	2/15	0/15
GP Pool 4	3	75	4.0%	0/15	0/15	2/15	0/15

All Subjects			% Response by Cohort				
			Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5
EBOV			0/15	1/15	1/15	0/15	0/15
Any Pool			7/15	8/15	6/15	8/15	7/15

All Subjects			% Response by Cohort				
			Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5
EBOV			0.0%	6.7%	13.3%	6.7%	0.0%
GP pool 1			40.0%	53.3%	26.7%	46.7%	40.0%
GP pool 2			33.3%	26.7%	20.0%	33.3%	33.3%
GP pool 3			0.0%	6.7%	13.3%	13.3%	0.0%
GP pool 4			0.0%	0.0%	13.3%	6.7%	0.0%

Figure 33

## Responder Analysis

### Vaccine Responders – Baseline Outliers (n=8) Removed

All Subjects		% Response by Cohort					
Responder	Total	% Responders	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5
EBOV	19	67	28.4%	2/12	5/13	3/14	4/15
GP Pool 1	44	67	65.7%	7/12	11/13	8/14	8/15
GP Pool 2	33	67	49.3%	6/12	9/13	7/14	5/15
GP Pool 3	6	67	9.0%	0/12	4/13	1/14	0/15
GP Pool 4	4	67	6.0%	0/12	2/13	1/14	0/15

All Subjects		% Response by Cohort					
Responder	Total	% Responders	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5
EBOV	19	67	28.4%	2/12	5/13	3/14	4/15
Any Pool	46	67	68.7%	8/12	11/13	9/14	10/15

All Subjects		% Response by Cohort					
Responder	Total	% Responders	Cohort 1	Cohort 2	Cohort 3	Cohort 4	Cohort 5
EBOV	19	67	28.4%	16.7%	38.5%	21.4%	26.7%
GP pool 1	46	67	58.3%	84.6%	57.1%	76.9%	53.3%
GP pool 2	50	67	50.0%	69.2%	50.0%	38.5%	40.0%
GP pool 3	0	67	0.0%	30.8%	7.1%	0.0%	6.7%
GP pool 4	0	67	0.0%	15.4%	7.1%	0.0%	6.7%

Figure 34

**EBOV001 ICS**

- 47 subjects from all cohorts (1-5) are included in analysis. Cohort 5 is currently underrepresented.
- ICS analysis performed at baseline and week 14
- A single EBOV peptide pool composed of Pools 1-4 is used for stimulation

**Cohort descriptions**

Cohort	Vaccine	Plasmids included in vaccine	Schedule	Route	Dose (mg)
1	INO-4201	pGX4201	0-4-12 weeks	IM	2
2	INO-4202	pGX4202	0-4-12 weeks	IM	2
3	INO-4201	pGX4201	0-4-12 weeks	ID	2
4	INO-4212	pGX4201 and pGX4202	0-4-12 weeks	IM	4
5	INO-4212 + INO-3012	pGX4201, pGX4202, and pGX6301	0-4-12 weeks	IM	4+1

Figure 35

# EBOV001 ICS

## Wilcoxon Paired analysis based on cohort

	Cohort 1 (24-tailed)	Cohort 2 (2-tailed)	Cohort 3 (2-tailed)	Cohort 4 (2-tailed)	Cohort 5 (2-tailed)
CD4 IFNg and TNFa	.770	.252	.695	.438	
CD4 IFNg	.688	.105	.713	.663	
CD4 IFNg and/or TNFa	.945	.121	.0029	.547	
CD4 TNFa	.945	.301	.0078	.408	
CD8 IFNg and TNFa	.770	.922	.027	.164	
CD8 IFNg	.844	.133	.221	.125	
CD8 IFNg and/or TNFa	.945	.695	.0010	.844	
CD8 TNFa	.910	.734	.0010	.742	

Evaluated subjects

Cohort	n=
1	12
2	12
3	11
4	9

Yellow = significant

Red = unevaluable due to N

Figure 36

## EBOV001 ICS – Cohort 3 (INO4201 ID) Cytokines in CD4+ T cells




Figure 37

## EBOV001 ICS – Cohort 3 Cytokines in CD8+ T cells




Figure 38

Vaccine Responders: All (n=75) subjects by cohort

- Vaccine responder is defined as meeting the threshold and having more SFUs post day 0

Figure 39

## Vaccine Responders: All (n=75) subjects by cohort

- Vaccine responders is defined as meeting the threshold and having more SFUs post day 0
- Threshold = Mean + 2 x STDEV of total population's response on Day 0 for each pool

	4201-009	4201-011	4201-014	4201-017	4202-011	4202-027	4202-028	4202-030	4202-031	4203-014	4203-017	4203-040	4203-042	4203-043
Cohort	4	4	4	4	4	4	4	4	4	4	4	4	4	4
GP1	Non													
GP2	Non													
GP3	Non													
GP4	Non													
Any pool	Non													

	4201-018	4201-019	4201-020	4201-021	4201-022	4201-023	4202-024	4202-025	4203-034	4203-044	4203-045	4203-046	4203-047	4203-049	4203-050
Cohort	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GP1	Non														
GP2	Non														
GP3	Non														
GP4	Non														
Any pool	Non														

Figure 40

## Median responses by cohort and pool (n=75)

Cohort	Median EBOV response					All Subjects
	1	2	3	4	5	
EBOV-Baseline	26.7	25.0	20.6	27.9	13.3	21.7
EBOV-Wk2	33.3	8.3	20.0	21.7	15.0	19.2
EBOV-Wk6	60.0	83.3	133.3	102.5	80.8	83.3
EBOV-Wk14	58.3	75.4	77.5	105.8	58.3	77.5
GP pool 1 -Baseline	6.7	3.3	5.0	6.3	1.7	4.2
GP pool 1 -Wk2	6.7	3.3	5.0	3.3	1.7	5.0
GP pool 1 -Wk6	17.5	30.0	23.3	25.8	13.3	23.3
GP pool 1 -Wk14	28.3	18.3	23.3	29.2	23.3	25.0
GP pool 2-Baseline	6.7	3.3	3.3	10.6	3.3	6.3
GP pool 2-Wk2	0.8	3.3	3.3	9.2	3.3	5.0
GP pool 2-Wk6	11.7	30.0	28.3	21.7	15.8	18.3
GP pool 2-Wk14	13.3	18.3	18.7	23.3	16.7	18.2
GP pool 3-Baseline	0.0	5.0	0.0	3.3	3.3	3.3
GP pool 3-Wk2	3.3	0.0	3.3	3.3	1.7	2.5
GP pool 3-Wk6	5.0	16.7	10.0	8.3	1.7	8.3
GP pool 3-Wk14	3.3	5.0	10.0	12.5	1.7	5.8
GP pool 4-Baseline	1.7	6.7	5.0	5.8	1.7	3.3
GP pool 4-Wk2	5.0	3.3	8.3	5.0	5.0	5.0
GP pool 4-Wk6	8.3	29.2	36.7	30.0	19.2	21.7
GP pool 4-Wk14	21.7	14.2	31.7	26.7	13.3	21.7

EBOV response = summed response of pools 1-4

Figure 41

## Mean responses by cohort and pool (n=75)

Cohort	Mean ELISpot Response					All Subjects
	1	2	3	4	5	
EBOV-Baseline	124.6	116.3	85.8	148.9	44.6	103.4
EBOV-Wk2	112.5	66.8	168.7	154.1	41.7	107.2
EBOV-Wk6	147.1	206.0	295.3	291.3	88.3	203.5
EBOV-Wk14	128.3	121.8	160.6	280.1	128.1	163.9
GP pool 1 -Baseline	17.9	8.9	5.8	7.2	2.7	8.5
GP pool 1 -Wk2	21.9	6.0	6.4	11.4	3.1	10.3
GP pool 1 -Wk6	29.4	62.4	22.1	47.1	24.0	37.5
GP pool 1 -Wk14	38.7	33.8	25.3	69.6	31.7	40.3
GP pool 2-Baseline	6.8	17.4	9.2	18.6	5.8	11.8
GP pool 2-Wk2	4.2	20.7	9.8	23.7	6.6	12.6
GP pool 2-Wk6	28.4	52.7	27.8	46.2	28.2	34.9
GP pool 2-Wk14	24.0	31.0	21.9	58.7	53.4	37.8
GP pool 3-Baseline	27.8	8.2	26.6	44.6	12.0	23.6
GP pool 3-Wk2	21.1	15.0	46.6	43.6	13.4	28.1
GP pool 3-Wk6	25.0	35.5	80.5	86.0	5.2	41.6
GP pool 3-Wk14	13.1	27.2	36.1	60.6	6.7	30.0
GP pool 4-Baseline	69.9	81.8	44.1	78.4	24.1	59.4
GP pool 4-Wk2	65.3	25.2	93.8	75.4	18.6	56.3
GP pool 4-Wk6	66.2	56.4	164.9	137.9	32.9	89.6
GP pool 4-Wk14	46.6	29.8	77.2	91.2	38.3	55.6

EBOV response = summed response of pools 1-4

Figure 42





Figure 43



Figures 44A – 44C




Figure 45





Figure 46

## Long-term immunogenicity with Ebola GP DNA Vaccine formulations in NHPs




Strong antibody responses >6months post-vaccination

Figure 47


## EBOV GP DNA Vaccine Memory Study: IM Delivery

Group	Vaccine	Constructs	Schedule	n	Dose
1	Trivalent	pGX4201 + pGX4202 + pGX4203 + opt IL-12 (pGX6006)	0-4-8 (3 injections)	5	3 mg + 3 mg + 3 mg + 0.2 mg
2	Trivalent	pGX4201 (old con) + pGX4202 (Guinea-GP) + pGX4203 (new con) + opt IL-12 (pGX6006)	0-4 (2 injections)	5	3 mg + 3 mg + 3 mg + 0.2 mg
3	Bivalent	pGX4201 + pGX4202 + opt IL-12 (pGX6006)	0-4 (2 injections)	5	4.5 mg + 4.5 mg + 0.2 mg
4	Trivalent	pGX4201 + pGX4202 + pGX4203 + opt IL-12 (pGX6006)	0 (1 injection)	5	3 mg + 3 mg + 3 mg + 0.2 mg




- \* immunized animals Jan-March 2016
- \* followed immune responses over 12 months following final dose
- \* gave a 1-year boost February 2017

Figure 48




Increase in total IgG antibody responses following the 1 year boost

Figure 49




Increase in total IgG antibody responses following the 1 year boost

Figure 50



**Increase IFN $\gamma$  ELISPOT responses following the 1 year boost.  
Magnitude of boost is not as high in the 3 injection group.**

Figure 51



**Increase IFN $\gamma$  ELISPOT responses following the 1 year boost.  
Remarkably strong boost in single immunization group.**

Figure 52




Figure 53

## Example: Single immunization IFN $\gamma$ ELISPOT – 12 month time point (before final boost)




Figure 54

## Example: Single immunization IFN $\gamma$ ELISPOT After the 1 year boost




Figure 55

## Summary – Long Term Memory

- EBOV-GP DNA vaccine elicits long-term immune responses
- Strong recall response following a 1 year boost
  - This response is remarkably high in the group that received a single IM injection
- Next steps: memory study with intradermal delivery
  - Working on securing a challenge slot for this study

Figure 56

## EBOV-001: INO-4212 DNA Vaccine Clinical Trial

- \* Initial study enrolled 75 healthy volunteers across 5 cohorts
- \* 3 dose regimen (weeks 0, 4, 12)
- \* 2-8°C stable vaccine formulation: Does not require frozen cold-chain
- \* 1 year stability at room temperature (25°C)

### Cohort descriptions

Cohort	Vaccine	Vaccination Schedule (Weeks)	# Volunteers (Actual)	Vaccine Route	Dose	
1	INO-4201	Pre-2014 consensus	0-4-12	16 (14)	IM	2 mg
2	INO-4202	2014 Guinea	0-4-12	16 (16)	IM	2 mg
3	INO-4201	Pre-2014 consensus	0-4-12	16 (13)	ID	2 mg
4	INO-4212	(4201 + 4202)	0-4-12	16 (14)	IM	4 mg
5	INO-4212 + INO-9012	4212 + human IL-12	0-4-12	16 (14)	IM	4 mg + 1 mg

Figure 57

## Comparison of Binding Antibodies in EBOV-001 to RVSV-EBOV

All 5 EBOV-001 cohorts had significant increases at both Weeks 6 and 14 compared to Week 0




Figure 58

## EBOV-001: ID Delivery Expansion Cohorts

Based on the seroconversion observed cohort 3 (ID delivery) 6 additional ID cohorts were added to explore different doses, dose regimens and impact of IL-12 DNA as an immuno-adjuvant

Cohort	Vaccine	Dose Schedule (Weeks)	# Volunteers	Vec. Route	Dose (mg)
1	INO-4201	04-12	15	ID	2
2	INO-4202	04-12	15	ID	2
3	INO-4201	04-12	20*	ID	2
4	INO-4212	04-12	15	ID	4
5	INO-4212 + INO-9012	04-12	15	ID	4 + 1
6	INO-4201	04-12	20	ID	1
7	INO-4201	04	20	ID	2
8	INO-4201	04	20	ID	1
9	INO-4201 + INO-9012	04-12	20	ID	1.6 + 0.4
10	INO-4201 + INO-9012	0-4	20	ID	1.6 + 0.4
11	INO-4201 + INO-9012	04-12	20	ID	0.8 + 0.2
		TOTAL	200		

\* Part 2 enrolled an additional 5 subjects will be enrolled in cohort 5

Figure 59

## ID Cohorts to Week 14

ADI ELISA - No baseline subtraction





Figure 60

**FILOVIRUS CONSENSUS ANTIGENS,  
NUCLEIC ACID CONSTRUCTS AND  
VACCINES MADE THEREFROM, AND  
METHODS OF USING SAME****CROSS REFERENCE TO RELATED  
APPLICATION**

[0001] This application is a continuation of U.S. patent application Ser. No. 17/404,143, filed Aug. 17, 2021, which is a continuation of U.S. patent application Ser. No. 16/098,912, filed Nov. 5, 2018, which is a U.S. national stage application filed under 35 U.S.C. § 371 claiming benefit to International Patent Application No. PCT/US17/31215, filed May 5, 2017, which claims priority to U.S. Provisional Application No. 62/332,372, filed May 5, 2016, U.S. Provisional Application No. 62/402,519, filed Sep. 30, 2016, and U.S. Provisional Application No. 62/483,979, filed Apr. 11, 2017, each of which is incorporated by reference herein in its entirety.

[0002] REFERENCE TO A "SEQUENCE LISTING" SUBMITTED AS AN XML FILE The Sequence Listing written in the XML file: "206108-0059-02US\_Replacement\_Sequence listing.xml"; created on Apr. 25, 2025, and 119,714 bytes in size, is hereby incorporated by reference.

**FIELD OF THE INVENTION**

[0003] The present invention relates to vaccines for inducing immune responses and preventing filovirus infection and/or treating individuals infected with filovirus, particularly infection by Ebolavirus. The present invention relates to consensus Ebolavirus proteins and nucleic acid molecules which encode the same.

**BACKGROUND OF THE INVENTION**

[0004] The Filoviridae are non-segmented, single stranded RNA viruses which contain two divergent genera, Marburgvirus (MARV) and Ebolavirus (EBOV). Members from each can cause severe and highly lethal hemorrhagic fever disease to which there is no cure or licensed vaccine (Bradfute S. B., et al. (2011) Filovirus vaccines. *Hum Vaccin* 7: 701-711; Falzarano D., et al. (2011) Progress in filovirus vaccine development: evaluating the potential for clinical use. *Expert Rev Vaccines* 10: 63-77; Fields B. N., et al. (2007) Fields' virology. Philadelphia: Lippincott Williams & Wilkins. 2 v. (xix, 3091, 1-3086 p.); Richardson J. S., et al. (2009) Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. *PLoS One* 4: e5308; and Towner J. S., et al. (2006) Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. *J Virol* 80: 6497-6516).

[0005] Due to lethality rates of up to 90% they have been described as "one of the most virulent viral diseases known to man" by the World Health Organization. The US Centers for Disease Control and Prevention has classified them as 'Category A Bioterrorism Agents' due in part to their potential threat to national security if weaponized (Burki T. K. (2011) USA focuses on Ebola vaccine but research gaps remain. *Lancet* 378: 389). These 'high priority' agents could in theory be easily transmitted, result in high mortality rates, cause major public health impact and panic, and require special action for public health preparedness (CDC (2011) Bioterrorism Agents/Diseases. Atlanta: Centers for Disease Control and Prevention).

[0006] The haemorrhagic fever diseases are acute infectious with no carrier state, although they are easily transmissible among humans and nonhuman primates by direct contact with contaminated bodily fluids, blood, and tissue (Feldmann H., et al. (2003) Ebola virus: from discovery to vaccine. *Nat Rev Immunol* 3: 677-685). During outbreak situations, reuse of medical equipment, health care facilities with limited resources, and untimely application of prevention measures escalate transmission of the disease, allowing amplification of infections in medical settings.

[0007] Since the natural reservoirs of these zoonotic pathogens are likely to be African bats and pigs (Kobinger G. P., et al. (2011) Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. *J Infect Dis* 204: 200-208), the latter possibly being more of an amplifying host, the manner in which the virus first appears at the start of an outbreak is thought to occur through human contact with an infected animal. Unpredictable endemic surfacing in the Philippines, potentially Europe, and primarily Africa of this disease further constitutes a major public health concern (Outbreak news. (2009) Ebola Reston in pigs and humans, Philippines. *Wkly Epidemiol Rec* 84: 49-50).

[0008] Experiments have been performed to determine the capacity of the vaccine for inducing protective efficacy and broad CTL including experiments in rodent preclinical studies. (Fenimore P W, et al. (2012). Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage. *PLoS ONE* 7: e44769; Hensley L E, et al. (2010). Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. *PLoS Pathog* 6: e1000904; Zahn R, et al (2012). Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. *PLoS ONE* 7: e44115; Geisbert T W, Feldmann H (2011). Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. *J Infect Dis* 204 Suppl 3: S1075-1081; and Grant-Klein R J, Van Deusen N M, Badger C V, Hannaman D, Dupuy L C, Schmaljohn C S (2012). A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. *Hum Vaccin Immunother* 8; Grant-Klein R J, Altamura L A, Schmaljohn C S (2011). Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses. *Virus Res* 162: 148-161).

[0009] Vaccine-induced adaptive immune responses have been described in numerous preclinical animal models (Blaney J E, et al. (2011). Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. *J Virol* 85: 10605-10616; Dowling W, et al. (2007). Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. *J Virol* 81: 1821-1837; Jones S M, et al. (2005). Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. *Nat Med* 11: 786-790; Kalina W V, Warfield K L, Olinger G G, Bavari S (2009). Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. *Virol J* 6: 132; Kobinger G P, et al. (2006). Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. *Virology* 346: 394-401; Olinger G G, et al. (2005). Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. *J Virol* 79: 14189-14196; Rao M, Bray M, Alving C R, Jahrling P, Matyas G

R (2002). Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. *J Virol* 76: 9176-9185; Rao M, Matyas G R, Grieder F, Anderson K, Jahrling P B, Alving C R (1999). Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. *Vaccine* 17: 2991-2998; Richardson J S, et al. (2009). Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. *PLoS One* 4: e5308; Vanderzanden L, et al (1998). DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. *Virology* 246: 134-144; Warfield K L, et al. (2005). Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. *J Immunol* 175: 1184-1191; Jones S M, et al. (2007). Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. *J Infect Dis* 196 Suppl2: S404-412 Grant-Klein R J, Van Deusen N M, Badger C V, Hannaman D, Dupuy L C, Schmaljohn C S (2012). A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. *Hum Vaccin Immunother* 8; Geisbert T W, et al. (2010). Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. *J Virol* 84: 10386-10394.) Viral vaccines have shown promise and include mainly the recombinant adenoviruses and vesicular stomatitis viruses. Non-infectious strategies such as recombinant DNA and Ag-coupled virus-like particle (VLP) vaccines have also demonstrated levels of preclinical efficacy and are generally considered to be safer than virus-based platforms. Virus-specific Abs, when applied passively, can be protective when applied either before or immediately after infection (Gupta M, Mahanty S, Bray M, Ahmed R, Rollin P E (2001). Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. *J Virol* 75: 4649-4654; Marzi A, et al. (2012). Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. *PLoS ONE* 7: e36192; Parren P W, Geisbert T W, Maruyama T, Jahrling P B, Burton D R (2002). Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. *J Virol* 76: 6408-6412; Qiu X, et al. (2012). Ebola G P-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection. *PLoS Negl Trop Dis* 6: e1575; Wilson J A, et al. (2000). Epitopes involved in antibody-mediated protection from Ebola virus. *Science* 287: 1664-1666; Sullivan N J, et al. (2011). CD8(+) cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. *Nat Med* 17: 1128-1131; Bradfute S B, Warfield K L, Bavari S (2008). Functional CD8+ T cell responses in lethal Ebola virus infection. *J Immunol* 180: 4058-4066; Warfield K L, Olinger G G (2011). Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. *J Biomed Biotechnol* 2011: 984241). T cells have also been shown to provide protection based on studies performed in knockout mice, depletion studies in NHPs, and murine adoptive transfer studies where efficacy was greatly associated with the lytic function of adoptively-transferred CD8+ T cells.

However, little detailed analysis of this response as driven by a protective vaccine has been reported.

[0010] Countermeasure development will ultimately require an improved understanding of protective immune correlates and how they are modulated during infection. This proves difficult when infected individuals who succumb to filoviral disease fail to mount an early immune response. These fast-moving hemorrhagic fever diseases result in immune dysregulation, as demonstrated by the lack of a virus-specific Ab response and a great reduction in gross T cell numbers, leading to uncontrolled viral replication and multi-organ infection and failure. Conversely, survivors of Ebola virus (EBOV) disease exhibit an early and transient IgM response, which is quickly followed by increasing levels of virus-specific IgG and CTL. These observations suggest that humoral and cell-mediated immune responses play a role in conferring protection against disease. These data are also supported by numerous preclinical efficacy studies demonstrating the contribution of vaccine-induced adaptive immunity to protection against lethal challenge. However, mounting evidence has demonstrated a critical role for T cells in providing protection where efficacy was greatly associated with the functional phenotype of CD8+ T cells. While these recent studies highlight the importance of T cells in providing protection, their precise contributions remain uncharacterized and controversial. Furthermore, little detailed analysis of this response driven by a protective vaccine has been reported.

## SUMMARY OF THE INVENTION

[0011] Isolated nucleic acid molecules comprising one or more nucleic acid sequences encoding a first consensus Zaire ebolavirus envelope glycoprotein immunogen (ZEBOVCON), a nucleic acid encoding a second consensus Zaire ebolavirus envelope glycoprotein immunogen (ZEBOVCON2), or a nucleic acid encoding a ZEBOV Guinea 2014 Outbreak envelope glycoprotein immunogen (ZEBOVGUI) are provided.

[0012] In one embodiment, the ZEBOVCON comprises an amino acid sequence that is at least 95% homologous to SEQ ID NO:1, a fragment of an amino acid sequence that is at least 95% homologous to SEQ ID NO:1, an amino acid sequence that is at least 99% homologous to SEQ ID NO:1, a fragment of an amino acid sequence that is at least 99% homologous to SEQ ID NO:1, an amino acid sequence of SEQ ID NO:1, or a fragment of SEQ ID NO:1.

[0013] In one embodiment, the ZEBOVCON2 comprises an amino acid sequence that is at least 95% homologous to SEQ ID NO:68, a fragment of an amino acid sequence that is at least 95% homologous to SEQ ID NO:68, an amino acid sequence that is at least 99% homologous to SEQ ID NO:68, a fragment of an amino acid sequence that is at least 99% homologous to SEQ ID NO:68, an amino acid sequence of SEQ ID NO:68, or a fragment of SEQ ID NO:68.

[0014] In one embodiment, the ZEBOVGUI comprises an amino acid sequence that is at least 95% homologous to SEQ ID NO:67, a fragment of an amino acid sequence that is at least 95% homologous to SEQ ID NO:67, an amino acid sequence that is at least 99% homologous to SEQ ID NO:67, a fragment of an amino acid sequence that is at least 99% homologous to SEQ ID NO:67, an amino acid sequence of SEQ ID NO:67, or a fragment of SEQ ID NO:67.

[0015] In some embodiments, the fragments comprise at least 600 amino acids, at least 630 amino acids, or at least 660 amino acids.

[0016] In one embodiment, ZEBOVCON is linked to an IgE signal peptide. In one embodiment, ZEBOVCON2 is linked to an IgE signal peptide. In one embodiment, ZEBOVGUI is linked to an IgE signal peptide.

[0017] In one embodiment, the nucleic acid encoding ZEBOVCON comprises a nucleic acid sequence at least 95% homologous SEQ ID NO:69, or a fragment thereof. In one embodiment, the nucleic acid encoding ZEBOVGUI comprises a nucleic acid sequence at least 95% homologous SEQ ID NO:72, or a fragment thereof. In one embodiment, the nucleic acid encoding ZEBOVCON2 comprises a nucleic acid sequence at least 95% homologous SEQ ID NO:70, or a fragment thereof.

[0018] In one embodiment, the nucleic acid encoding ZEBOVCON comprises a nucleic acid transcribed from a DNA sequence at least 95% homologous SEQ ID NO:69, or a fragment thereof. In one embodiment, the nucleic acid encoding ZEBOVGUI comprises a nucleic acid transcribed from a DNA sequence at least 95% homologous SEQ ID NO:72, or a fragment thereof. In one embodiment, the nucleic acid encoding ZEBOVCON2 comprises a nucleic acid transcribed from a DNA sequence at least 95% homologous SEQ ID NO:70, or a fragment thereof.

[0019] A composition comprising one or more nucleic acid sequence encoding one or more of ZEBOVCON, ZEBOVCON2 and ZEBOVGUI is also provided. In one embodiment, the composition comprises two or more nucleic acid sequence encoding two or more of ZEBOVCON, ZEBOVCON2 and ZEBOVGUI. In one embodiment, the composition comprises two nucleic acid molecules. In one embodiment, the composition comprises three or more nucleic acid sequence encoding ZEBOVCON, ZEBOVCON2 and ZEBOVGUI. In one embodiment, the composition comprises three nucleic acid molecules.

[0020] The invention also provides novel sequence for producing immunogens in mammalian cells or viral vectors.

[0021] A composition comprising a nucleic acid sequence that encodes a consensus Zaire ebolavirus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a consensus Sudan ebolavirus envelope glycoprotein immunogen, and a nucleic acid sequence that encodes a Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen is provided. The amino acid sequence of the consensus Zaire ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:1 (ZEBOV CON), a fragment of SEQ ID NO:1, an amino acid sequence that is homologous to SEQ ID NO:1, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:1. Amino acid sequences that are homologous to SEQ ID NO:1 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:1. Fragments of SEQ ID NO:1 or fragments of amino acid sequences that are homologous to SEQ ID NO:1 are typically 600 or more, 630 or more, or 660 or more amino acids. The amino acid sequence of the consensus Sudan ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:2 (SUDV CON), a fragment of SEQ ID NO:2, an amino acid sequence that is homologous to SEQ ID NO:2, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:2. Amino acid sequences that are homologous to SEQ ID NO:1 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:2. Fragments of SEQ ID NO:2 or fragments of amino acid sequences that are homologous to SEQ ID NO:2 are typically 600 or more, 630 or more, or 660 or more amino acids. The amino acid sequence of the Marburg marburgvirus first consensus envelope glycoprotein immunogen may be SEQ ID NO:4 (MARV RAV), a fragment of SEQ ID NO:4, an amino acid sequence that is homologous to SEQ ID NO:4, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:4. Amino acid sequences that are homologous to SEQ ID NO:4 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:4. Fragments of SEQ ID NO:4 or fragments of amino acid sequences that are homologous to SEQ ID NO:4 are typically 600 or more, 637 or more, or 670 or more amino acids. The amino acid sequence of the Marburg marburgvirus second consensus envelope glycoprotein immunogen may be SEQ ID NO:5 (MARV OZO), a

more, homologous to SEQ ID NO:2. Fragments of SEQ ID NO:2 or fragments of amino acid sequences that are homologous to SEQ ID NO:2 are typically 600 or more, 630 or more, or 660 or more amino acids. The amino acid sequence of the Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen may be SEQ ID NO:3 (MARV ANG), a fragment of SEQ ID NO:3, an amino acid sequence that is homologous to SEQ ID NO:3, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:3. Amino acid sequences that are homologous to SEQ ID NO:3 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:3. Fragments of SEQ ID NO:3 or fragments of amino acid sequences that are homologous to SEQ ID NO:3 are typically 600 or more, 637 or more, or 670 or more amino acids. The amino acid sequence may optionally comprise a leader sequences such as the IgE leader.

[0022] A composition comprising a nucleic acid sequence that encodes a consensus Zaire ebolavirus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a consensus Sudan ebolavirus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a Marburg marburgvirus first consensus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a Marburg marburgvirus second consensus envelope glycoprotein immunogen, and a nucleic acid sequence that encodes a Marburg marburgvirus third consensus envelope glycoprotein immunogen is also provided. The amino acid sequence of the consensus Zaire ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:1 (ZEBOV CON), a fragment of SEQ ID NO:1, an amino acid sequence that is homologous to SEQ ID NO:1, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:1. Amino acid sequences that are homologous to SEQ ID NO:1 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:1. Fragments of SEQ ID NO:1 or fragments of amino acid sequences that are homologous to SEQ ID NO:1 are typically 600 or more, 630 or more, or 660 or more amino acids. The amino acid sequence of the consensus Sudan ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:2 (SUDV CON), a fragment of SEQ ID NO:2, an amino acid sequence that is homologous to SEQ ID NO:2, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:2. Amino acid sequences that are homologous to SEQ ID NO:1 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:2. Fragments of SEQ ID NO:2 or fragments of amino acid sequences that are homologous to SEQ ID NO:2 are typically 600 or more, 630 or more, or 660 or more amino acids. The amino acid sequence of the Marburg marburgvirus first consensus envelope glycoprotein immunogen may be SEQ ID NO:4 (MARV RAV), a fragment of SEQ ID NO:4, an amino acid sequence that is homologous to SEQ ID NO:4, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:4. Amino acid sequences that are homologous to SEQ ID NO:4 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:4. Fragments of SEQ ID NO:4 or fragments of amino acid sequences that are homologous to SEQ ID NO:4 are typically 600 or more, 637 or more, or 670 or more amino acids. The amino acid sequence of the Marburg marburgvirus second consensus envelope glycoprotein immunogen may be SEQ ID NO:5 (MARV OZO), a

fragment of SEQ ID NO:5, an amino acid sequence that is homologous to SEQ ID NO:5, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:5. Amino acid sequences that are homologous to SEQ ID NO:5 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:4. Fragments of SEQ ID NO:5 or fragments of amino acid sequences that are homologous to SEQ ID NO:5 are typically 600 or more, 637 or more, or 670 or more amino acids. The amino acid sequence of the Marburg marburgvirus third consensus envelope glycoprotein immunogen may be SEQ ID NO:6 (MARV MUS), a fragment of SEQ ID NO:6, an amino acid sequence that is homologous to SEQ ID NO:6, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:6. Amino acid sequences that are homologous to SEQ ID NO:6 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:6. Fragments of SEQ ID NO:6 or fragments of amino acid sequences that are homologous to SEQ ID NO:6 are typically 600 or more, 637 or more, or 670 or more amino acids. The amino acid sequence may optionally comprise a leader sequences such as the IgE leader. In some embodiments, the composition further comprises a nucleic acid sequence that encodes the Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen. The amino acid sequence of the Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen may be SEQ ID NO:3 (MARV ANG), a fragment of SEQ ID NO:3, an amino acid sequence that is homologous to SEQ ID NO:3, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:3. Amino acid sequences that are homologous to SEQ ID NO:3 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:3. Fragments of SEQ ID NO:3 or fragments of amino acid sequences that are homologous to SEQ ID NO:3 are typically 600 or more, 637 or more, or 670 or more amino acids. The amino acid sequence may optionally comprise a leader sequences such as the IgE leader.

[0023] Also provided is a composition comprising a nucleic acid sequence that encodes a consensus Zaire ebolavirus envelope glycoprotein immunogen, and a nucleic acid sequence that encodes a consensus Sudan ebolavirus envelope glycoprotein immunogen. The amino acid sequence of the consensus Zaire ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:1 (ZEBOV CON), a fragment of SEQ ID NO:1, an amino acid sequence that is homologous to SEQ ID NO:1, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:1. Amino acid sequences that are homologous to SEQ ID NO:1 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:1. Fragments of SEQ ID NO:1 or fragments of amino acid sequences that are homologous to SEQ ID NO:1 are typically 600 or more, 630 or more, or 660 or more amino acids. The amino acid sequence of the consensus Sudan ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:2 (SUDV CON), a fragment of SEQ ID NO:2, an amino acid sequence that is homologous to SEQ ID NO:2, or a fragment of an amino acid sequence that is homologous to SEQ ID NO:2. Amino acid sequences that are homologous to SEQ ID NO:1 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:2. Fragments of SEQ ID NO:2 or fragments of amino

acid sequences that are homologous to SEQ ID NO:2 are typically 600 or more, 630 or more, or 660 or more amino acids. The amino acid sequence may optionally comprise a leader sequences such as the IgE leader.

[0024] A composition comprising a nucleic acid sequence that encodes a consensus Zaire ebolavirus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a consensus Sudan ebolavirus envelope glycoprotein immunogen, and a nucleic acid sequence that encodes a Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen is provided. The nucleic acid sequence that encodes a consensus Zaire ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:64, a fragment of SEQ ID NO:64, a nucleic acid sequence that is homologous to SEQ ID NO:64, or a fragment of a nucleotide sequence that is homologous to SEQ ID NO:64. Nucleic acid sequences that are homologous to SEQ ID NO:64 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:64. Fragments of SEQ ID NO:64 or fragments of amino acid sequences that are homologous to SEQ ID NO:64 typically encode 600 or more, 630 or more, or 660 or more amino acids of the consensus Zaire ebolavirus envelope glycoprotein immunogen encoded by SEQ ID NO:64. The nucleic acid sequence that encodes a consensus Sudan ebolavirus envelope glycoprotein immunogen may be SEQ ID NO:65, a fragment of SEQ ID NO:65, a nucleic acid sequence that is homologous to SEQ ID NO:65, or a fragment of a nucleotide sequence that is homologous to SEQ ID NO:65. Nucleic acid sequences that are homologous to SEQ ID NO:65 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:65. Fragments of SEQ ID NO:65 or fragments of amino acid sequences that are homologous to SEQ ID NO:65 typically encode 600 or more, 630 or more, or 660 or more amino acids of the consensus Sudan ebolavirus envelope glycoprotein immunogen encoded by SEQ ID NO:65. The nucleic acid sequence that encodes Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen may be SEQ ID NO:66, a fragment of SEQ ID NO:66, a nucleic acid sequence that is homologous to SEQ ID NO:66, or a fragment of a nucleotide sequence that is homologous to SEQ ID NO:66. Nucleic acid sequences that are homologous to SEQ ID NO:66 are typically 95% or more, 96% or more, 97% or more, 99% or more, or 99% or more, homologous to SEQ ID NO:66. Fragments of SEQ ID NO:66 or fragments of amino acid sequences that are homologous to SEQ ID NO:66 typically encode 600 or more, 630 or more, or 670 or more amino acids of the Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen encoded by SEQ ID NO:66. The nucleic acid sequences may optionally include sequences that encode leader sequences such as the IgE leader linked to the sequences encoding the immunogens.

[0025] Each of the different nucleic acid sequences may be on a single nucleic acid molecule, may each be on a separate nucleic acid molecules or various permutations. Nucleic acid molecules may be plasmids.

[0026] The composition may be formulated for delivery to an individual using electroporation.

[0027] The composition may further comprise nucleic acid sequences that encode one or more proteins selected from the group consisting of: IL-12, IL-15 and IL-28.

**[0028]** The composition may be used in methods of inducing an immune response against a filovirus. The filovirus may be selected from the group consisting of: Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire.

**[0029]** Methods of treating an individual who has been diagnosed with filovirus comprising administering a therapeutically effective amount of the composition to an individual are provided. The filovirus may be selected from the group consisting of: Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire.

**[0030]** Method of preventing filovirus infection in an individual are provided. The methods comprise administering a prophylactically effective amount of the composition to an individual. The filovirus may be selected from the group consisting of: Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire.

**[0031]** Compositions comprising two or more proteins selected from the group consisting of: a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, a Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen, a first consensus Marburg marburgvirus envelope glycoprotein immunogen, a second consensus Marburg marburgvirus envelope glycoprotein immunogen and a third consensus Marburg marburgvirus envelope glycoprotein immunogen are provided.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0032]** FIGS. 1A-1C refer to the polyvalent-vaccine construction strategy and expression experiments in Example 1. FIG. 1A shows phylogenetic trees for MGP (top), SGP (lower right), and ZGP (lower left). Significant support values are indicated (\*) as verified by bootstrap analysis. A consensus strategy was adopted for the ZGP and SGP immunogens (CON VACCINE). Scale bars signify distance of amino acids per site and analyses were conducted using MEGA version 5 software. GP transgenes were commercially synthesized, genetically optimized, and subcloned into modified pVAX1 mammalian expression vectors. Antigen expression was analyzed following transfection of HEK 293T cells by Western immunoblotting and FACS. Western immunoblotting results are shown in FIG. 1B and FACS in FIG. 1C. For a comparative control, rVSV expressing MGP, SGP, or ZGP was run concurrently with each GP sample and species-specific anti-GP1 mAbs were used for detection. Size is indicated (kDa). For FACS, transfected cells were indirectly stained with mouse-derived GP-specific serum reagents followed by extensive washing and goat anti-mouse IgG and MHC class I. Western immunoblotting and FACS experiments were repeated at least three times with similar results. Significance for unrooted phylogenetic trees was determined by maximum-likelihood method and verified by bootstrap analysis and significant support values ( $\geq 80\%$ ; 1,000 bootstrap replicates) were determined by MEGA version 5 software.

**[0033]** FIGS. 2A-2H show results from experiments in Example 1 in which complete protection against MARV and ZEBOV challenge was observed. Animal survival data is shown in FIG. 2A and FIG. 2E. FIG. 2A shows trivalent vaccinated animals survived post MARV challenge while control animals all died by day 10. FIG. 2E shows trivalent vaccinated animals survived post ZEBOV challenge while control animals all died by day 7. Data for % change in body weight for vaccinated and control animal are displayed in

FIG. 2B for vaccinated challenged with MARV. The y axis indicates change in body weight as shown in FIG. 2F. The light solid line is for Trivalent vaccinated animals. The light dashed line is for TriAVE, the average results of the Trivalent vaccinated animals. The dark solid line is for control animals. The dark dashed line is for Control AVE, the average result for the control animals. The light solid lines and light dashed lines remain steady on the graph in the days post challenge showing no significant weight loss among vaccinated animals. The dark solid lines and dark dashed lines decline on the graph from days 0-9 post challenge ending with the dagger denote animals that succumbed to disease by day 10. Data for % change in body weight for vaccinated and control animal are displayed in FIG. 2F for vaccinated challenged with ZEBOV. The y axis shows change in body weight as a percent. The light solid line is for Trivalent vaccinated animals. The light dashed line is for TriAVE, the average results of the Trivalent vaccinated animals. The dark solid line is for control animals. The dark dashed line is for Control AVE, the average result for the control animals. The light solid lines and light dashed lines remain steady on the graph in the days post challenge showing no significant weight loss among vaccinated animals. The dark solid lines and dark dashed lines decline on the graph from days 0-6 post challenge ending with the dagger denote animals that succumbed to disease before day 8. (n=3 for gpMARV and n=6 for gpZEBOV). Binding Abs (FIG. 2C and FIG. 2G) and NAbS (FIG. 2D and FIG. 2H) were measured in serum from vaccinated animals before (Pre) and after the first (1x) and second (2x) immunizations. Analysis was conducted on pooled serum (FIG. 2H). \*p<0.1; \*\*p<0.001; \*\*\*p<0.0001.

**[0034]** FIGS. 3A-3C show results from Example 1 demonstrating induction of neutralizing Abs. B cell responses were assessed in mice (n=5/group) 20 days following each of two vaccinations, spaced three weeks between injections with 40  $\mu$ g of E-DNA vaccination. FIG. 3A shows serum GP-specific IgG responses from vaccinated (solid lines) mice or pre-bled (dotted lines) mice were measured by ELISA. The data is summarized in FIG. 3B. All responses from pEBOS- and pEBOZ-immunized animals were measured against sucrose-purified ZGP since SGP was not available for this study. IgG responses from pMARV-immunized mice were measured against MARV-Ozolin GP or with negative control sucrose-purified Nipah G protein. Neutralization activity of serum samples was measured against ZEBOV-EGFP, SUDV-Boniface and MARV-Angola in a BSL-4 facility and NAb titers are shown in FIG. 3C. NAbS against SUDV-Boniface were assayed based on cytopathic effect (CPE) on CV-1 cells and those against MARV-Angola were assayed using an immunofluorescent assay. Averages are shown in FIG. 3B and FIG. 3C and error bars represent SEM. Group analyses were completed by matched, two-tailed, unpaired t test. Experiments were repeated at least two times with similar results and \*p<0.1; \*\*p<0.01; \*\*\*p<0.001.

**[0035]** FIGS. 4A-4D shows refer to broad T cells responses generated by vaccination. In FIG. 4A H-2<sup>b</sup> (light bars) and H-2<sup>d</sup> (dark bars) mice (n=5/group) were immunized twice with either pMARV, pEBOS or pEBOZ DNA, and IFN $\gamma$  responses were measured by IFN $\gamma$  ELISPOT assay. Splenocytes harvested 8 days after the second immunization were incubated in the presence of individual GP peptides (15-mers overlapping by 9 amino acids) and results

are shown in stacked bar graphs. Epitope-containing peptides were identified ( $\geq 10$  AVE spots AND  $\geq 80\%$  response rate), confirmed by flow cytometry and characterized in the population of total activated IFN $\gamma$ + and CD44+CD4+ and/or CD8+ T cells (Tables 1-6), and peptide numbers of positive inducers are indicated above the bars. Peptides containing CD4+ epitopes alone, CD8+ epitopes alone (\*), and dual CD4+ and CD8+ epitopes (\*\*) are numbered. Putative shared and/or partial epitopes were explored for contiguous positive peptide responses (Tables 1-6). FIG. 4B shows amino acid similarity plots comparing GP sequences from MARV, SUDV, and ZEBOV viruses displayed in FIG. 1A. FIG. 4C is a diagram showing putative domains within the ZEBOV GP (GenBank #VGP\_EBOZM). SP, signal peptide; RB, receptor binding; MUC, mucin-like region; FC, furin cleavage site; TM, transmembrane region. In FIG. 4D, total subdominant (darker shade) and immunodominant (lighter shade) T cell epitopic responses are displayed as a percentage of the total IFN $\gamma$  response generated by each vaccine. Experiments were repeated at least two times with similar results.

[0036] FIGS. 5A-5D show data from experiment assessing protective ‘single-dose’ vaccination induced neutralizing Abs and CTL. H-2 $k$  mice (n=10/group) were vaccinated once i.m. with pEBOZ E-DNA and then challenged 28 days later with 1,000 LD<sub>50</sub> of mZEBOV in a BSL-4 facility. Mice were weighed daily and monitored for disease progression. Animal survival data in FIG. 5A. Vaccinated animals survived challenge while control animals died by day 7. FIG. 5B shows data for % change in body weight in challenged animals. Data from immunized animals is shown as a solid light line; the average data for immunized animals is shown as a dashed light line. Data from control animals is shown as a solid dark line; the average data for control animals is shown as a dashed dark line. The light solid lines and light dashed lines remain steady within the range of about 85%-120% on the graph in the days post challenge showing no significant weight loss among vaccinated animals. The dark solid lines and dark dashed lines decline on the graph from days 0-6 post challenge ending with the dagger denote animals that succumbed to disease by day 7. NAb measured prior to challenge; the data shown in FIG. 5C. T cell responses after a single pEBOZ immunization as measured by FACS are summarized as AVE % of total CD44+/IFN $\gamma$ + CD4+(dark) or CD8+(light) cells in FIG. 5D. T<sub>h</sub>-1 type effector markers were assessed (TNF and T-bet) and data for CD44+/IFN $\gamma$ +CD4+ and CD8+ T cells were compared with total T cell data which was as follows: For Total Cells: TNF 2.9 $\pm$ 0.8, Tbet 13.0 $\pm$ 1.1. For CD4+/CD44+/IFN $\gamma$ + Cells: TNF 61.4 $\pm$ 3.1, Tbet 72.6 $\pm$ 2.0. For CD8+/CD44+/IFN $\gamma$ + Cells: TNF 33.0 $\pm$ 3.3, Tbet 992.1 $\pm$ 1.4 (\*p<0.1; \*\*\*p<0.001; \*\*\*\*p<0.0001). Group analyses were completed by matched, two-tailed, unpaired t test and survival curves were analyzed by log-rank (Mantel-Cox) test. Experiments were performed twice with similar results and error bars represent SEM.

[0037] FIG. 6 shows a GP-specific T cell gating disclosed in Example 1.

[0038] FIGS. 7A and 7B show that vaccination experiments in Example 1 generated robust T cells.

[0039] FIGS. 8A and 8B show T cell induction by ‘single-dose’ vaccination disclosed in Example 1.

[0040] FIG. 9 depicts the vaccination strategy against Ebola. Ebola viral glycoproteins are the major target for

vaccines. Currently, three vaccines are currently in clinical trials which are immunogenic protective in non-human primates (NHPs) and have single dose protection. However, these vaccines develop anti-vector immunity, show adverse reactions in human clinical trials, have uncertain duration of memory response and may not be suitable for all populations.

[0041] FIG. 10 refers to the EBOV glycoprotein vaccine construction and formulation strategy and expression experiments in Example 7.

[0042] FIG. 11 shows results from experiments in Example 7 demonstrating a single immunization of DNA vaccine is immunogenic in mice.

[0043] FIG. 12 shows results from Example 7 demonstrating a single immunization is fully protective in mice against lethal mouse-adapted Ebola virus challenge.

[0044] FIG. 13 shows results from Example 7 demonstrating individual GP DNA vaccine constructs induce robust memory responses in mice.

[0045] FIG. 14 shows results from Example 7 demonstrating efficacy of GP DNA vaccines in non-human primates.

[0046] FIG. 15 shows results from Example 7 demonstrating GP DNA vaccine formulations are immunogenic in NHPs.

[0047] FIG. 16 shows results from Example 7 demonstrating GP DNA formulation vaccines protect against lethal Zaire Ebola virus (Makona) challenge.

[0048] FIG. 17 shows EBOV-001 phase I clinical (NCT02464670) study strategy.

[0049] FIG. 18 shows results from Example 7 demonstrating EBOV-001 seroconversion in the phase I clinical trial.

[0050] FIG. 19 shows results from Example 7 demonstrating induction of Ebola GP Specific T-Cell Responses (ELISpot) in Representative Patients.

[0051] FIG. 20 shows results from Example 7 demonstrating a comparison with other Ebola vaccine platforms currently in clinical trials.

[0052] FIG. 21 shows the cohort descriptions and cohort demographics for the ELISA experiments from Example 8.

[0053] FIG. 22 shows results from Example 8 demonstrating ELISA Titers by Cohort and Time point for cohorts 1-3.

[0054] FIG. 23 shows results from Example 8 demonstrating ELISA Titers by Cohort and Time point for cohorts 4 and 5.

[0055] FIG. 24 shows results from Example 8 demonstrating an ELISA Summary for all cohorts.

[0056] FIG. 25 shows the cohort descriptions and cohort demographics for the ELISpot experiments from Example 8.

[0057] FIG. 26 shows results from Example 8 demonstrating subject responses by peptide pool for cohort 1.

[0058] FIG. 27 shows results from Example 8 demonstrating subject responses by peptide pool for cohort 2.

[0059] FIG. 28 shows results from Example 8 demonstrating subject responses by peptide pool for cohort 3.

[0060] FIG. 29 shows results from Example 8 demonstrating subject responses by peptide pool for cohort 4.

[0061] FIG. 30 shows results from Example 8 demonstrating subject responses by peptide pool for cohort 5.

[0062] FIG. 31 shows results from Example 8 demonstrating ELISpot summary by cohort.

[0063] FIG. 32 shows results from Example 8 demonstrating ELISpot summary by cohort.

[0064] FIG. 33 shows results from Example 8 demonstrating analysis of vaccine responders for all subjects.

[0065] FIG. 34 shows results from Example 8 demonstrating analysis of vaccine responders for subjects with baseline outliers removed.

[0066] FIG. 35 shows the cohort descriptions and cohort demographics for the ICS experiments from Example 8.

[0067] FIG. 36 shows results from Example 8 demonstrating Wilcoxon Paired analysis based on cohort for ICS experiments.

[0068] FIG. 37 shows results from Example 8 demonstrating ICS analysis for cohort 3 (INO4201 ID) Cytokines in CD4+ T cells.

[0069] FIG. 38 shows results from Example 8 demonstrating ICS analysis for cohort 3 Cytokines in CD8+ T cells.

[0070] FIG. 39 shows results from Example 8 demonstrating a detailed analysis of vaccine responders for each subject in cohorts 1-3.

[0071] FIG. 40 shows results from Example 8 demonstrating a detailed analysis of vaccine responders for each subject in cohorts 4-5.

[0072] FIG. 41 shows results from Example 8 demonstrating median responses by cohort and pool.

[0073] FIG. 42 shows results from Example 8 demonstrating mean responses by cohort and pool.

[0074] FIG. 43 shows results demonstrating that bivalent and trivalent DNA vaccines elicit long-term immune responses *in vivo* in cynomolgus macaques. Serum and peripheral blood mononuclear cells (PBMCs) were collected 2-weeks post-each DNA injection and monthly following final injection. Total IgG endpoint titers against Guinea-GP and Mayinga-GP were assayed by ELISA. Cellular immune responses against Ebola GP following DNA immunization. PBMCs were collected from NHPs and assayed by ELISPOT-IFN $\gamma$  for T cells responses following stimulation with pools of GP peptides.

[0075] FIG. 44, comprising FIG. 44A through FIG. 44C, shows results demonstrating protection in cynomolgous macaques with bivalent and trivalent DNA vaccines against lethal EBOV challenge. FIG. 44A) Survival. Animals were challenged with 1000TCID50 of lethal Guinea Makona C07 EBOV and survival was monitored for 28 days post-challenge, FIG. 44B) Clinical score. Clinical signs of disease were monitored throughout the course of infection. FIG. 44C) Viral load. Viremia during the course of infection was assayed from blood by TCID50 assay.

[0076] FIG. 45 shows a quantification ELISA using the ADI human anti-Zaire Ebola virus glycoprotein IgG kit to assess the amount of ZEBOV specific IgG antibody in the sera of each vaccinated subject at study entry and 2 weeks post each immunization. Statistical analyses were performed using two tailed Wilcoxon Sign Rank test.

[0077] FIG. 46 shows an Interferon Gamma ELISpot response. PBMCs were isolated from vaccinated subjects at study entry and 2 weeks post each immunization and stimulated with Ebola peptides spanning the full length GP in an IFN $\gamma$  ELISpot assay. The graph represents EBOV-GP specific spot forming units per million PBMCs. Lines within boxes represent Median response. Individual dots represent outlier data.

[0078] FIG. 47 depicts experimental results demonstrating long-term immunogenicity with Ebola GP DNA vaccine formulations in non-human primates (NHPs). Strong antibody responses are observed greater than 6 months post-vaccination.

[0079] FIG. 48 depicts the Memory study of intramuscular delivery of EBOV GP DNA vaccine. NHPs were immunized over a 3 month period with bivalent or trivalent EBOV GP DNA vaccine formulations. The immune responses were followed over a 12 months following the final dose. A 1 year boost was given at month 13.

[0080] FIG. 49 depicts the total IgG endpoint titers of animals receiving a trivalent DNA GP formulation. An increase in total IgG antibody response was observed following the 1-year boost.

[0081] FIG. 50 depicts the total IgG endpoint titers of animals receiving a bivalent or trivalent DNA GP formulation. An increase in total IgG antibody response was observed following the 1-year boost.

[0082] FIG. 51 depicts the ELISPOT of trivalent DNA GP formulations. Increase IFN $\gamma$  ELISPOT responses following the 1 year boost. Magnitude of boost is not as high in the 3 injection group.

[0083] FIG. 52 depicts the ELISPOT of bivalent or trivalent DNA GP formulations. Increase IFN $\gamma$  ELISPOT responses following the 1 year boost. There was a remarkably strong boost in single immunization group.

[0084] FIG. 53 depicts a summary of IFN $\gamma$  ELISPOT results. 17/19 animals had increased T cell responses following the boost. 1/19 animals maintained the same level of T cell responses. 1/19 animals had worse T cell responses following the boost, however this animal was consistently high over the past year in the 3 injection group.

[0085] FIG. 54 depicts an exemplary IFN $\gamma$  ELISPOT for animals in the single immunization group at the 12 month time point, before the 1-year boost.

[0086] FIG. 55 depicts an exemplary IFN $\gamma$  ELISPOT for animals in the single immunization group after the 1-year boost.

[0087] FIG. 56 depicts the results of the IM memory study. The EBOV GP DNA vaccines elicit long term immune response with a strong recall following a 1 year boost. Intradermal delivery studies are carried out to study the immune response of intradermal EBOV GP DNA vaccines.

[0088] FIG. 57 depicts a summary of the EBOV DNA vaccine clinical trial (EBOV-001). Healthy volunteers receive a 3 dose regimen of INO-4201, INO-4202, INO-4212 or INO-4212 and INO-9021.

[0089] FIG. 58 depicts a comparison of binding antibodies in EBOV-001 to rVSV EBOV. All EBOV-001 cohorts had significant increases at both weeks 6 and 14 compared to week 0.

[0090] FIG. 59 depicts a summary of the Intradermal Delivery of EBOV GP DNA vaccine study. Cohorts were added to explore dosing, dose regimens and use of IL-12 DNA as an immuno-adjuvant.

[0091] FIG. 60 depicts the results of ID cohorts at week 14. Sereoreactivity was observed in 125/127 (98.4%) subjects in all ID cohorts.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0092] In one aspect of the invention, it is desired that the consensus antigen provides for improved transcription and translation, including having one or more of the following: low GC content leader sequence to increase transcription; mRNA stability and codon optimization; eliminating to the extent possible *cis*-acting sequence motifs (i.e., internal TATA-boxes).

[0093] In some aspects of the invention, it is desired to generate a consensus antigen that generates a broad immune response across multiple strains, including having one or more of the following: incorporate all available full-length sequences; computer generate sequences that utilize the most commonly occurring amino acid at each position; and increase cross-reactivity between strains.

[0094] Diversity among the Filoviridae is relatively high. Intensive efforts have been aimed at developing a universal and broadly-reactive filovirus vaccine that would ideally provide protection against multiple species responsible for the highest human case-fatality rates. However, this proves difficult due to the relative high level of diversity among the Filoviridae. The EBOV are currently classified into five distinct species, Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SUDV), Reston ebolavirus (RESTV), Bundibugyo ebolavirus (BDBV) and TarForest ebolavirus (TAFV; formerly Cote d'Ivoire ebolavirus), the first two responsible for the highest lethality rates and the most likely candidates for weaponization. Diversity is lower among the Marburg viruses (MARV) of which can also be up to 90% lethal. Currently, there is only one classified species, Marburg marburgvirus (formerly Lake Victoria marburgvirus), although a recent amendment proposes that it contain two viruses including the Ravn virus (RAVV). Adding to the complexity for polyvalent-vaccine development, the MARV and EBOV are highly divergent, in which there exists about 67% divergence at the nucleotide level. Furthermore, phylogenetic diversity among the filoviral GP is also very high (82% overall). These allude to the potential of the filoviruses to evolve, as demonstrated by the recent emergence of BDBV in 2007. Therefore, due to relative divergence among the Filoviridae, we hypothesized that development of an effective polyvalent-filovirus vaccine will likely require a cocktail of immunogenic components.

[0095] A synthetic polyvalent-filovirus DNA vaccine against Marburg marburgvirus (MARV), Zaire ebolavirus (ZEBOV), and Sudan ebolavirus (SUDV) was developed. The novel polyvalent-filovirus vaccine comprised by three DNA plasmids encoding the envelope glycoprotein (GP) genes of Marburg marburgvirus (MARV), Sudan ebolavirus (SUDV) or Zaire ebolavirus (ZEBOV), adopting the multi-agent approach. As a filoviral vaccine candidate, an enhanced DNA (DNA)-based platform exhibits many advantages given recent advances in genetic optimization and delivery techniques (Bagarazzi M L, et al. (2012). Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses. *Sci Transl Med* 4: 155ral38; Kee S T, Gehl J. W. LE (2011). *Clinical Aspects of Electroporation*, Springer, New York, NY.; Hirao L A, et al. (2011). Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. *J Infect Dis* 203: 95-102). As such, each GP was genetically-optimized, subcloned into modified mammalian expression vectors, and then delivered using *in vivo* electroporation (EP).

[0096] Preclinical efficacy studies were performed in guinea pigs and mice using rodent-adapted viruses, while murine T cell responses were extensively analyzed using a novel modified assay described herein. T cell responses were extensively analyzed including the use of a novel method for epitope identification and characterization described herein.

This model provides an important preclinical tool for studying protective immune correlates that could be applied to existing platforms.

[0097] Vaccination in preclinical rodent studies was highly potent, elicited robust neutralizing antibodies (Nabs) and CTL expressing T<sub>h</sub>1-type markers, and completely protected against MARV and ZEBOV challenge. Comprehensive T cell analysis as extensively analyzed using a novel modified assay described herein (Shedlock D J, et al. (2012). Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. *Hum Vaccin Immunother* 8: 1668-1681) revealed cytotoxic T lymphocytes of great magnitude, epitopic breadth, and T<sub>h</sub>1-type marker expression. In total, 52 novel T cell epitopes from two different mouse genetic backgrounds were identified (19 of 20 MARV epitopes, 15 of 16 SUDV, and 18 of 22 ZEBOV) and occurred primarily in highly conserved regions of their respective glycoproteins (GPs). These data represent the most comprehensive report of preclinical glycoprotein epitopes to date.

[0098] In developing a strategy to provide protection against multiple species responsible for the highest human case-fatality rates, we focused on MARV, SUDV, and ZEBOV. Due to their relative divergence, we hypothesized that development of a polyvalent-filovirus vaccine would require a cocktail of components that can be quickly and easily adapted in response to future outbreak strains and/or species. While overall diversity among the EBOV is about 33%, amino acid identity increases substantially when SUDV and ZEBOV are analyzed separately (~94% identity within each species). Therefore, as shown in FIG. 1A, a two component strategy for coverage of the most lethal EBOV, one plasmid GP vaccine for SUDV and another for ZEBOV was designed. Since GP diversity among each species was relatively low (5.6% for SUDV and 7.1% for ZEBOV), consensus immunogens were developed increase inter-species coverage, a strategy shown previously to enhance protection among divergent strains of influenza and HIV. These GP sequences were consensus for all reported outbreak sequences (GenBank) as determined by alignment using Vector NTI software (Invitrogen, CA, USA). Non-consensus residues, 4 amino acids each in SUDV (95, 203, 261, and 472) and ZEBOV (314, 377, 430, and 440), were weighted towards Gulu and Mbomo/Mbanza, respectively. Gulu was chosen since it was responsible for the highest human case-fatality rate of any Filoviridae outbreak (n=425), while Mbomo/Mbanza was chosen since they were the most recent and lethal outbreaks with published sequence data. The consensus GP for SUDV (SUDV CON VACCINE) and ZEBOV (ZEBOV CON VACCINE) were phylogenetically intermediary their parentally aligned strains.

[0099] Identification of proteins in FIG. 1A are as follows: MARV Durba (05DRC99) '99: ABE27085; Uganda (01Uga07) '07: ACT79229; Durba (07DRC99) '99: ABE27078; Ozolin '75: VGP\_MABVO; Musoke '80: VGP\_MABVM; Popp '67: VGP\_MABVP; Leiden '08: AEW11937; Angola '05: VGP\_MABA; Ravn '87: VGP\_MABVR; Durba (09DRC99) '99: ABE27092; Uganda (02Uga07) '07: ACT79201. SUDV: Boniface '76: VGP\_EBOSB; Maleo '79: VGP\_EBOSM; Yambio '04: ABY75325; Gulu '00: VGP\_EBOSU. ZEBOV: Booue '96: AAL25818; Mayibout '96: AEK25495; Mekouka '94: AAC57989, VGP\_EBOG4; Kikwit '95: VGP\_EBOZ5;

Yambuku (Ekron) '76: VGP\_EBOEC; Yambuku (Mayinga) '76: VGP\_EBOZM; Kasai '08: AER59712; Kasai '07: AER59718; Etoumbi '05: ABW34742; Mbomo/Mbandza '03: ABW34743.

[0100] A sequence listing provided herewith contains a list of 72 sequences including the following

[0101] SEQ ID NO:1 is the amino acid sequence of ZEBOV CON (CONGP1), which is a consensus Zaire ebolavirus envelope glycoprotein immunogen.

[0102] SEQ ID NO:2 is the amino acid sequence of SUDV CON, which is a consensus Sudan ebolavirus envelope glycoprotein immunogen.

[0103] SEQ ID NO:3 is the amino acid sequence of MARV or MARV ANG, which is the amino acid sequence of the Marburg marburgvirus Angola 2005 envelope glycoprotein and a Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen.

[0104] SEQ ID NO:4 is the amino acid sequence of MARV CON1, which is the first consensus Marburg marburgvirus envelope glycoprotein immunogen.

[0105] SEQ ID NO:5 is the amino acid sequence of MARV CON2, which is the second consensus Marburg marburgvirus envelope glycoprotein immunogen.

[0106] SEQ ID NO:6 is the amino acid sequence of MARV CON3, which is the third consensus Marburg marburgvirus envelope glycoprotein immunogen.

[0107] SEQ ID NOs:7-25 are peptides derived from MARV ANG.

[0108] SEQ ID NO:26-41 are peptides derived from SUDV CON.

[0109] SEQ ID NO: 42-62 are peptides derived from ZEBOV CON.

[0110] SEQ ID NO:63 is the sequence of the IgE signal peptide: MDWTWILFLVAAATRVHS.

[0111] SEQ ID NO:64 is the nucleotide sequence insert in plasmid pEB0Z which encodes consensus Zaire ebolavirus envelope glycoprotein immunogen.

[0112] SEQ ID NO:65 is the nucleotide sequence insert in plasmid pEB0S which encodes consensus Sudan ebolavirus envelope glycoprotein immunogen.

[0113] SEQ ID NO:66 is the nucleotide sequence insert in plasmid pMARZ ANG which encodes the Marburg marburgvirus Angola 2005 envelope glycoprotein.

[0114] SEQ ID NO:67 is the amino acid sequence of ZEBOVGUI (GuineaGP), which is a consensus Zaire ebolavirus envelope glycoprotein immunogen isolated from the 2014 Outbreak in Guinea.

[0115] SEQ ID NO:68 is the amino acid sequence of ZEBOVCON2 (CONGP2), which is a second consensus Zaire ebolavirus envelope glycoprotein.

[0116] SEQ ID NO:69 is the nucleotide sequence insert in plasmid pZEBOVGUI which encodes consensus Zaire ebolavirus envelope glycoprotein immunogen isolated from the 2014 Outbreak in Guinea.

[0117] SEQ ID NO:70 is the nucleotide sequence insert in plasmid pEB0ZCON2 which encodes a second consensus Zaire ebolavirus envelope glycoprotein.

[0118] SEQ ID NO:71 is the nucleotide sequence of plasmid pEB0ZCON2 which encodes a second consensus Zaire ebolavirus envelope glycoprotein.

[0119] SEQ ID NO:72 is the nucleotide sequence insert in plasmid pZEBOVGUI which encodes a Zaire ebolavirus envelope glycoprotein immunogen isolated from the 2014 Outbreak in Guinea.

[0120] In some embodiments, the strategy employs coding sequences for three filovirus immunogens selected from: MARV, SUDV, ZEBOV, ZEBOVGUI and ZEBOVCON2. MARV immunogen is the glycoprotein of the Angola 2005 isolate. For SUDV ZEBOV, ZEBOVGUI, and ZEBOVCON2 consensus glycoprotein sequences were designed.

[0121] In some embodiments, the strategy employs coding sequences for five filovirus immunogens. Three MARV immunogens are provided. Consensus glycoprotein Ozolin, Musoke, or Ravn derived from three clusters, were designed. These three MARV immunogens are targets for immune responses together the SUDV, ZEBOV or ZEBOVCON2, ZEBOVGUI consensus glycoprotein sequences that were designed.

[0122] In some embodiments, the strategy employs coding sequences for six filovirus immunogens. Four MARV immunogens are provided: three consensus glycoproteins derived from three clusters were designed. These three MARV immunogens are targets for immune responses together the SUDV, ZEBOV and ZEBOVCON2, ZEBOVGUI consensus glycoprotein sequences that were designed, the MARV immunogen is the glycoprotein of the Angola 2005 isolate.

[0123] As a candidate for filoviral vaccines, DNA vaccines exhibit a multitude of advantages including rapid and inexpensive up-scale production, stability at room temperature, and ease of transport, all of which further enhance this platform from an economic and geographic perspective. Due to the synthetic nature of the plasmids, Ag sequences can be quickly and easily modified in response to newly emergent species and/or expanded to include additional vaccine components and/or regimen for rapid response during outbreak settings. For example, the MARV strategies herein can be easily expanded for greater coverage by the co-administration of additional plasmids encoding consensus MARV GP (MGP) immunogens for other phylogenetic clusters.

[0124] While 'first-generation' DNA vaccines were poorly immunogenic, recent technological advances have dramatically improved their immunogenicity in clinical trials. Optimization of plasmid DNA vectors and their encoded Ag genes have led to increases in in vivo immunogenicity. Cellular uptake and subsequent Ag expression are substantially amplified when highly-concentrated plasmid vaccine formulations are administered with in vivo electroporation, a technology that uses brief square-wave electric pulses within the vaccination site to drive plasmids into transiently permeabilized cells. In theory, a cocktail of DNA plasmids could be assembled for directing a highly-specialized immune response against any number of variable Ags. Immunity can be further directed by co-delivery with plasmid molecular adjuvants encoding species-specific cytokine genes as well as 'consensus-engineering' of the Ag amino acid sequences to help bias vaccine-induced immunity towards particular strains. This strategy has been shown to enhance protection among divergent strains of influenza virus and HIV. Due in parts to these technological advancements, immunization regimens including these DNA vaccines are highly versatile and extremely customizable.

## 1. Definitions.

[0125] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in the specification and the appended

claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

[0126] For recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6, 9, and 7.0 are explicitly contemplated.

a. Adjuvant

[0127] “Adjuvant” as used herein may mean any molecule added to the DNA plasmid vaccines described herein to enhance antigenicity of the one or more consensus filovirus immunogens encoded by the DNA plasmids and encoding nucleic acid sequences described hereinafter.

b. Antibody

[0128] “Antibody” may mean an antibody of classes IgG, IgM, IgA, IgD or IgE, or fragments, fragments or derivatives thereof, including Fab, F(ab')<sup>2</sup>, Fd, and single chain antibodies, diabodies, bispecific antibodies, bifunctional antibodies and derivatives thereof. The antibody may be an antibody isolated from the serum sample of mammal, a polyclonal antibody, affinity purified antibody, or mixtures thereof which exhibits sufficient binding specificity to a desired epitope or a sequence derived therefrom.

c. Coding Sequence

[0129] “Coding sequence” or “encoding nucleic acid” as used herein may mean refers to the nucleic acid (RNA or DNA molecule) that comprise a nucleotide sequence which encodes a protein. The coding sequence may also comprise a DNA sequence which encodes an RNA sequence. The coding sequence may further include initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of an individual or mammal to whom the nucleic acid is administered. In some embodiments, the coding sequence may optionally further comprise a start codon that encodes an N terminal methionine or a signal peptide such as an IgE or IgG signal peptide.

d. Genetic Construct

[0130] “Genetic construct” as used herein refers to the DNA or RNA molecules that comprise a nucleotide sequence which encodes a protein, such as an immunogen. The genetic construct may also refer to a DNA molecule which transcribes RNA. The coding sequence includes initiation and termination signals operably linked to regulatory elements including a promoter and polyadenylation signal capable of directing expression in the cells of the individual to whom the nucleic acid molecule is administered. As used herein, the term “expressible form” refers to gene constructs that contain the necessary regulatory elements operable linked to a coding sequence that encodes a protein such that when present in the cell of the individual, the coding sequence will be expressed.

e. Complement

[0131] “Complement” or “complementary” as used herein may mean a nucleic acid may mean Watson-Crick (e.g., A-T/U and C-G) or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules.

f. Consensus or Consensus Sequence

[0132] “Consensus” or “consensus sequence” as used herein may mean a synthetic nucleic acid sequence, or corresponding polypeptide sequence, constructed based on analysis of an alignment of multiple subtypes of a particular

filovirus antigen, that can be used to induce broad immunity against multiple subtypes or serotypes of a particular filovirus antigen.

[0133] Consensus Zaire ebolavirus envelope glycoprotein immunogen refers to SEQ ID NO:1, fragments of SEQ ID NO:1, variants of SEQ ID NO:1 and fragment of variants of SEQ ID NO:1. (ZEBOV or ZEBOV CON or ZEBOV CON VACCINE). Plasmids comprising coding sequences of SEQ ID NO:1 may be referred to as pZEBOV or pEBOZ. Coding sequences for consensus Zaire ebolavirus envelope glycoprotein immunogen include SEQ ID NO:64, fragments of SEQ ID NO:64, variants of SEQ ID NO:64 and fragment of variants of SEQ ID NO:64. Plasmid pEBOZ comprises SEQ ID NO:64.

[0134] Consensus Sudan ebolavirus envelope glycoprotein immunogen refers to SEQ ID NO:2, fragments of SEQ ID NO:2, variants of SEQ ID NO:2 and fragment of variants of SEQ ID NO:2. (SUDV or SUDV CON or SUDV CON VACCINE) Plasmids comprising coding sequences of SEQ ID NO:2 may be referred to as pSUDV or pEBOS. Coding sequences for consensus Sudan ebolavirus envelope glycoprotein immunogen include SEQ ID NO:65, fragments of SEQ ID NO:65, variants of SEQ ID NO:65 and fragment of variants of SEQ ID NO:65. Plasmid pEBOS comprises SEQ ID NO:65.

[0135] Marburg marburgvirus Angola 2005 envelope glycoprotein is not a consensus but a protein sequence derived from an isolate. It has sequence SEQ ID NO:3. Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen refers to SEQ ID NO:3, fragments of SEQ ID NO:3, variants of SEQ ID NO:3 and fragment of variants of SEQ ID NO:3. (MARV or MARV ANG or MARV ANG or MARV ANG VACCINE) Plasmids comprising coding sequences of SEQ ID NO:3 may be referred to as pMARV or pMARV-ANG. Coding sequences for Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen include SEQ ID NO:66, fragments of SEQ ID NO:66, variants of SEQ ID NO:66 and fragment of variants of SEQ ID NO:66. Plasmid pMARV ANG comprises SEQ ID NO:66.

[0136] The first consensus Marburg marburgvirus envelope glycoprotein immunogen refers to SEQ ID NO:4, fragments of SEQ ID NO:4, variants of SEQ ID NO:4 and fragment of variants of SEQ ID NO:4. SEQ ID NO:4 is a Marburg marburgvirus consensus sequence from the Ravn cluster consensus (Ravn, Durba (09DRC99) and Uganda (02Uga07Y). (MARV CON1 or MARV-RAV CON or MARV-RAV CON VACCINE) Plasmids comprising coding sequences of SEQ ID NO:4 may be referred to as pMARV-RAV.

[0137] The second consensus Marburg marburgvirus envelope glycoprotein immunogen refers to SEQ ID NO:5, fragments of SEQ ID NO:5, variants of SEQ ID NO:5 and fragment of variants of SEQ ID NO:5. SEQ ID NO:5 is a Marburg marburgvirus consensus sequence from the Ozolin cluster consensus (Ozolin, Uganda (01Uga07), and Durba (05 and 07DRC99)). (MARV CON2 or MARV-OZO CON or MARV-OZO CON VACCINE) Plasmids comprising coding sequences of SEQ ID NO:5 may be referred to as pMARV-OZO.

[0138] The third consensus Marburg marburgvirus envelope glycoprotein immunogen refers to SEQ ID NO:6, fragments of SEQ ID NO:6, variants of SEQ ID NO:6 and fragment of variants of SEQ ID NO:6. SEQ ID NO:6 is a

Marburg marburgvirus consensus sequence from the Musoke cluster consensus (Musoke, Popp, and Leiden). (MARV CON1 or MARV-MUS CON or MARV-MUS CON VACCINE) Plasmids comprising coding sequences of SEQ ID NO:6 may be referred to as pMARV-MUS.

**[0139]** Consensus Zaire ebolavirus GP envelope glycoprotein immunogen refers to SEQ ID NO:67, fragments of SEQ ID NO:67, variants of SEQ ID NO:67 and fragment of variants of SEQ ID NO:67. (ZEBOVGUI or ZEBOVGUI VACCINE). Plasmids comprising coding sequences of SEQ ID NO:67 may be referred to as pZEBOVGUI or pEBOZGUI. Coding sequences for consensus Zaire ebolavirus Guinea 2014 envelope glycoprotein immunogen include SEQ ID NO:69, fragments of SEQ ID NO:69, variants of SEQ ID NO:69 and fragment of variants of SEQ ID NO:69. Plasmid pEBOZGUI comprises SEQ ID NO:69.

**[0140]** A second consensus Zaire ebolavirus envelope glycoprotein immunogen refers to SEQ ID NO:68 fragments of SEQ ID NO:68, variants of SEQ ID NO:68 and fragment of variants of SEQ ID NO:68. (ZEBOV2 or ZEBOVCON2 or ZEBOVCON2 VACCINE) Plasmids comprising coding sequences of SEQ ID NO:68 may be referred to as pEBOVCON2. Coding sequences for second consensus Zaire ebolavirus envelope glycoprotein immunogen include SEQ ID NO:70, fragments of SEQ ID NO:70, variants of SEQ ID NO:70 and fragment of variants of SEQ ID NO:70. Plasmid pEBOVCON2 comprises SEQ ID NO:70.

#### g. Constant Current

**[0141]** “Constant current” as used herein to define a current that is received or experienced by a tissue, or cells defining said tissue, over the duration of an electrical pulse delivered to same tissue. The electrical pulse is delivered from the electroporation devices described herein. This current remains at a constant amperage in said tissue over the life of an electrical pulse because the electroporation device provided herein has a feedback element, preferably having instantaneous feedback. The feedback element can measure the resistance of the tissue (or cells) throughout the duration of the pulse and cause the electroporation device to alter its electrical energy output (e.g., increase voltage) so current in same tissue remains constant throughout the electrical pulse (on the order of microseconds), and from pulse to pulse. In some embodiments, the feedback element comprises a controller.

#### h. Current Feedback or Feedback

**[0142]** “Current feedback” or “feedback” as used herein may be used interchangeably and may mean the active response of the provided electroporation devices, which comprises measuring the current in tissue between electrodes and altering the energy output delivered by the EP device accordingly in order to maintain the current at a constant level. This constant level is preset by a user prior to initiation of a pulse sequence or electrical treatment. The feedback may be accomplished by the electroporation component, e.g., controller, of the electroporation device, as the electrical circuit therein is able to continuously monitor the current in tissue between electrodes and compare that monitored current (or current within tissue) to a preset current and continuously make energy-output adjustments to maintain the monitored current at preset levels. The feedback loop may be instantaneous as it is an analog closed-loop feedback.

#### i. Decentralized Current

**[0143]** “Decentralized current” as used herein may mean the pattern of electrical currents delivered from the various needle electrode arrays of the electroporation devices described herein, wherein the patterns minimize, or preferably eliminate, the occurrence of electroporation related heat stress on any area of tissue being electroporated.

#### j. Electroporation

**[0144]** “Electroporation,” “electro-permeabilization,” or “electro-kinetic enhancement” (“EP”) as used interchangeably herein may refer to the use of a transmembrane electric field pulse to induce microscopic pathways (pores) in a bio-membrane; their presence allows biomolecules such as plasmids, oligonucleotides, siRNA, drugs, ions, and water to pass from one side of the cellular membrane to the other.

#### k. Feedback Mechanism

**[0145]** “Feedback mechanism” as used herein may refer to a process performed by either software or hardware (or firmware), which process receives and compares the impedance of the desired tissue (before, during, and/or after the delivery of pulse of energy) with a present value, preferably current, and adjusts the pulse of energy delivered to achieve the preset value. A feedback mechanism may be performed by an analog closed loop circuit.

#### l. Fragment

**[0146]** “Fragment” may mean a polypeptide fragment of a filovirus immunogen that is capable of eliciting an immune response in a mammal against filovirus by recognizing the particular filovirus antigen. The filovirus envelope glycoprotein immunogen may optionally include a signal peptides and/or a methionine at position 1, proteins 98% or more homologous to the consensus sequences set forth herein, proteins 99% or more homologous to the consensus sequences set forth herein, and proteins 100% identical to the consensus sequences set forth herein, in each case with or without signal peptides and/or a methionine at position 1. A fragment may or may not for example comprise a fragment of a filovirus immunogen linked to a signal peptide such as an immunoglobulin signal peptide for example IgE signal peptide or IgG signal peptide.

**[0147]** Fragments of any of ZEBOV CON, SUDV CON, MARV ANG, MARV-RAV CON, MARV-OZO CON, MARV-MUS CON, ZEBOVGUI or ZEBOVCON2 or variants thereof, in each case with or without signal peptides and/or a methionine at position 1, may comprise 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more percent of the length of the particular full length ZEBOV CON, SUDV CON, MARV ANG, MARV-RAV CON, MARV-OZO CON, MARV-MUS CON, ZEBOVGUI or ZEBOVCON2 or variants thereof. Fragments refer to fragments polypeptides 100% identical to the sequences ZEBOV CON, SUDV CON, MARV ANG, MARV-RAV CON, MARV-OZO CON, MARV-MUS CON, ZEBOVGUI or ZEBOVCON2 in each case with or without signal peptides and/or a methionine at position 1. Fragments also refer to fragments of variants, i.e. polypeptides that 95% or more, 98% or more, or 99% or more homologous to the sequences ZEBOV CON, SUDV CON, MARV ANG, MARV-RAV CON, MARV-OZO CON, MARV-MUS CON, ZEBOVGUI or ZEBOVCON2, in each case with or without signal peptides and/or a methionine at

position 1. The fragment may comprise a fragment of a polypeptide that is 98% or more homologous, 99% or more homologous, or 100% identical to the filovirus immunogens set forth in SEQ ID NOS: 1-6, 67-68 and additionally comprise a signal peptide such as an immunoglobulin signal peptide which is not included when calculating percent homology. In some embodiments, a fragment of SEQ ID NOS: 1-6, 67-68 linked to a signal peptide such as an immunoglobulin signal peptide for example IgE signal peptide or IgG signal peptide. The fragment may comprise fragments of SEQ ID NOS: 1-6, 67-68 including the N terminal methionine. Fragments also refer to fragments of a polypeptide that is 95% or more, 98% or more, or 99% or more homologous to the sequence disclosed in SEQ ID NOS: 1-6, 67-68. If a signal peptide is present it is not included when calculating percent homology.

**[0148]** In some embodiments, fragments of SEQ ID NOS: 1-6, 67-68 or variants thereof may comprise 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 610, 620, 630, 640, 650, 660, 670 or more contiguous amino acids of any of SEQ ID NOS: 1-6 or variants thereof. In some embodiments, fragments of SEQ ID NOS: 1-6 or variants thereof may comprise 15, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 610, 620, 630, 640, 650, 660, 670, 675 or less contiguous amino acids of any of SEQ ID NOS: 1-6, 67-68 or variants thereof.

**[0149]** “Fragment” may also mean a fragment of a nucleic acid sequence that encodes a filovirus immunogen, the nucleic acid fragment encoding a fragment of filovirus immunogen that is capable of eliciting an immune response in a mammal against filovirus by recognizing the particular filovirus antigen. Fragments of nucleic acid fragment encoding a filovirus immunogen or variants thereof, in each case with or without signal peptides and/or a methionine at position 1, may comprise 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more percent of the length of the particular full length nucleic acid sequence that encodes a filovirus immunogen or variants thereof. The fragment may comprise a fragment of nucleotide sequence that encodes polypeptide that is 98% or more homologous, 99% or more homologous, or 100% identical to the filovirus immunogens set forth in SEQ ID NOS: 1-6, 67-68 and additionally comprise a signal peptide such as an immunoglobulin signal peptide which is not included when calculating percent homology. In some embodiments, fragment of nucleotide sequence that encodes a fragment of SEQ ID NOS: 1-6, 67-68 linked to a signal peptide such as an immunoglobulin signal peptide for example IgE signal peptide or IgG signal peptide. Coding sequences of a signal peptide sis present it is not included when calculating percent homology. In some embodiments, fragment of nucleotide sequence that encodes fragments of SEQ ID NOS: 1-6 or variants thereof may comprises sequences that encode 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 610, 620, 630, 640, 650, 660, 670 or more contiguous amino acids of any of SEQ ID NOS: 1-6, 67-68 or variants thereof. In some embodiments, fragment of nucleotide sequence that encodes fragments of SEQ ID NOS: 1-6, 67-68 or variants thereof may sequences that encode comprise 15, 20, 30, 40, 50, 75,

100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 610, 620, 630, 640, 650, 660, 670, 675 or less contiguous amino acids of any of SEQ ID NOS: 1-6, 67-68 or variants thereof.

**[0150]** In some embodiments, fragments are fragments of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72. Fragments of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72, in each case with or without signal peptides and/or a methionine at position 1, may comprise 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more percent of the length of the particular full length nucleic acid sequence that encodes a filovirus immunogen or variants thereof. The fragment of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 may comprise a fragment of nucleotide sequence that encodes polypeptide that is 98% or more homologous, 99% or more homologous, or 100% identical to the filovirus immunogens encoded by of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 and additionally comprise a signal peptide such as an immunoglobulin signal peptide which is not included when calculating percent homology. Fragments of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 may comprises sequences that encode 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 610, 620, 630, 640, 650, 660, 670 or more contiguous amino acids of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 or variants thereof. Fragments of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 may comprises sequences that encode 15, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 610, 620, 630, 640, 650, 660, 670, 675 or less contiguous amino acids of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 or variants thereof. In some embodiments, fragments are fragments of RNA transcribed from or encoded by SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72

m. Identical

**[0151]** “Identical” or “identity” as used herein in the context of two or more nucleic acids or polypeptide sequences, may mean that the sequences have a specified percentage of residues that are the same over a specified region. The percentage may be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of single sequence are included in the denominator but not the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) may

be considered equivalent. Identity may be performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0.

n. Impedance

[0152] "Impedance" as used herein may be used when discussing the feedback mechanism and can be converted to a current value according to Ohm's law, thus enabling comparisons with the preset current.

o. Immune Response

[0153] "Immune response" as used herein may mean the activation of a host's immune system, e.g., that of a mammal, in response to the introduction of one or more filovirus consensus antigen via the provided DNA plasmid vaccines. The immune response can be in the form of a cellular or humoral response, or both.

p. Nucleic Acid

[0154] "Nucleic acid" or "oligonucleotide" or "polynucleotide" as used herein may mean at least two nucleotides covalently linked together. The depiction of a single strand also defines the sequence of the complementary strand. Thus, a nucleic acid also encompasses the complementary strand of a depicted single strand. Many variants of a nucleic acid may be used for the same purpose as a given nucleic acid. Thus, a nucleic acid also encompasses substantially identical nucleic acids and complements thereof. A single strand provides a probe that may hybridize to a target sequence under stringent hybridization conditions. Thus, a nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions.

[0155] Nucleic acids may be single stranded or double stranded, or may contain portions of both double stranded and single stranded sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods.

q. Operably Linked

[0156] "Operably linked" as used herein may mean that expression of a gene is under the control of a promoter with which it is spatially connected. A promoter may be positioned 5' (upstream) or 3' (downstream) of a gene under its control. The distance between the promoter and a gene may be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance may be accommodated without loss of promoter function.

r. Promoter

[0157] "Promoter" as used herein may mean a synthetic or naturally-derived molecule which is capable of conferring, activating or enhancing expression of a nucleic acid in a cell. A promoter may comprise one or more specific transcriptional regulatory sequences to further enhance expression and/or to alter the spatial expression and/or temporal expression of same. A promoter may also comprise distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A promoter may be derived from sources including viral, bacterial, fungal, plants, insects, and animals. A promoter may regulate the expression of a gene component constitutively, or differentially with respect to cell, the tissue

or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal ions, or inducing agents. Representative examples of promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV40 late promoter and the CMV IE promoter.

s. Stringent Hybridization Conditions

[0158] "Stringent hybridization conditions" as used herein may mean conditions under which a first nucleic acid sequence (e.g., probe) will hybridize to a second nucleic acid sequence (e.g., target), such as in a complex mixture of nucleic acids. Stringent conditions are sequence-dependent and will be different in different circumstances. Stringent conditions may be selected to be about 5-10° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm may be the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions may be those in which the salt concentration is less than about 1.0 M sodium ion, such as about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g., about 10-50 nucleotides) and at least about 60° C. for long probes (e.g., greater than about 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal may be at least 2 to 10 times background hybridization. Exemplary stringent hybridization conditions include the following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42° C., or, 5×SSC, 1% SDS, incubating at 65° C., with wash in 0.2×SSC, and 0.1% SDS at 65° C.

t. Substantially Complementary

[0159] "Substantially complementary" as used herein may mean that a first sequence is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the complement of a second sequence over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more nucleotides or amino acids, or that the two sequences hybridize under stringent hybridization conditions.

u. Substantially Identical

[0160] "Substantially identical" as used herein may mean that a first and second sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more nucleotides or amino acids, or with respect to nucleic acids, if the first sequence is substantially complementary to the complement of the second sequence.

v. Variant

[0161] "Variant" used herein with respect to a nucleic acid may mean (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or portion thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or the

complement thereof; or (iv) a nucleic acid that hybridizes under stringent conditions to the referenced nucleic acid, complement thereof, or a sequences substantially identical thereto.

[0162] "Variant" with respect to a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Variant may also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., J. Mol. Biol. 157:105-132 (1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indexes of 2 are substituted. The hydrophilicity of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. U.S. Pat. No. 4,554,101, incorporated fully herein by reference. Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity, as is understood in the art. Substitutions may be performed with amino acids having hydrophilicity values within  $\pm 2$  of each other. Both the hydrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity, hydrophilicity, charge, size, and other properties. Variants are preferably homologous to SEQ ID NO:1-6, 67-68 by 95% or more, 96% or more, 97% or more, 98% or more or 99% or more.

[0163] "Variant" with respect to a nucleic acid sequence that encodes the same specific amino acid sequence differs in nucleotide sequence by use of different codons. Variants of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 that encode the same amino acid sequence as those encoded by SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 may be any degree of homology, preferably 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more or 99% or more. Variants of RNA transcribed by SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 that encode the same amino acid sequence as those encoded by SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 may be any degree of homology, preferably 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more or 99% or more.

or more. Variant may also be variants of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 that encode protein which are variants of the proteins encoded by SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity, typically the amino acid sequences are homologous by 95% or more, 96% or more, 97% or more, 98% or more or 99% or more. Variant may also be variants of RNA transcribed by SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 that encode protein which are variants of the proteins encoded by the RNA transcribed by SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:70, or SEQ ID NO:72 with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity, typically the amino acid sequences are homologous by 95% or more, 96% or more, 97% or more, 98% or more or 99% or more

w. Vector

[0164] "Vector" used herein may mean a nucleic acid sequence containing an origin of replication. A vector may be a plasmid, bacteriophage, bacterial, viral vector, artificial chromosome or yeast artificial chromosome. A vector may be a DNA or RNA vector. A vector may be either a self-replicating extrachromosomal vector or a vector which integrates into a host genome.

## 2. Proteins

[0165] Provided herein are filovirus immunogens that can be used to induce broad immunity against multiple subtypes or serotypes of a particular filovirus antigen. Consensus filovirus antigens may include consensus amino acid sequences of Marburgvirus filovirus glycoprotein MARV RAV immunogen, consensus amino acid sequences of Marburgvirus filovirus glycoprotein MARV OZO immunogen, consensus amino acid sequences of Marburgvirus filovirus glycoprotein MARV MUS immunogen, isolate amino acid sequences of Marburgvirus filovirus glycoprotein MARV ANG immunogen, consensus amino acid sequences of Zaire ebolavirus glycoprotein ZEBOV immunogen, consensus amino acid sequences of Zaire ebolavirus glycoprotein ZEBOV2014 immunogen, isolate amino acid sequences of Zaire ebolavirus glycoprotein ZEBOVCON2 immunogen, and consensus amino acid sequences of Sudan ebolavirus glycoprotein SUDV immunogen, respectively. In some embodiments, the immunogens may comprise a signal peptide from a different protein such as an immunoglobulin protein, for example an IgE signal peptide or an IgG signal peptide.

[0166] The amino acid sequence for immunogens include SEQ ID NO:1-6, 67-68 variants thereof and fragments of SEQ ID NO:1-6, 67-68 and variants thereof, optionally including a signal peptide such as for example an IgE or IgG signal peptide.

## 3. Coding Sequences Encoding Proteins

[0167] Coding sequences encoding the proteins set forth herein may be generated using routine methods. Composition comprising a nucleic acid sequence that encodes a consensus Zaire ebolavirus envelope glycoprotein immuno-

gen, comprising a nucleic acid sequence that encodes a second consensus Zaire ebolavirus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen envelope glycoprotein immunogen, a nucleic acid sequence that encodes a consensus Sudan ebolavirus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen are provided and a nucleic acid sequence that encodes a first consensus Marburg marburgvirus envelope glycoprotein immunogen, a nucleic acid sequence that encodes a second consensus Marburg marburgvirus envelope glycoprotein immunogen, and a nucleic acid sequence that encodes a third consensus Marburg marburgvirus envelope glycoprotein immunogen can be generated based upon the amino acid sequences disclosed.

[0168] Nucleic acid sequence may encode a full length consensus Zaire ebolavirus envelope glycoprotein immunogen, a full length second consensus Zaire ebolavirus envelope glycoprotein immunogen, a full length consensus Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen envelope glycoprotein immunogen, a full length consensus Sudan ebolavirus envelope glycoprotein immunogen, a full length Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen, a full length first consensus Marburg marburgvirus envelope glycoprotein immunogen, a full length second consensus Marburg marburgvirus envelope glycoprotein immunogen, or a full length third consensus Marburg marburgvirus envelope glycoprotein immunogen. Nucleic acid sequences may comprise a sequence that encodes SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:67, or SEQ ID NO:68. Nucleic acid sequence may comprise SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69 SEQ ID NO:70, or SEQ ID NO:72. In one embodiment the nucleotide sequence comprises an RNA sequence transcribed from a DNA sequence described herein. For example, nucleic acids may comprise an RNA sequence transcribed by the DNA sequence of SEQ ID NOs: 64, 65, 66, 69, 70 or 72, a fragment thereof or a variant thereof. Nucleic acid sequence may optionally comprise coding sequences that encode a signal peptide such as for example an IgE or IgG signal peptide.

[0169] Nucleic acid sequence may encode a fragment of a full length consensus Zaire ebolavirus envelope glycoprotein immunogen, a fragment of a full length second consensus Zaire ebolavirus envelope glycoprotein immunogen, a fragment of a full length Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen envelope glycoprotein immunogen, a fragment of a full length consensus Sudan ebolavirus envelope glycoprotein immunogen, a fragment of a full length Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen, a fragment of a full length first consensus Marburg marburgvirus envelope glycoprotein immunogen, a fragment of a full length second consensus Marburg marburgvirus envelope glycoprotein immunogen, or a fragment of a full length third consensus Marburg marburgvirus envelope glycoprotein immunogen. Nucleic acid sequence may comprise a sequence that encodes a fragment of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:67, or SEQ ID NO:68. Nucleic acid sequence may comprise a fragment of SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69 SEQ ID NO:70, or SEQ ID

NO:72. Fragment sizes are disclosed herein as set forth in section entitled "Fragments". Nucleic acid sequence may optionally comprise coding sequences that encode a signal peptide such as for example an IgE or IgG signal peptide.

[0170] Nucleic acid sequences may encode a protein homologous to a full length consensus Zaire ebolavirus envelope glycoprotein immunogen, a full length second consensus Zaire ebolavirus envelope glycoprotein immunogen, a full length Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen envelope glycoprotein immunogen, a protein homologous to a full length consensus Sudan ebolavirus envelope glycoprotein immunogen, a protein homologous to a full length Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen, a protein homologous to a full length first consensus Marburg marburgvirus envelope glycoprotein immunogen, a protein homologous to a full length second consensus Marburg marburgvirus envelope glycoprotein immunogen, or a protein homologous to a full length third consensus Marburg marburgvirus envelope glycoprotein immunogen. Nucleic acid sequence may comprise a sequence that encodes a protein homologous to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:67, or SEQ ID NO:68. Nucleic acid sequence may be homologous to SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69 SEQ ID NO:70, or SEQ ID NO:72. Degrees of homology are discussed herein such as in the section referring to Variants. Nucleic acid sequence may optionally comprise coding sequences that encode a signal peptide such as for example an IgE or IgG signal peptide.

[0171] Nucleic acid sequence may encode a protein homologous to fragment of a full length consensus Zaire ebolavirus envelope glycoprotein immunogen, a protein homologous to fragment of a full length second consensus Zaire ebolavirus envelope glycoprotein immunogen, a protein homologous to fragment of a full length Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, a protein homologous to a fragment of a full length consensus Sudan ebolavirus envelope glycoprotein immunogen, a protein homologous to a fragment of a full length Marburg marburgvirus Angola 2005 envelope glycoprotein immunogen, a protein homologous to a fragment of a full length first consensus Marburg marburgvirus envelope glycoprotein immunogen, a protein homologous to a fragment of a full length second consensus Marburg marburgvirus envelope glycoprotein immunogen, or a protein homologous to a fragment of a full length third consensus Marburg marburgvirus envelope glycoprotein immunogen. Nucleic acid sequence may comprise a sequence that encodes a protein homologous to a fragment of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:67, or SEQ ID NO:68. Nucleic acid sequence may comprise a fragment homologous to SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:69 SEQ ID NO:70, or SEQ ID NO:72. Degrees of homology are discussed herein such as in the section referring to Variants. Nucleic acid sequence may optionally comprise coding sequences that encode a signal peptide such as for example an IgE or IgG signal peptide.

[0172] SEQ ID NO:64 is the nucleotide sequence insert in plasmid pEBOZ which encodes consensus Zaire ebolavirus envelope glycoprotein immunogen.

[0173] SEQ ID NO:65 is the nucleotide sequence insert in plasmid pEBOS which encodes consensus Sudan ebolavirus envelope glycoprotein immunogen.

[0174] SEQ ID NO:66 is the nucleotide sequence insert in plasmid pMARZ ANG which encodes the Marburg marburgvirus Angola 2005 envelope glycoprotein.

[0175] SEQ ID NO:69 is the nucleotide sequence insert in plasmid pEBOZGUI which encodes consensus Zaire ebolavirus GP envelope glycoprotein immunogen

[0176] SEQ ID NO:70 is the nucleotide sequence insert in plasmid pEBOZCON2 which encodes a second consensus Zaire ebolavirus envelope glycoprotein

#### 4. Vectors

[0177] Vectors include, but are not limited to, plasmids, expression vectors, recombinant viruses, any form of recombinant “naked DNA” vector, and the like. A “vector” comprises a nucleic acid which can infect, transfect, transiently or permanently transduce a cell. It will be recognized that a vector can be a naked nucleic acid, or a nucleic acid complexed with protein or lipid. The vector optionally comprises viral or bacterial nucleic acids and/or proteins, and/or membranes (e.g., a cell membrane, a viral lipid envelope, etc.). Vectors include, but are not limited to replicons (e.g., RNA replicons, bacteriophages) to which fragments of DNA may be attached and become replicated. Vectors thus include, but are not limited to RNA, autonomous self-replicating circular or linear DNA or RNA (e.g., plasmids, viruses, and the like, see, e.g., U.S. Pat. No. 5,217,879), and include both the expression and non-expression plasmids. Where a recombinant microorganism or cell culture is described as hosting an “expression vector” this includes both extra-chromosomal circular and linear DNA and DNA that has been incorporated into the host chromosome(s). Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host’s genome.

##### a. Plasmid

[0178] Plasmid may comprise a nucleic acid sequence that encodes one or more of the various immunogens disclosed above including coding sequences that encode synthetic, consensus antigen capable of eliciting an immune response against filoproteins.

[0179] A single plasmid may contain coding sequence for a single filoprotein immunogen, coding sequence for two filoprotein immunogens, coding sequence for three filoprotein immunogens, coding sequence for four filoprotein immunogens, coding sequence for five filoprotein immunogens or coding sequence for six filoprotein immunogens. A single plasmid may contain a coding sequence for a single filoprotein immunogen which can be formulated together. In some embodiments, a plasmid may comprise coding sequence that encodes IL-12, IL-15 and/or IL-28.

[0180] The plasmid may further comprise an initiation codon, which may be upstream of the coding sequence, and a stop codon, which may be downstream of the coding sequence. The initiation and termination codon may be in frame with the coding sequence.

[0181] The plasmid may also comprise a promoter that is operably linked to the coding sequence. The promoter operably linked to the coding sequence may be a promoter from simian virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV)

promoter such as the bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter, Epstein Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. The promoter may also be a promoter from a human gene such as human actin, human myosin, human hemoglobin, human muscle creatine, or human metallothionein. The promoter may also be a tissue specific promoter, such as a muscle or skin specific promoter, natural or synthetic. Examples of such promoters are described in US patent application publication no. US20040175727, the contents of which are incorporated herein in its entirety.

[0182] The plasmid may also comprise a polyadenylation signal, which may be downstream of the coding sequence. The polyadenylation signal may be a SV40 polyadenylation signal, LTR polyadenylation signal, bovine growth hormone (bGH) polyadenylation signal, human growth hormone (hGH) polyadenylation signal, or human β-globin polyadenylation signal. The SV40 polyadenylation signal may be a polyadenylation signal from a pCEP4 plasmid (Invitrogen, San Diego, CA).

[0183] The plasmid may also comprise an enhancer upstream of the coding sequence. The enhancer may be human actin, human myosin, human hemoglobin, human muscle creatine or a viral enhancer such as one from CMV, FMDV, RSV or EBV. Polynucleotide function enhances are described in U.S. Pat. Nos. 5,593,972, 5,962,428, and WO94/016737, the contents of each are fully incorporated by reference.

[0184] The plasmid may also comprise a mammalian origin of replication in order to maintain the plasmid extrachromosomally and produce multiple copies of the plasmid in a cell. The plasmid may be pVAX1, pCEP4 or pREP4 from Invitrogen (San Diego, CA), which may comprise the Epstein Barr virus origin of replication and nuclear antigen EBNA-1 coding region, which may produce high copy episomal replication without integration. The backbone of the plasmid may be pAV0242. The plasmid may be a replication defective adenovirus type 5 (Ad5) plasmid.

[0185] The plasmid may also comprise a regulatory sequence, which may be well suited for gene expression in a cell into which the plasmid is administered. The coding sequence may comprise a codon that may allow more efficient transcription of the coding sequence in the host cell.

[0186] The coding sequence may also comprise an Ig leader sequence. The leader sequence may be 5' of the coding sequence. The consensus antigens encoded by this sequence may comprise an N-terminal Ig leader followed by a consensus antigen protein. The N-terminal Ig leader may be IgE or IgG.

[0187] The plasmid may be pSE420 (Invitrogen, San Diego, Calif.), which may be used for protein production in *Escherichia coli* (*E. coli*). The plasmid may also be pYES2 (Invitrogen, San Diego, Calif.), which may be used for protein production in *Saccharomyces cerevisiae* strains of yeast. The plasmid may also be of the MAXBAC™ complete baculovirus expression system (Invitrogen, San Diego, Calif.), which may be used for protein production in insect cells. The plasmid may also be pcDNA I or pcDNA3 (Invitrogen, San Diego, Calif), which may be used for protein production in mammalian cells such as Chinese hamster ovary (CHO) cells.

**b. RNA Vectors**

[0188] In one embodiment, the nucleic acid is an RNA molecule. Accordingly, in one embodiment, the invention provides an RNA molecule encoding one or more of the envelope glycoprotein (GP) genes of Marburg marburgvirus (MARV), Sudan ebolavirus (SUDV) or Zaire ebolavirus (ZEBOV). The RNA may be plus-stranded. Accordingly, in some embodiments, the RNA molecule can be translated by cells without needing any intervening replication steps such as reverse transcription. A RNA molecule useful with the invention may have a 5' cap (e.g. a 7-methylguanosine). This cap can enhance in vivo translation of the RNA. The 5' nucleotide of a RNA molecule useful with the invention may have a 5' triphosphate group. In a capped RNA this may be linked to a 7-methylguanosine via a 5'-to-5' bridge. A RNA molecule may have a 3' poly-A tail. It may also include a poly-A polymerase recognition sequence (e.g. AAUAAA) near its 3' end. A RNA molecule useful with the invention may be single-stranded.

**c. Linear Vectors**

[0189] Also provided herein is a linear nucleic acid vaccine, or linear expression cassette ("LEC"), that is capable of being efficiently delivered to a subject via electroporation and expressing one or more desired antigens. The LEC may be any linear DNA devoid of any phosphate backbone. The DNA may encode one or more antigens. The LEC may contain a promoter, an intron, a stop codon, a polyadenylation signal. The expression of the antigen may be controlled by the promoter. The LEC may not contain any antibiotic resistance genes and/or a phosphate backbone. The LEC may not contain other nucleic acid sequences unrelated to the desired antigen gene expression.

[0190] The LEC may be derived from any plasmid capable of being linearized. The plasmid may be capable of expressing the antigen. The plasmid may be pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing the DNA and enabling a cell to translate the sequence to an antigen that is recognized by the immune system.

[0191] The LEC may be derived from any plasmid capable of being linearized. The plasmid may be capable of expressing the antigen. The plasmid may be pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing the DNA and enabling a cell to translate the sequence to a antigen that is recognized by the immune system.

**d. Viral Vectors**

[0192] In one embodiment, viral vectors are provided herein which are capable of delivering a nucleic acid of the invention to a cell. The expression vector may be provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et al. (2001), and in Ausubel et al. (1997), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. In general, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers. (See, e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193. Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., human cells. Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex

virus I, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Pat. Nos. 5,350,674 and 5,585,362.

**5. Compositions**

[0193] Compositions are provided which comprise nucleic acid molecules. The compositions may comprise a plurality of copies of a single nucleic acid molecule such a single plasmid, a plurality of copies of two or more different nucleic acid molecules such as two or more different plasmids. For example a composition may comprise plurality of two, three, four, five, six, seven, eight, nine or ten or more different nucleic acid molecules. Such compositions may comprise plurality of two, three, four, five, six, or more different plasmids.

[0194] Compositions may comprise nucleic acid molecules, such as plasmids, that collectively contain coding sequence for a single filoprotein immunogen selected from the group consisting of one or more a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebolavirus envelope glycoprotein immunogen, a Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen.

[0195] Composition comprise nucleic acid sequence that encode the combination of: a consensus Zaire ebolavirus envelope glycoprotein immunogen and a consensus Sudan ebolavirus envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen and a second consensus Zaire ebolavirus envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen and a Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen and the Marburg marburgvirus Angola 2005 envelope glycoprotein; or a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen and the second consensus Zaire ebolavirus envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen and the Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebolavirus envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen, a Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen; or a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, a consensus



any permutation or on five plasmids in any permutation but are preferably on six separate plasmids.

[0205] Compositions that comprise nucleic acid sequence that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen may be on a single plasmid or on two plasmids in any permutation, or on three plasmids in any permutation or on four plasmids in any permutation or on five plasmids in any permutation or on six plasmids in any permutation but are preferably on seven separate plasmids.

[0206] Compositions that comprise nucleic acid sequence that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, the Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen may be on a single plasmid or on two plasmids in any permutation, or on three plasmids in any permutation or on four plasmids in any permutation or on five plasmids in any permutation or on six plasmids in any permutation but are preferably on seven separate plasmids.

[0207] Likewise, compositions that comprise nucleic acid sequence that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebolavirus envelope glycoprotein immunogen, the Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen may be on a single plasmid or on two plasmids in any permutation, or on three plasmids in any permutation or on four plasmids in any permutation or on five plasmids in any permutation or on six plasmids in any permutation or on seven plasmids in any permutation but are preferably on eight separate plasmids.

## 6. Vaccine

[0208] Provided herein is a vaccine capable of generating in a mammal an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and/or Ebolavirus Zaire. The vaccine may comprise each plasmid as discussed above. The vaccine may comprise a plurality of the plasmids, or combinations thereof. The vaccine may be provided to induce a therapeutic or prophylactic immune response.

[0209] Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen and a consensus Sudan ebolavirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen,

and a Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen and a second consensus Zaire ebola virus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen and a second consensus Zaire ebola virus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen and the Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen and the Marburg marburgvirus Angola 2005 envelope glycoprotein. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebola virus envelope glycoprotein immunogen and the Marburg marburgvirus Angola 2005 envelope glycoprotein. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen and the Marburg marburgvirus Angola 2005 envelope glycoprotein. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebola virus envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a Zaire ebolavirus 2014 envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a Consensus Zaire ebolavirus

Zaire ebolavirus Guinea envelope glycoprotein immunogen, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebola virus envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, the Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines may be used to deliver nucleic acid molecules that encode a consensus Zaire ebolavirus envelope glycoprotein immunogen, a second consensus Zaire ebola virus envelope glycoprotein immunogen, the Consensus Zaire ebolavirus Guinea envelope glycoprotein immunogen, a consensus Sudan ebolavirus envelope glycoprotein immunogen, the Marburg marburgvirus Angola 2005 envelope glycoprotein, the first consensus Marburg marburgvirus envelope glycoprotein immunogen, the second consensus Marburg marburgvirus envelope glycoprotein immunogen and the third consensus Marburg marburgvirus envelope glycoprotein immunogen. Vaccines are preferably compositions comprising plasmids.

**[0210]** The vaccine may further comprise a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient may be functional molecules as vehicles, adjuvants, carriers, or diluents. The pharmaceutically acceptable excipient may be a transfection facilitating agent, which may include surface active agents, such as immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs, vesicles such as squalene and squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents.

**[0211]** The transfection facilitating agent is a polyanion, polycation, including poly-L-glutamate (LGS), or lipid. The transfection facilitating agent is poly-L-glutamate, and more preferably, the poly-L-glutamate is present in the vaccine at a concentration less than 6 mg/ml. The transfection facilitating agent may also include surface active agents such as

immune-stimulating complexes (ISCOMS), Freunds incomplete adjuvant, LPS analog including monophosphoryl lipid A, muramyl peptides, quinone analogs and vesicles such as squalene and squalene, and hyaluronic acid may also be used administered in conjunction with the genetic construct. In some embodiments, the DNA plasmid vaccines may also include a transfection facilitating agent such as lipids, liposomes, including lecithin liposomes or other liposomes known in the art, as a DNA-liposome mixture (see for example WO9324640), calcium ions, viral proteins, poly-anions, polycations, or nanoparticles, or other known transfection facilitating agents. Preferably, the transfection facilitating agent is a polyanion, polycation, including poly-L-glutamate (LGS), or lipid. Concentration of the transfection agent in the vaccine is less than 4 mg/ml, less than 2 mg/ml, less than 1 mg/ml, less than 0.750 mg/ml, less than 0.500 mg/ml, less than 0.250 mg/ml, less than 0.100 mg/ml, less than 0.050 mg/ml, or less than 0.010 mg/ml.

**[0212]** The pharmaceutically acceptable excipient may be one or more adjuvants. An adjuvant may be other genes that are expressed from the same or from an alternative plasmid or are delivered as proteins in combination with the plasmid above in the vaccine. The one or more adjuvants may be proteins and/or nucleic acid molecules that encode proteins selected from the group consisting of: CCL20,  $\alpha$ -interferon (IFN- $\alpha$ ),  $\beta$ -interferon (IFN- $\beta$ ),  $\gamma$ -interferon, platelet derived growth factor (PDGF), TNF $\alpha$ , TNF $\beta$ , GM-CSF, epidermal growth factor (EGF), cutaneous T cell-attracting chemokine (CTACK), epithelial thymus-expressed chemokine (TECK), mucosae-associated epithelial chemokine (MEC), IL-12, IL-15 including IL-15 having the signal sequence or coding sequence that encodes the signal sequence deleted and optionally including a different signal peptide such as that from IgE or coding sequence that encodes a difference signal peptide such as that from IgE, IL-28, MHC, CD80, CD86, IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-18, MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , IL-8, L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, MadCAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF, G-CSF, mutant forms of IL-18, CD40, CD40L, vascular growth factor, fibroblast growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGFR, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, I $\kappa$ B, Inactive NIK, SAPK, SAP-1, INK, interferon response genes, NF $\kappa$ B, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof or a combination thereof. In some embodiments adjuvant may be one or more proteins and/or nucleic acid molecules that encode proteins selected from the group consisting of: CCL-20, IL-12, IL-15, IL-28, CTACK, TECK, MEC or RANTES. Examples of IL-12 constructs and sequences are disclosed in PCT application no. PCT/US1997/019502 and corresponding U.S. application Ser. No. 08/956,865, and U.S. Provisional Application Ser. No. 61/569,600 filed Dec. 12, 2011, which are each incorporated herein by reference. Examples of IL-15 constructs and sequences are disclosed in PCT application no. PCT/US04/18962 and corresponding U.S. application Ser. No. 10/560,650, and in PCT application no. PCT/US07/00886 and

corresponding U.S. application Ser. No. 12/160,766, and in PCT application no. PCT/US10/048827, which are each incorporated herein by reference. Examples of IL-28 constructs and sequences are disclosed in PCT application no. PCT/US09/039648 and corresponding U.S. application Ser. No. 12/936,192, which are each incorporated herein by reference. Examples of RANTES and other constructs and sequences are disclosed in PCT application no. PCT/US1999/004332 and corresponding U.S. Application Serial No. and 09/622452, which are each incorporated herein by reference. Other examples of RANTES constructs and sequences are disclosed in PCT application no. PCT/US Serial No. 11/024098, which is incorporated herein by reference. Examples of RANTES and other constructs and sequences are disclosed in PCT application no. PCT/US1999/004332 and corresponding U.S. application Ser. No. 09/622,452, which are each incorporated herein by reference. Other examples of RANTES constructs and sequences are disclosed in PCT application no. PCT/US11/024098, which is incorporated herein by reference. Examples of chemokines CTACK, TECK and MEC constructs and sequences are disclosed in PCT application no. PCT/US2005/042231 and corresponding U.S. application Ser. No. 11/719,646, which are each incorporated herein by reference. Examples of OX40 and other immunomodulators are disclosed in U.S. application Ser. No. 10/560,653, which is incorporated herein by reference. Examples of DR5 and other immunomodulators are disclosed in U.S. application Ser. No. 09/622,452, which is incorporated herein by reference.

[0213] The vaccine may further comprise a genetic vaccine facilitator agent as described in U.S. Serial No. 021,579 filed Apr. 1, 1994, which is fully incorporated by reference.

[0214] The vaccine may comprise the consensus antigens and plasmids at quantities of from about 1 nanogram to 100 milligrams; about 1 microgram to about 10 milligrams; or preferably about 0.1 microgram to about 10 milligrams; or more preferably about 1 milligram to about 2 milligram. In some preferred embodiments, pharmaceutical compositions according to the present invention comprise about 5 nanogram to about 1000 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 10 nanograms to about 800 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 0.1 to about 500 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 1 to about 350 micrograms of DNA. In some preferred embodiments, the pharmaceutical compositions contain about 25 to about 250 micrograms, from about 100 to about 200 microgram, from about 1 nanogram to 100 milligrams; from about 1 microgram to about 10 milligrams; from about 0.1 microgram to about 10 milligrams; from about 1 milligram to about 2 milligram, from about 5 nanogram to about 1000 micrograms, from about 10 nanograms to about 800 micrograms, from about 0.1 to about 500 micrograms, from about 1 to about 350 micrograms, from about 25 to about 250 micrograms, from about 100 to about 200 microgram of the consensus antigen or plasmid thereof.

[0215] The vaccine may be formulated according to the mode of administration to be used. An injectable vaccine pharmaceutical composition may be sterile, pyrogen free and particulate free. An isotonic formulation or solution may be used. Additives for isotonicity may include sodium chloride, dextrose, mannitol, sorbitol, and lactose. The vac-

cine may comprise a vasoconstriction agent. The isotonic solutions may include phosphate buffered saline. Vaccine may further comprise stabilizers including gelatin and albumin. The stabilizing may allow the formulation to be stable at room or ambient temperature for extended periods of time such as LGS or polycations or polyanions to the vaccine formulation.

[0216] The vaccine may be stable for is stable at room temperature (25° C.) for more than 1 week, in some embodiments for more than 2 weeks, in some embodiments for more than 3 weeks, in some embodiments for more than 4 weeks, in some embodiments for more than 5 weeks, and in some embodiments for more than 6 weeks. In some embodiments, the vaccine is stable for more than one month, more than 2 months, more than 3 months, more than 4 months, more than 5 months, more than 6 months, more than 7 months, more than 8 months, more than 9 months, more than 10 months, more than 11 months, or more than 12 months. In some embodiments, the vaccine is stable for more than 1 year, more than 2 years, more than years, or more than 5 years. In one embodiment, the vaccine is stable under refrigeration (2-8° C.). Accordingly, in one embodiment, the vaccine does not require frozen cold-chain. A vaccine is stable if it retains its biological activity for a sufficient period to allow its intended use (e.g., to generate an immune response in a subject). For example, for vaccines that are to be stored, shipped, etc., it may be desired that the vaccines remain stable for months to years.

## 7. Methods of Delivery the Vaccine

[0217] Provided herein is a method for delivering the vaccine for providing genetic constructs and proteins of the consensus antigen which comprise epitopes that make them particular effective against immunogens of filovirus, particularly Marburgvirus, Ebolavirus Sudan and/or Ebolavirus Zaire, against which an immune response can be induced. The method of delivering the vaccine or vaccination may be provided to induce a therapeutic and prophylactic immune response. The vaccination process may generate in the mammal an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and/or Ebolavirus Zaire. The vaccine may be delivered to an individual to modulate the activity of the mammal's immune system and enhance the immune response. The delivery of the vaccine may be the transfection of the consensus antigen as a nucleic acid molecule that is expressed in the cell and delivered to the surface of the cell upon which the immune system recognized and induces a cellular, humoral, or cellular and humoral response. The delivery of the vaccine may be used to induce or elicit an immune response in mammals against filovirus, particularly Marburgvirus, Ebolavirus Sudan and/or Ebolavirus Zaire by administering to the mammals the vaccine as discussed above.

[0218] Upon delivery of the vaccine and plasmid into the cells of the mammal, the transfected cells will express and secrete consensus antigens for each of the plasmids injected from the vaccine. These proteins will be recognized as foreign by the immune system and antibodies will be made against them. These antibodies will be maintained by the immune system and allow for an effective response to subsequent infections by filovirus, particularly Marburgvirus, Ebolavirus Sudan and/or Ebolavirus Zaire.

[0219] The vaccine may be administered to a mammal to elicit an immune response in a mammal. The mammal may

be human, primate, non-human primate, cow, cattle, sheep, goat, antelope, bison, water buffalo, bison, bovids, deer, hedgehogs, elephants, llama, alpaca, mice, rats, and chicken.

#### a. Combination Treatments

**[0220]** The vaccine may be administered in combination with other proteins and/or genes encoding CCL20,  $\alpha$ -interferon,  $\gamma$ -interferon, platelet derived growth factor (PDGF), TNF $\alpha$ , TNF $\beta$ , GM-CSF, epidermal growth factor (EGF), cutaneous T cell-attracting chemokine (CTACK), epithelial thymus-expressed chemokine (TECK), mucosae-associated epithelial chemokine (MEC), IL-12, IL-15 including IL-15 having the signal sequence deleted and optionally including the different signal peptide such as the IgE signal peptide, MHC, CD80, CD86, IL-28, IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-18, MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , IL-8, RANTES, L-selectin, P-selectin, E-selectin, CD34, GlyCAM-1, Mad-CAM-1, LFA-1, VLA-1, Mac-1, p150.95, PECAM, ICAM-1, ICAM-2, ICAM-3, CD2, LFA-3, M-CSF, G-CSF, mutant forms of IL-18, CD40, CD40L, vascular growth factor, fibroblast growth factor, IL-7, nerve growth factor, vascular endothelial growth factor, Fas, TNF receptor, Flt, Apo-1, p55, WSL-1, DR3, TRAMP, Apo-3, AIR, LARD, NGFR, DR4, DR5, KILLER, TRAIL-R2, TRICK2, DR6, Caspase ICE, Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive NIK, SAP K, SAP-1, INK, interferon response genes, NFKB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAP1, TAP2 and functional fragments thereof or combinations thereof. In some embodiments, the vaccine is administered in combination with one or more of the following nucleic acid molecules and/or proteins: nucleic acid molecules selected from the group consisting of nucleic acid molecules comprising coding sequence that encode one or more of CCL20, IL-12, IL-15, IL-28, CTACK, TECK, MEC and RANTES or functional fragments thereof, and proteins selected from the group consisting of: CCL02, IL-12 protein, IL-15 protein, IL-28 protein, CTACK protein, TECK protein, MEC protein or RANTES protein or functional fragments thereof.

**[0221]** The vaccine may be administered by different routes including orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, intrapleurally, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intranasal, intrathecal, and intraarticular or combinations thereof. For veterinary use, the composition may be administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal. The vaccine may be administered by traditional syringes, needleless injection devices, "microparticle bombardment gene guns", or other physical methods such as electroporation ("EP"), "hydrodynamic method", or ultrasound.

**[0222]** The plasmid of the vaccine may be delivered to the mammal by several well-known technologies including DNA injection (also referred to as DNA vaccination) with and without in vivo electroporation, liposome mediated, nanoparticle facilitated, recombinant vectors such as recombinant adenovirus, recombinant adenovirus associated virus and recombinant vaccinia. The consensus antigen may be delivered via DNA injection and along with in vivo electroporation.

#### b. Electroporation

**[0223]** Administration of the vaccine via electroporation of the plasmids of the vaccine may be accomplished using electroporation devices that can be configured to deliver to a desired tissue of a mammal a pulse of energy effective to cause reversible pores to form in cell membranes, and preferable the pulse of energy is a constant current similar to a preset current input by a user. The electroporation device may comprise an electroporation component and an electrode assembly or handle assembly. The electroporation component may include and incorporate one or more of the various elements of the electroporation devices, including: controller, current waveform generator, impedance tester, waveform logger, input element, status reporting element, communication port, memory component, power source, and power switch. The electroporation may be accomplished using an *in vivo* electroporation device, for example CELLECTRA EP system (VGX Pharmaceuticals, Blue Bell, PA) or Elgen electroporator (Genetronics, San Diego, CA) to facilitate transfection of cells by the plasmid.

**[0224]** The electroporation component may function as one element of the electroporation devices, and the other elements are separate elements (or components) in communication with the electroporation component. The electroporation component may function as more than one element of the electroporation devices, which may be in communication with still other elements of the electroporation devices separate from the electroporation component. The elements of the electroporation devices existing as parts of one electromechanical or mechanical device may not be limited as the elements can function as one device or as separate elements in communication with one another. The electroporation component may be capable of delivering the pulse of energy that produces the constant current in the desired tissue, and includes a feedback mechanism. The electrode assembly may include an electrode array having a plurality of electrodes in a spatial arrangement, wherein the electrode assembly receives the pulse of energy from the electroporation component and delivers same to the desired tissue through the electrodes. At least one of the plurality of electrodes is neutral during delivery of the pulse of energy and measures impedance in the desired tissue and communicates the impedance to the electroporation component. The feedback mechanism may receive the measured impedance and can adjust the pulse of energy delivered by the electroporation component to maintain the constant current.

**[0225]** A plurality of electrodes may deliver the pulse of energy in a decentralized pattern. The plurality of electrodes may deliver the pulse of energy in the decentralized pattern through the control of the electrodes under a programmed sequence, and the programmed sequence is input by a user to the electroporation component. The programmed sequence may comprise a plurality of pulses delivered in sequence, wherein each pulse of the plurality of pulses is delivered by at least two active electrodes with one neutral electrode that measures impedance, and wherein a subsequent pulse of the plurality of pulses is delivered by a different one of at least two active electrodes with one neutral electrode that measures impedance.

**[0226]** The feedback mechanism may be performed by either hardware or software. The feedback mechanism may be performed by an analog closed-loop circuit. The feedback occurs every 50 s, 20 s, 10 ps or 1 ps, but is preferably a real-time feedback or instantaneous (i.e., substantially

instantaneous as determined by available techniques for determining response time). The neutral electrode may measure the impedance in the desired tissue and communicates the impedance to the feedback mechanism, and the feedback mechanism responds to the impedance and adjusts the pulse of energy to maintain the constant current at a value similar to the preset current. The feedback mechanism may maintain the constant current continuously and instantaneously during the delivery of the pulse of energy.

[0227] Examples of electroporation devices and electroporation methods that may facilitate delivery of the DNA vaccines of the present invention, include those described in U.S. Pat. No. 7,245,963 by Draghia-Akli, et al., U.S. Patent Pub. 2005/0052630 submitted by Smith, et al., the contents of which are hereby incorporated by reference in their entirety. Other electroporation devices and electroporation methods that may be used for facilitating delivery of the DNA vaccines include those provided in co-pending and co-owned U.S. patent application Ser. No. 11/874,072, filed Oct. 17, 2007, which claims the benefit under 35 USC 119(e) to U.S. Provisional Applications Ser. No. 60/852,149, filed Oct. 17, 2006, and 60/978,982, filed Oct. 10, 2007, all of which are hereby incorporated in their entirety.

[0228] U.S. Pat. No. 7,245,963 by Draghia-Akli, et al. describes modular electrode systems and their use for facilitating the introduction of a biomolecule into cells of a selected tissue in a body or plant. The modular electrode systems may comprise a plurality of needle electrodes; a hypodermic needle; an electrical connector that provides a conductive link from a programmable constant-current pulse controller to the plurality of needle electrodes; and a power source. An operator can grasp the plurality of needle electrodes that are mounted on a support structure and firmly insert them into the selected tissue in a body or plant. The biomolecules are then delivered via the hypodermic needle into the selected tissue. The programmable constant-current pulse controller is activated and constant-current electrical pulse is applied to the plurality of needle electrodes. The applied constant-current electrical pulse facilitates the introduction of the biomolecule into the cell between the plurality of electrodes. The entire content of U.S. Pat. No. 7,245,963 is hereby incorporated by reference.

[0229] U.S. Patent Pub. 2005/0052630 submitted by Smith, et al. describes an electroporation device which may be used to effectively facilitate the introduction of a biomolecule into cells of a selected tissue in a body or plant. The electroporation device comprises an electro-kinetic device ("EKD device") whose operation is specified by software or firmware. The EKD device produces a series of programmable constant-current pulse patterns between electrodes in an array based on user control and input of the pulse parameters, and allows the storage and acquisition of current waveform data. The electroporation device also comprises a replaceable electrode disk having an array of needle electrodes, a central injection channel for an injection needle, and a removable guide disk. The entire content of U.S. Patent Pub. 2005/0052630 is hereby incorporated by reference.

[0230] The electrode arrays and methods described in U.S. Pat. No. 7,245,963 and U.S. Patent Pub. 2005/0052630 may be adapted for deep penetration into not only tissues such as muscle, but also other tissues or organs. Because of the configuration of the electrode array, the injection needle (to deliver the biomolecule of choice) is also inserted com-

pletely into the target organ, and the injection is administered perpendicular to the target issue, in the area that is pre-delineated by the electrodes. The electrodes described in U.S. Pat. No. 7,245,963 and U.S. Patent Pub. 2005/005263 are preferably 20 mm long and 21 gauge.

[0231] Additionally, contemplated in some embodiments that incorporate electroporation devices and uses thereof, there are electroporation devices that are those described in the following patents: U.S. Pat. No. 5,273,525 issued Dec. 28, 1993, U.S. Pat. No. 6,110,161 issued Aug. 29, 2000, U.S. Pat. No. 6,261,281 issued Jul. 17, 2001, and U.S. Pat. No. 6,958,060 issued Oct. 25, 2005, and U.S. Pat. No. 6,939,862 issued Sep. 6, 2005. Furthermore, patents covering subject matter provided in U.S. Pat. No. 6,697,669 issued Feb. 24, 2004, which concerns delivery of DNA using any of a variety of devices, and U.S. Pat. No. 7,328,064 issued Feb. 5, 2008, drawn to method of injecting DNA are contemplated herein. The above-patents are incorporated by reference in their entirety.

#### c. Method of Preparing DNA Plasmids

[0232] Provided herein is methods for preparing the DNA plasmids that comprise the DNA vaccines discussed herein. The DNA plasmids, after the final subcloning step into the mammalian expression plasmid, can be used to inoculate a cell culture in a large scale fermentation tank, using known methods in the art.

[0233] The DNA plasmids for use with the EP devices of the present invention can be formulated or manufactured using a combination of known devices and techniques, but preferably they are manufactured using an optimized plasmid manufacturing technique that is described in a licensed, co-pending U.S. provisional application U.S. Ser. No. 60/939,792, which was filed on May 23, 2007. In some examples, the DNA plasmids used in these studies can be formulated at concentrations greater than or equal to 10 mg/mL. The manufacturing techniques also include or incorporate various devices and protocols that are commonly known to those of ordinary skill in the art, in addition to those described in U.S. Ser. No. 60/939,792, including those described in a licensed patent, U.S. Pat. No. 7,238,522, which issued on Jul. 3, 2007. The above-referenced application and patent, U.S. Ser. No. 60/939,792 and U.S. Pat. No. 7,238,522, respectively, are hereby incorporated in their entirety.

### EXAMPLES

[0234] The present invention is further illustrated in the following Example. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

## Example 1

## Methods

## Plasmid Vaccine Construction

[0235] The pMARV, pEBOS, and pEBOZ plasmid DNA constructs encode full-length GP proteins. An amino acid consensus strategy was used for the pEBOS and pEBOZ, while a type-matched sequence from the 2005 Angola outbreak strain was used (GenBank #VGP\_MABVR) for pMARV (Towner J S, et al. (2006). Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. *J Virol* 80: 6497-6516). Consensus sequences were determined by alignment of the prevailing ZEBOV and SUDV GP amino acid sequences and generating a consensus for each. Each vaccine GP gene was genetically optimized for expression in humans (including codon- and RNA-optimization for enhancing protein expression (GenScript, Piscataway, NJ)), synthesized commercially, and then sub-cloned (GenScript, Piscataway, NJ) into modified pVAX1 mammalian expression vectors (Invitrogen, Carlsbad, CA) under the control of the cytomegalovirus immediate-early (CMV) promoter; modifications include 2A>C, 3C>T, 4T>G, 241C>G, 1,942C>T, 2,876A>-, 3,277C>T, and 3,753G>C. Phylogenetic analysis was performed by multiple-alignment with ClustalW using MEGA version 5 software. Alternatively, GP diversity among the MARV was much higher (~70% identity) in comparison, so a consensus strategy was not adopted. For coverage of MARV, we chose to utilize the MGP sequence from the 2005 outbreak in Angola (GenBank #VGP\_MABVR) since it was solely responsible for the largest and deadliest MARV outbreak to date. This sequence was greater than 10% divergent from either of its closest cluster of relative strains including Musoke, Popp and Leiden (10.6% divergence), or Uganda (01Uga07), Durba (05DRC99 and 07DRC99) and Ozolin (10.3% divergence). Altogether, a three-plasmid strategy formed the foundation for our novel trivalent polyvalent-filovirus vaccine strategy.

## Transfections and Immunoblotting

[0236] Human Embryonic Kidney (HEK) 293T cells were cultured, transfected, and harvested. Briefly, cells were grown in DMEM with 10% FBS, 1% Pen-strep, sodium pyruvate, and L-glutamine. Cells were cultured in 150 mm Corning dishes and grown to 70% confluence overnight in a 37° incubator with 5% CO<sub>2</sub>. Dishes were transfected with 10-25 µg of Filoviridae pDNA using either a Calphos™ Mammalian Transfection Kit protocol (Clonetech) or Lipofectamine™ 2000 reagent (Invitrogen) per the manufacturer's protocol and then incubated for 24-48 h. Cells were harvested with ice cold PBS, centrifuged and washed, and then pelleted for Western immunoblot or FACS analysis. Standard Western blotting was used and GP-specific MAbs for GP1 detection were generated. Data from Western immunoblotting experiments is shown in FIG. 1B. Data from FACS analysis is shown in FIG. 1C.

## Animals, Vaccinations, and Challenge

[0237] Adult female C57BL/6 (H-2<sup>b</sup>), BALB/cJ (H-2<sup>d</sup>), and Bl0.Br (H-2<sup>k</sup>) mice were purchased from The Jackson Laboratory (Bar Harbor, ME) while Hartley guinea pigs were from Charles River (Wilmington, MA). All animal

experimentation was conducted following UPenn IACUC and School of Medicine Animal Facility, or NML Institutional Animal Care Committee of the PHAC and the Canadian Council on Animal Care guidelines for housing and care of laboratory animals and performed in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of NIH after pertinent review and approval by the abovementioned institutions. UPenn and NML comply with NIH policy on animal welfare, the Animal Welfare Act, and all other applicable federal, state and local laws.

[0238] Mice were immunized i.m. by needle injection with 40 µg of plasmid resuspended in water, while guinea pigs were immunized i.d., with 200 µg of each into three separate vaccination sites. Vaccinations were immediately followed by EP at the same site. Briefly, a three-pronged CELLECTRA® adaptive constant current Minimally Invasive Device was inserted approximately 2 mm i.d. (Inovio Pharmaceuticals, Inc., Blue Bell, PA). Square-wave pulses were delivered through a triangular 3-electrode array consisting of 26-gauge solid stainless steel electrodes and two constant-current pulses of 0.1 Amps were delivered for 52 msec/pulse separated by a 1 sec delay.

[0239] For lethal challenge studies, challenges were limited to rodent-adapted ZEBOV and MARV. Guinea pigs were challenged 28 days after the final vaccination by i.p. injection with 1,000 LD<sub>50</sub> of guinea pig-adapted ZEBOV (21.3 FFU/animal) (Richardson J S, Abou M C, Tran K N, Kumar A, Sahai B M, Kobinger G P (2011). Impact of systemic or mucosal immunity to adenovirus on ad-based Ebola virus vaccine efficacy in guinea pigs. *J Infect Dis* 204 Suppl 3: S1032-1042) or 1,000 LD<sub>50</sub> MARV-Angola (681 TCID50/animal). Briefly, the guinea-pig adapted MARV was made by the serial passage of wild-type MARV-Angola in outbred adult female Hartley guinea pigs. Seven days after inoculation, the animals were euthanized and livers were harvested and homogenized.

[0240] This homogenate was then injected i.p. into naive adult guinea pigs and the process repeated until animals lost weight, gloss of hair, and succumbed to infection similar to EBOV adaptation in guinea pigs. For mouse lethal challenge studies (Kobinger G P, et al. (2006). Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. *Virology* 346: 394-401), mice were injected i.p. with 200 µl of a 1,000 LD<sub>50</sub> (10 FFU/animal) of mouse-adapted ZEBOV. All animals were weighed daily and monitored for disease progression using an approved score sheet for at least 18 days for mice and 22 days for guinea pigs. All infectious work was performed in a 'Biosafety Level 4' (BSL4) facility at NML, PHAC.

## ELISA and Neutralization Assays

[0241] Antibody (Ab) titers were determined using 96-well ELISA plates coated with either sucrose-purified MARV Ozolin G P or ZGP, or with negative control sucrose-purified Nipah G protein at a concentration of 1:2,000. Briefly, the plates were then incubated for 18 h at 4° C., washed with PBS and 0.1% Tween-20, and 100 µl/sample of the sera were tested in triplicate (at dilutions 1:100, 1:400, 1:1,600, and 1:6,400 in PBS with 5% skim milk and 0.5% Tween-20). Following an incubation at 37° C. for 1 h in a moist container, the plates were washed and then 100 µl of goat anti-mouse IgG-conjugated HRP antibody (Cedarlane) was added (1:2,000 dilution) and incubated for another 37°

C. for 1 h in a moist container. After a wash, 100 µl of the ABST (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) and peroxidase substrate (Cedarlane) was added to visualize Ab binding. Again in a moist container, the plate was incubated for 30 min at 37° C. and then later read at 405 nm. Positive binding results were characterized by being >3 SD when subtracting the positive control from the negative control serum.

**[0242]** The ZEBOV neutralization assay was performed. Briefly, Sera collected from immunized mice and guinea pigs were inactivated at 56° C. for 45 minutes and serial dilutions of each sample (1:20, 1:40, etc . . . , for mice and 1:50 for guinea pigs, in 50 µl of DMEM) was mixed with equal volume of ZEBOV expressing the EGFP reporter gene (ZEBOV-EGFP) (100 transducing units/well, according to EGFP expression) and incubated at 37° C. for 90 minutes. The mixture was then transferred onto sub-confluent VeroE6 cells in 96-well flat-bottomed plates and incubated for 5-10 minutes at RT. Control wells were infected with equal amounts of the ZEBOV-EGFP virus without addition of serum or with non-immune serum. 100 µl of DMEM supplemented with 20% FBS was then added to each well and plates were incubated at 37° C. in 5% CO<sub>2</sub> for 48 h.

**[0243]** Alternatively, neutralization of MARV-Angola 368 was assessed using an immunofluorescent assay. A primary rabbit anti-MARV Ab and secondary goat anti-rabbit IgG FITC-conjugated Ab was used for detection. Neutralizing Abs (NAb) against SUDV Boniface were assayed based on cytopathic effect (CPE) on CV-1 cells. Cells were incubated with equal parts of immunized sera and SUDV Boniface for 10 days before subsequently fixed with 10% buffered formalin for 24 hours and examined under a light microscope. EGFP and FITC positive cells were counted in each well and sample dilutions showing >50% reduction in the number of green cells compared to controls scored positive for NAb. Alternatively, NAb against SUDV-Boniface were assayed based on cytopathic effect (CPE) on CV-1 cells. All infectious work was performed in the BSL4 laboratory of NML, PHAC.

#### Splenocyte Isolation

**[0244]** Mice were sacrificed 8-11 days following the final immunization and the spleens were harvested. Briefly, spleens were placed in RPMI 1640 medium (Mediatech Inc., Manassas, VA) supplemented with 10% FBS, 1× Anti-anti (Invitrogen), and 1×β-ME (Invitrogen). Splenocytes were isolated by mechanical disruption of the spleen using a Stomacher machine (Seward Laboratory Systems Inc., Bohemia, NY), and the resulting product was filtered using a 40 µm cell strainer (BD Falcon). The cells were then treated for 5 min with ACK lysis buffer (Lonza, Switzerland) for lysis of RBCs, washed in PBS, and then resuspended in RPMI medium for use in ELISPOT or FACS assay.

#### ELISPOT Assays

**[0245]** Standard IFNγ ELISPOT assay was performed. Briefly, 96-well plates (Millipore, Billerica, MA) were coated with anti-mouse IFN-7 capture antibody and incubated for 24 h at 4° C. (R&D Systems, Minneapolis, MN). The following day, plates were washed with PBS and then blocked for 2 h with blocking buffer (1% BSA and 5% sucrose in PBS). Splenocytes (1-2×10<sup>5</sup> cells/well) were plated in triplicate and stimulated overnight at 37° C. in 5%

CO<sub>2</sub> and in the presence of either RPMI 1640 (negative control), Con A (positive control), or GP peptides either individually (15-mers overlapping by 9 amino acids and spanning the lengths of their respective GP) or whole pooled (2.5 pg/ml final). After 18-24 h of stimulation, the plates were washed in PBS and then incubated for 24 h at 4° C. with biotinylated anti-mouse IFN-γ mAb (R&D Systems, Minneapolis, MN). Next, the plates were washed again in PBS, and streptavidin-alkaline phosphatase (MabTech, Sweden) was added to each well and incubated for 2 h at RT. Lastly, the plates were washed again in PBS and then BCIP/NBT Plus substrate (MabTech) was added to each well for 5-30 min for spot development. As soon as the development process was complete upon visual inspection, the plate were rinsed with distilled water and then dried overnight at RT. Spots were enumerated using an automated ELISPOT reader (Cellular Technology Ltd., Shaker Heights, OH).

**[0246]** For comprehensive analysis of T cell breadth, standard IFNγ ELISPOT was modified herein as previously described in Shedlock D J, et al. (2012). SUPRA. Identification and measurement of subdominant and immunodominant T cell epitopes were assessed by stimulating splenocytes with individual peptides as opposed to whole or matrix peptide pools; the traditional practice of pooling peptides for the sake of sample preservation, such as the use of matrix array pools, results in a reduction of assay sensitivity since total functional responses in pools containing multiple epitope-displaying peptides will effectively lower assay resolution, i.e. ‘drown-out’ those of lower magnitude. Thus, modified ELISPOT was performed with individual peptides (15-mers overlapping by 9 amino acids; 2.5 pg/ml final) spanning each GP immunogen. Peptides containing T cell epitopes were identified ( $\geq 10$  AVE IFNγ+ spots AND  $\geq 80\%$  animal response rate; summarized in Tables 1-6) and then later confirmed functionally and phenotypically by FACS. No shared or partial epitopes were identified, nor did FACS data or web-based epitope prediction software suggest the presence of a CD4+ or CD8+ T cell epitope that was preserved within consecutive peptides. Here, possible shared/partial T cell epitopes were addressed for all instances of contiguous peptide responses as identified by modified ELISPOT assay. Cells were stimulated individually with each of the contiguous peptides, as well as paired in combination for direct comparison, and were defined as ‘shared/partial’ if the combined response was not greater than either of the two individual responses. Also, it must be noted, that the epitopic response presented herein may not have been completely comprehensive since the ‘15-mer overlapping by 9 amino acids’ algorithm for generating peptides is biased towards complete coverage of CD8 T cell epitopes which may underestimate CD4 T cell responses due to the nature of class II-restricted epitopes being longer than 15 amino acids. Lastly, amino acid similarity plots were generated using Vector NTI software and the results are shown in FIG. 4B.

#### Flow Cytometry

**[0247]** Splenocytes were added to a 96-well plate (1×10<sup>6</sup> cells/well) and stimulated for 5-6 h with either individual peptides or ‘Minimal Peptide Pools’ (2.5 pg/ml final). Individual peptides stimulation was used for functional confirmation of all peptides identified by modified ELISPOT (Tables 1-6) as well as phenotypic characterization. Sple-

nocytes and transfected 293 Ts were first pre-stained with LIVE/DEAD® Fixable Violet Dead Cell Stain Kit (Invitrogen). For splenocytes, cells were surface-stained for CD19 (V450; clone 1D3), CD4 (PE-Cy7; clone RM4-5), CD8α (APC-Cy7; clone 53-6.7) and CD44 (PE-Cy5; clone IM7) (BD Biosciences, San Jose, CA), washed three times in PBS+1% FBS, permeabilized with BD Cytofix/Cytoperm™ kit, and then stained intracellularly with IFNγ (APC; clone XMG1.2), TNF (FITC; clone MP6-XT22), CD3 (PE-cy5.5; clone 145-2C11), and T-bet (PE; clone 4B10) (eBioscience, San Diego, CA). GP expression in transfected 293T cells was assessed 24 h post-transfection. Indirect staining was performed following a 30 min incubation at 4°C in PBS+1% FBS containing the indicated mouse-derived GP-specific polyclonal serum reagent (1:200 dilution), each produced by pooling serum from H-2<sup>b</sup> mice immunized three times with their respective DNA vaccine or pVAX1 empty vector control. Cells were then stained with FITC-conjugated goat anti-mouse IgG (BioLegend, San Diego, CA), washed extensively, and then stained for MHC class I (HLA-ABC; PE-Cy7; clone G46-2.6; BD). All cells were fixed in 1% paraformaldehyde. All data was collected using a LSRII flow cytometer (BD) and analyzed using FlowJo software (Tree Star, Ashland, OR). Splenocytes were gated for activated IFNγ-producing T cells that were CD3+ CD44+, CD4+ or CD8+, and negative for the B cell marker CD19 and viability dye.

[0248] FIG. 6 shows a GP-specific T cell gating. Functional and phenotypic analysis for peptides containing T cell epitopes as identified by ELISPOT was performed by FACS gating of total lymphocytes, live (LD) CD3+ cells that were negative for CD 19 and LIVE-DEAD (dump channel), singlets (excludes cell doublets), CD4+ and CD8+ cells, activated cells (CD44+), and peptide-specific IFNγ-producing T cells.

#### Statistical Analysis

[0249] Significance for unrooted phylogenetic trees was determined by maximum-likelihood method and verified by bootstrap analysis and significant support values ( $\geq 80\%$ ; 1,000 bootstrap replicates) were determined by MEGA version 5 software. Group analyses were completed by matched, two-tailed, unpaired t test and survival curves were analyzed by log-rank (Mantel-Cox) test. All values are mean $\pm$ SEM and statistical analyses were performed by GraphPad Prism (La Jolla, CA).

#### Results

##### Vaccine Construction and Expression

[0250] Phylogenetic analysis revealed relative conservation among the EBOV GPs (94.4% for SUDV and 92.9% for ZEBOV), whereas the MARV GP (MGP) were more divergent (~70% conserved). Thus, a consensus strategy, as determined by alignment of the prevailing ZEBOV and SUDV GP amino acid sequences, was adopted for the EBOV GPs, while a type-matched strategy was used for MARV employing the 2005 Angola outbreak sequence which was solely responsible for the largest and deadliest MARV outbreak. Each GP transgene was genetically optimized, synthesized commercially, and then subcloned into modified pVAX1 mammalian expression vector. Altogether,

a three-plasmid strategy formed the foundation for our novel polyvalent-filovirus vaccine strategy.

[0251] HEK 293T cells were transfected separately with each plasmid and GP expression was assessed by Western immunoblotting and FACS. A ~130 kDa protein was observed for each in cell lysates harvested 48 h post-transfection using species-specific anti-GP1 mAbs for detection. Results are shown in FIG. 1B. For a comparative control, recombinant vesicular stomatitis viruses (rVSV) expressing the respective GPs were loaded in concurrent lanes. Next, GP expression on the cell surface was analyzed 24 h post-transfection by indirect staining with GP-specific or control polyclonal serum by FACS. Results are shown in FIG. 1C. Cell surface expression was detected for all vaccine plasmids while little non-specific binding was observed; control serum did not react with GP-transfected cells nor did the positive sera with pVAX1-transfected cells (data shown for pEBOZ). As expected for the EBOV GPs, cell surface expression sterically occluded recognition of surface MHC class I, as well as 01-integrin (Francica J R, Varela-Rohena A, Medvec A, Plesa G, Riley J L, Bates P (2010). Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. *PLoS Pathog* 6: e1001098).

#### Complete Protection Against MARV and ZEBOV Challenge

[0252] To determine protective efficacy, we employed the guinea pig preclinical challenge model. Preclinical immunogenicity and efficacy studies were performed herein using the guinea pig and mouse models. The guinea pig preclinical model has been extensively used as a screening and ‘proof-of-concept’ tool for filoviral vaccine development. Although primary isolates of MARV and EBOV cause non-fatal illness in guinea pigs, a small number of passages in this host results in selection of variants able to cause fatal disease with pathological features similar to those seen in filovirus-infected primates. Similarly, mice have also been widely used for filoviral vaccine development, however, unlike the guinea pig model, immunodetection reagents for assessing immunity and T cell responses are extensively available. Infection with a murine-adapted ZEBOV (mZEBOV) results in disease characterized by high levels of virus in target organs and pathologic changes in livers and spleens akin to those found in EBOV-infected primates.

[0253] Guinea pigs (n=24) were immunized i.d. two times with 200 µg of each plasmid (pEBOZ, pEBOS and pMARV) into three separate vaccination sites or with pVAX1 empty vector control (n=9), and then boosted with the same vaccines one month later. Animals were challenged 28 days following the second immunization with 1,000 LD<sub>50</sub> of a guinea pig-adapted MARV-Angola (gpMARV) (n=9) or ZEBOV (gpZEBOV) (n=15) in a BSL-4 facility, and then observed and weighed daily. Results are shown in FIGS. 2A-2H. Vaccinated animals were completely protected while control-vaccinated animals succumbed to gpMARV by 10 days post-challenge (n=3; P 0.0052) or to gpZEBOV by day 7 post-challenge (n=6; P 0.0008) (FIG. 2A and FIG. 2E). Additionally, vaccinated animals were protected from weight loss (FIG. 2B and FIG. 2F; P<0.0001). It is likely that vaccine-induced Abs may have contributed to protection since GP-specific Abs in pooled serum exhibited a significant increase in binding (FIG. 2C and FIG. 2G) and neutralization (FIG. 2D and FIG. 2H) titers. Experiments were performed in a BSL-4 facility and repeated twice with

similar results and error bars in Figures A-2H represent SEM. Group analyses were completed by matched, two-tailed, unpaired t test and survival curves were analyzed by log-rank (Mantel-Cox) test.

#### Plasmid Vaccines were Highly Immunogenic

**[0254]** To better characterize immune correlates as driven by the protective DNA vaccine (plasmids pEBOZ, pEBOS and pMARV, also referred to as trivalent DNA vaccine), we next employed the mouse model which has been widely used as a screening and ‘proof-of-concept’ tool for filoviral vaccine development and in which extensive immunodetection reagents are available. First, B cell responses were assessed in H-2<sup>d</sup> mice (n=5/group) 20 days following each of two vaccinations, three weeks between injections with 40 µg of respective monovalent DNA vaccine. Data from these experiments is shown in FIGS. 3A-3C. While little GP-specific IgG was observed in pre-bleed control samples, as shown in FIG. 3A and FIG. 3B, a significant increase was detected in all animals following vaccination. Since purified SGP was not available, purified ZGP was used as a surrogate. IgG in SUDV-vaccinated mice bound ZGP, demonstrating the ability for vaccine-induced Ab generation as well as its capability for cross-species recognition. Additionally, seroconversion occurred in 100% of vaccinated animals after only one immunization, after which responses were significantly increased by homologous boost; AVE reciprocal endpoint dilution titres were boosted 22.1-fold in pMARV-immunized mice, and 3.4-fold and 8.6-fold in pEBOS- and pEBOZ-vaccinated animals, respectively. Samples were next assayed for neutralization of ZEBOV, SUDV-Boniface, and MARV-Angola in a BSL-4 facility. The results of the neutralization assay are shown in FIG. 3C. Significant increases in NAb titres were detected following vaccination in all animals.

**[0255]** Mice from two different genetic backgrounds (H-2<sup>d</sup> and H-2<sup>b</sup>; n=5/group) were immunized with 40 µg of respective plasmids pEBOZ, pEBOS and pMARV, homologous boosted after two weeks, and then sacrificed 8 days later for T cell analysis. Results from a novel modified ELISPOT assay to assess the comprehensive vaccine-induced T cell response, in which splenocytes were stimulated using individual peptides as opposed to matrix pools are shown in FIG. 4A. DNA vaccination induced robust IFNγ+ responses that recognized a diversity of T-cell epitopes (Tables 1-6). All positive epitope-comprising peptides were subsequently gated (See FIG. 6), confirmed, and further characterized by FACS. This modified ELISPOT approach proved extremely sensitive since background responses from control wells were low ( $7.2 \pm 0.2$  IFNγ-producing SFC/10<sup>6</sup> splenocytes in H-2<sup>b</sup> and  $9.2 \pm 0.5$  in H-2<sup>d</sup> mice). Results as shown in FIG. 4A revealed that vaccination with pMARV induced 9 measurable epitopes in H-2<sup>b</sup> mice and 11 in H-2<sup>d</sup>, pEBOS induced 9 and 8, and pEBOZ generated 10 and 12, in these respective strains. While five of nine (55.6%) of the epitopes from pMARV-immunized H-2<sup>b</sup> mice were CD8+, they accounted for about 57.3% of the total MGP-specific IFNγ+ response as measured by both ELISPOT and FACS confirmation and phenotypic analysis. Similarly, only 33% and 38% of confirmed epitopes were CD8-restricted in pEBOS-immunized H-2<sup>b</sup> and H-2<sup>d</sup> mice, respectively. However these epitopes comprised roughly 50-90% of the total response; CD8+ T cell responses were estimated to be approximately 56% in both mouse strains while FACS estimates were 51% and 90% in H-2<sup>b</sup> and H-2<sup>d</sup> mice,

respectively. Total CD8+ responses were lower in pEBOZ-vaccinated animals and measured between 33% and 57% (33% for both strains by ELISPOT and 6% and 57% for H-2<sup>b</sup> and H-2<sup>d</sup> mice, respectively, by FACS).

**[0256]** A single immunodominant epitope was detected in both mouse strains receiving pEBOS where an immunodominant epitope was loosely defined as generating an IFNγ response at least two-fold over the highest subdominant epitope; pMARV induced four H-2<sup>b</sup>-restricted immunodominant CD8+ epitopes within peptides MGP<sub>25-39</sub> (#5), MGP<sub>67-81</sub> (#12), MGP<sub>181-195</sub> (#31) and MGP<sub>385-399</sub> (#65), and an H-2d-restricted CD4+ epitope in MGP<sub>151-171</sub> (#27). Four of these epitopes occurred within highly conserved regions of MARV GP1, including three of which were located within the putative receptor binding domain, while only one occurred within the variable mucin-like region (MGP<sub>385-399</sub> (#65)) as shown in FIG. 4B and FIG. 4C. pEBOS stimulated CD8+ epitopes occurring in SUDV GP (SGP)<sub>19-33</sub> (#4) and SGP<sub>241-255</sub> (#41) in H-2<sup>b</sup> and H-2<sup>d</sup> mice, respectively, both in highly conserved regions of GP1. However, pEBOZ immunization revealed three immunodominant epitopes in H-2<sup>d</sup> mice (a CD8-restricted epitope located in the ZEBOV GP receptor binding domain (GP)<sub>139-153</sub> (#24), and two CD4-restricted epitopes ZGP<sub>175-189</sub> (#30) and ZGP<sub>391-405</sub> (#66)), occurring within the receptor binding domain and the mucin-like region, respectively. Only one immunodominant epitope was defined in H-2<sup>b</sup> mice which contained both a CD4+ and a CD8+ epitope (#89) and occurred in a highly conserved region of GP2. Overall, diverse epitope hierarchies were consistent and reproducible in each vaccine group. Furthermore, as shown in FIG. 4D, the subdominant response comprised a significant proportion of the total response; the total AVE subdominant response as measured by the modified ELISPOT assay was approximately 12%, 62%, and 74% in pMARV-, pEBOS- and pEBOZ-immunized H-2<sup>b</sup> mice, respectively, while responses in H-2<sup>d</sup> mice were 47%, 50% and 34%, respectively.

**[0257]** Lastly, total GP-specific T cell responses were measured by FACS using stimulation with minimal peptide pools containing only confirmed epitope-comprising peptides identified. Robust responses were detected in each of the vaccinated animals and were, in a majority of cases, comprised by both activated CD4+ and CD8+ T cells. Responses were GP-specific, since little IFNγ production was observed with a control peptide (h-Clip), and correlated well with ELISPOT data. The only instance where immunization did not induce remarkable CTL as measured by FACS was in H-2<sup>d</sup> mice vaccinated with pMARV in which no epitope identified by ELISPOT was confirmed to be CD8-restricted. Altogether, these data show that each of the vaccine plasmids was highly immunogenic in mice and yielded robust GP-specific T cell responses recognizing a diverse array of T cell epitopes including immunodominant epitopes within highly conserved regions of the GP. Furthermore, the highly diverse subdominant T cell response characterized herein might have otherwise been overlooked using traditional matrix array peptide pools for epitope identification.

**[0258]** T cell responses were measured for reactivity against minimal peptide pools comprised by all positively identified peptides for each respective GP by FACS. FIG. 7A shows DNA vaccine-induced T cell responses are shown from a representative animal and IFNγ-producing CD4+

(right) and CD8+ (left) cells are gated. FACS plots are shown. Incubation with h-CLIP peptide served as a negative control (Control). FIG. 7B shows results of gated cells in FIG. 7A are summarized as average % of total CD44+/IFN $\gamma$ +CD4+ or CD8+ cells and error bars represent SEM. Experiments were repeated at least two times with similar results.

#### 'Single-Dose' Protection in Mice

[0259] Vaccine efficacy against ZEBOV challenge was next assessed in the preclinical murine model. Mice were vaccinated only once due to strong NAb induction and protection data observed. Mice (H-2<sup>k</sup>; n=10/group) were immunized with 40  $\mu$ g of the pEBOZ DNA and protection was evaluated 28 days later by challenge with 1,000 LD<sub>50</sub> of mouse-adapted ZEBOV (mZEBOV) in a BSL4 facility. While all control animals succumbed to infection by day 7 post-challenge, FIG. 5A shows DNA-vaccinated mice were completely protected ( $P=0.0002$ ). In addition, as shown in FIG. 5B, control mice exhibited progressive loss of body weight until death ( $P<0.0001$ ).

[0260] To better understand the mechanisms of DNA-induced protection in a 'single-dose' model, we next assessed NAb and T cell generation. NAb were assessed 25 days post-vaccination, 3 days prior to challenge, and, as shown in FIG. 5C, a significant ( $P<0.0001$ ) increase was detected in all vaccinated animals (n=10/group); reciprocal endpoint dilution titers ranged from 19 to 42, 27.3 $\pm$ 2.5.

[0261] We next evaluated the generation of ZGP-specific T cells and increased the scope of our analysis to compare responses in mice immunized with either the pEBOZ alone, or in a trivalent formulation IFN-7 production (n=5) was assessed 11 days later by FACS using whole ZGP peptide pools; the data is shown in FIG. 5D. IFN $\gamma$ -producing T cells were detected in all animals and were specific for ZGP peptides since stimulation with a control peptide did not induce cytokine production. Immunization with either the monovalent or trivalent formulation induced robust IFN $\gamma$  T cell responses that, when compared, were not significantly different P 0.0920.

[0262] Since CTL may be important in eliminating virus-infected cells (Warfield K L, et al. (2005)). Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. *J Immunol* 175: 1184-1191; Kalina W V, Warfield K L, Olinger G G, Bavari S (2009). Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. *Virology* 36: 132; Olinger G G, et al. (2005). Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. *J Virol* 79: 14189-14196; Sullivan N J, et al. (2011). CD8(+) cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. *Nat Med* 17: 1128-1131; and Geisbert T W, et al. (2010). Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. *J Virol* 84: 10386-10394), production of an additional effector cytokine, TNF, as well as a developmental restriction factor, T-box transcription factor TBX21 (T-bet), known to correlate with T<sub>H</sub>1-type CTL immunity and cytotoxicity were measured and the results were as follows. For Total Cells: TNF 2.9 $\pm$ 0.8, Tbet 13.0 $\pm$ 1.1. For CD4+/CD44+/IFN $\gamma$ + Cells: TNF 61.4 $\pm$ 3.1, Tbet 72.6 $\pm$ 2.0. For CD8+/CD44+/IFN $\gamma$ + Cells: TNF 33.0 $\pm$ 3.3, Tbet 992.1 $\pm$ 1.4 (\*p<0.1; \*\*\*p<0.001; \*\*\*\*p<0.

0001). We found that ~61% and ~33% of activated CD4+ and CD8+ T cells, respectively, also produced TNF in addition to IFN $\gamma$ . Furthermore, a majority of IFN $\gamma$ -producing T cells expressed high levels of T-bet; about 73% and 92% of CD8+ and CD4+ T cells, respectively, were CD44+ and produced IFN $\gamma$  following ZGP peptide stimulation.

[0263] FIGS. 8A and 8B show T cell induction by 'single-dose' vaccination. T cell responses in H-2<sup>k</sup> mice after a single pEBOZ immunization or a single trivalent vaccination, comprised by the three vaccine plasmids in separate sites, as measured by FACS are shown (a) and summarized (b) as AVE % of total CD44+/IFN $\gamma$ +CD4+ (purple) or CD8+ (orange) cells. Pseudocolor FACS plots are from a representative animal and IFN $\gamma$ -producing CD4+ (right) and CD8+ (left) cells are gated. Incubation with h-CLIP peptide served as a negative control (Control). Experiments were performed twice with similar results, error bars represent SEM; ns, no significance.

#### Discussion

[0264] We report development and evaluation of a polyvalent-filoviral vaccine in preclinical rodent immunogenicity and efficacy studies. Complete protection against challenge with gpMARV and gpZEBOV was observed following two DNA vaccine doses in guinea pigs, as well as with a 'single-dose' DNA vaccine in mice against mZEBOV. To date, genetic vaccination of guinea pigs has included either injection of naked DNA (Sullivan N J, Sanchez A, Rollin P E, Yang Z Y, Nabel G J (2000). Development of a preventive vaccine for Ebola virus infection in primates. *Nature* 408: 605-609) or DNA delivered by gene gun (Dowling W, et al. (2006). The influences of glycosylation on the antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. *J Virol* 81: 1821-1837; Vanderzanden L, et al. (1998). DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. *Virology* 246: 134-144; and Riemenschneider J, et al (2003). Comparison of individual and combination DNA vaccines for *B. anthracis*, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. *Vaccine* 21: 4071-4080), however, either method required at least three vaccinations to achieve complete protection. Improved protection herein may be due to the induction of robust Abs since a single DNA vaccination generated GP-specific IgG binder titers that were comparable in magnitude to titers in protected animals following gene gun administration; DNA vaccination induced 3.85 and 2.18 log 10 ZGP and MGP-specific Ab titers, respectively, after a single administration versus 2.7 and 3.0 after three gene gun vaccinations. For comparison with an alternative 'single-dose' protective strategy in guinea pigs, an Ag-coupled virus-like particle (VLP) platform generated Ab titers that were only slightly higher than observed following DNA vaccination (Swenson D L, Warfield K L, Negley D L, Schmaljohn A, Aman M J, Bavari S (2005). Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. *Vaccine* 23: 3033-3042). Furthermore, a recombinant adenovirus (rAd) approach induced ZGP-specific NAb titers that were lower than those from a single DNA vaccination (53 reciprocal endpoint dilution titer versus 88 herein) (Kobinger G P, et al. (2006). Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. *Virology* 346: 394-401). Vaccination with rVSV (Jones S M, et al (2007). Assessment of a vesicular stomatitis virus-based vaccine by

use of the mouse model of Ebola virus hemorrhagic fever. *J Infect Dis* 196 Suppl 2: S404-412) generated ZGP-specific Ab titers that were similar to the current platform. Altogether, these data demonstrate that DNA vaccination was capable of inducing binding and neutralizing Abs that were comparable to non-replicating viral platforms and that these data may help, in part, to explain strong guinea pig survival data herein.

**[0265]** The generation of NAbS by protective DNA vaccination may have benefitted by transgene-expressed mature GP structures. In vitro transfection studies confirmed that the vaccine-encoded GP were highly expressed, post-translationally cleaved (FIG. 1), transported to the cell surface, and sterically occluded the immunodetection of cell surface molecules (FIG. 1C). Therefore, it was highly likely that the vaccine immunogens formed herein matured into heterotrimeric spikes that would otherwise be functional upon virion assembly during infection. This may be important for the generation and display of virologically-relevant neutralizing determinants which would be subsequently critical for the induction of conformation-dependent Nabs (Dowling W, et al. (2007). Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. *J Virol* 81: 1821-1837; Shedlock D J, Bailey M A, Popernack P M, Cunningham J M, Burton D R, Sullivan N J (2010). Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. *Virology* 401: 228-235). Thus, in this regard, the expression of native anchored structures may be superior to soluble derivatives in the capacity for generating NAbS (Sullivan N J, et al. (2006). Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. *PLoS Med* 3: e177; Xu L, et al. (1998). Immunization for Ebola virus infection. *Nat Med* 4: 37-42).

**[0266]** To better characterize T cells responses as driven by a protective vaccine, we performed immunogenicity and efficacy studies in mice and determined ‘single-dose’ complete protection against mZEBOV with DNA vaccination (FIGS. 5A-5D). To date, the most effective platforms conferring complete protection in this model are VLP, either with (Warfield K L, et al. (2005). Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. *J Immunol* 175: 1184-1191; Warfield K L, Swenson D L, Olinger G G, Kalina W V, Aman M J, Bavari S (2007). Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. *J Infect Dis* 196 Suppl 2: S430-437) or without (Sun Y, et al. (2009). Protection against lethal challenge by Ebola virus-like particles produced in insect cells. *Virology* 383: 12-21) adjuvant, rAd vaccination ((Kobinger G P, et al. (2006) SUPRA; Choi J H, et al. (2012). A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. *Mol Pharm* 9: 156-167; Richardson J S, et al. (2009). Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. *PLoS One* 4: e5308), or rRABV vaccination (Blaney J E, et al. (2011). Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. *J Virol* 85: 10605-10616). However, characterization of T cell responses were severely limited in these studies and were restricted to splenocyte stimulation with either two (Warfield K L, (2007), SUPRA) or one (Warfield K L, et al. (2005) SUPRA) peptides previously described to contain ZGP T cell epitopes (War-

field K L, et al. (2005) SUPRA. Olinger G G, et al. (2005) SUPRA; Kobinger G P, et al. (2006), SUPRA; Sun Y, et al. (2009). Choi, J H, et al. (2012). Herein, we report induction of robust and broad CTL by protective vaccination as extensively analyzed by a novel modified T cell assay (FIG. 4A and Tables 1-6). In total, 52 novel T cell epitopes were identified including numerous immunodominant epitopes occurring primarily in highly conserved regions of GP. Of the 22 total ZGP epitopes identified, only 4 have been previously reported. Moreover, only one of the 20 MGP (Kalina W V, Warfield K L, Olinger G G, Bavari S (2009). Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. *Virol J* 6: 132) and one of 16 SGP epitopes were previously described. As such, this the most comprehensive report of preclinical GP epitopes to date, describing GP epitopes from multiple filoviruses in two different mouse genetic backgrounds.

**[0267]** Another novel finding resulting from these analyses was the assessment of the vaccine-induced subdominant T cell responses, which we show comprised a significant percentage of the total T cell response, widely ranging between 12%-74% (FIG. 4D). This may be particularly important since subdominant responses can significantly contribute to protection. Thus, it may prove informative in the future to determine the specific contributions of the subdominant and immunodominant epitopic T cell responses to protection. Notably, these responses may have otherwise been overlooked using traditional matrix array peptide pools for epitope identification. As such, limited epitope detection in previous studies may have been directly related to lower levels of vaccine-induced immunity, the use of less sensitive standard assays, and/or the use of peptide arrangements and/or algorithms favoring detection of immunodominant CD8+ epitopes.

**[0268]** Although immune correlates of protection against the filoviruses remain controversial, data generated by this highly immunogenic approach provides a unique opportunity with which to study T cell immunity as driven by a protective vaccine. DNA vaccination herein induced strong ZGP-specific T cells, a large part of which were characterized by T<sub>h</sub>1-type multifunctional CTL expressing high levels of T-bet, also shown to correlate with T cell cytotoxicity in humans. It is clear that previous stand-alone DNA vaccine platforms capable of generating mainly humoral immune responses and cellular immunity skewed towards CD4+ T cells may likely benefit from in vivo EP delivery which has been recently demonstrated to induce potent CD8+ T cells in NHPs and the clinic. Thus, data herein are consistent with this approach as a stand-alone or prime-boost modality in NHP immunogenicity and efficacy studies. This approach offers an attractive vaccination strategy that can be quickly and inexpensively modified and/or produced for rapid response during Filoviridae bio-threat situations and outbreaks. In addition, this model approach provides an important tool for studying protective immune correlates against filoviral disease and could be applied to existing platforms to guide future strategies.

#### Example 2

**[0269]** A trivalent vaccine is provided which comprises three plasmids. The first plasmid comprises a nucleic acid sequence that encodes a Zaire ebolavirus consensus immunogen which is based upon ZEBOV CON, SEQ ID NO:1, modified to include an IgE signal peptide at the N terminus

of the Zaire ebolavirus consensus immunogen. The second plasmid comprises a nucleic acid sequence that encodes a Sudan ebolavirus consensus immunogen which is based upon SUDV CON, SEQ ID NO:2, modified to include an IgE signal peptide at the N terminus of the Sudan ebolavirus consensus immunogen. The third plasmid comprises a nucleic acid sequence that encodes a Marburg marburgvirus Angola (MARV immunogen which is based upon MARV ANG, SEQ ID NO:3, modified to include an IgE signal peptide at the N terminus of the Marburg marburgvirus Angola immunogen.

#### Example 3

**[0270]** A five plasmid vaccine is provided. The first plasmid comprises a nucleic acid sequence that encodes a Zaire ebolavirus consensus immunogen which is ZEBOV CON, SEQ ID NO:1. The second plasmid comprises a nucleic acid sequence that encodes a Sudan ebolavirus consensus immunogen which is SUDV CON, SEQ ID NO:2. The third plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:4, a Marburg marburgvirus—Ravn cluster consensus (MARV-RAV CON) using Marburg marburgvirus Ravn, Durba (09DRC99) and Uganda (02Uga07Y). The fourth plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:5, a Marburg marburgvirus—Ozolin cluster consensus (MARV-OZO CON) using Ozolin, Uganda (01Uga07), and Durba (05 and 07DRC99). The fifth plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:6, a Marburg marburgvirus—Musoke cluster consensus (MARV-MUS CON) using (Musoke, Popp, and Leiden). The sixth plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:3, a Marburg marburgvirus Angola 2005 isolate glycoproteins immunogen.

#### Example 4

**[0271]** A five plasmid vaccine is provided. The first plasmid comprises a nucleic acid sequence that encodes a Zaire ebolavirus consensus immunogen which is based upon ZEBOV CON, SEQ ID NO:1, modified to include an IgE signal peptide at the N terminus of the Zaire ebolavirus consensus immunogen. The second plasmid comprises a nucleic acid sequence that encodes a Sudan ebolavirus consensus immunogen which is based upon SUDV CON, SEQ ID NO:2, modified to include an IgE signal peptide at the N terminus of the Sudan ebolavirus consensus immunogen. The third plasmid comprises a nucleic acid sequence that encodes Marburg marburgvirus Rav consensus based upon SEQ ID NO:4, a Marburg marburgvirus—Ravn cluster consensus (MARV-RAV CON) using Marburg marburgvirus Ravn Durba (09DRC99) and Uganda (02Uga07Y) and modified to include an IgE signal peptide at the N terminus of the consensus Marburg marburgvirus—Ravn immunogen. The fourth plasmid comprises a nucleic acid sequence that encodes Marburg marburgvirus Ozo consensus based upon SEQ ID NO:5, a Marburg marburgvirus—Ozolin cluster consensus (MARV-OZO CON) using Ozolin, Uganda (01Uga07), and Durba (05 and 07DRC99) and modified to include an IgE signal peptide at the N terminus of the consensus Marburg marburgvirus—Ozo immunogen. The fifth plasmid comprises a nucleic acid sequence that encodes Marburg marburgvirus Mus consensus based upon SEQ ID NO:6, a Marburg marburgvirus—Musoke cluster consensus (MARV-MUS CON) using (Musoke, Popp, and Leiden) and modified to include an IgE signal peptide at the N terminus of the consensus Marburg marburgvirus—Mus immunogen.

#### Example 5

**[0272]** A six plasmid vaccine is provided. The first plasmid comprises a nucleic acid sequence that encodes a Zaire ebolavirus consensus immunogen which is ZEBOV CON, SEQ ID NO:1. The second plasmid comprises a nucleic acid sequence that encodes a Sudan ebolavirus consensus immunogen which is SUDV CON, SEQ ID NO:2. The third plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:4, a Marburg marburgvirus—Ravn cluster consensus (MARV-RAV CON) using Marburg marburgvirus—Ravn, Durba (09DRC99) and Uganda (02Uga07Y). The fourth plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:5, a Marburg marburgvirus—Ozolin cluster consensus (MARV-OZO CON) using Ozolin, Uganda (01Uga07), and Durba (05 and 07DRC99). The fifth plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:6, a Marburg marburgvirus—Musoke cluster consensus (MARV-MUS CON) using (Musoke, Popp, and Leiden). The sixth plasmid comprises a nucleic acid sequence that encodes SEQ ID NO:3, a Marburg marburgvirus Angola 2005 isolate glycoproteins immunogen.

#### Example 6

**[0273]** A five plasmid vaccine is provided. The first plasmid comprises a nucleic acid sequence that encodes a Zaire ebolavirus consensus immunogen which is based upon ZEBOV CON, SEQ ID NO:1, modified to include an IgE signal peptide at the N terminus of the Zaire ebolavirus consensus immunogen. The second plasmid comprises a nucleic acid sequence that encodes a Sudan ebolavirus consensus immunogen which is based upon SUDV CON, SEQ ID NO:2, modified to include an IgE signal peptide at the N terminus of the Sudan ebolavirus consensus immunogen. The third plasmid comprises a nucleic acid sequence that encodes Marburg marburgvirus Rav consensus based upon SEQ ID NO:4, a Marburg marburgvirus—Ravn cluster consensus (MARV-RAV CON) using Marburg marburgvirus Ravn Durba (09DRC99) and Uganda (02Uga07Y) and modified to include an IgE signal peptide at the N terminus of the consensus Marburg marburgvirus—Ravn immunogen. The fourth plasmid comprises a nucleic acid sequence that encodes Marburg marburgvirus Ozo consensus based upon SEQ ID NO:5, a Marburg marburgvirus—Ozolin cluster consensus (MARV-OZO CON) using Ozolin, Uganda (01Uga07), and Durba (05 and 07DRC99) and modified to include an IgE signal peptide at the N terminus of the consensus Marburg marburgvirus—Ozo immunogen. The fifth plasmid comprises a nucleic acid sequence that encodes Marburg marburgvirus Mus consensus based upon SEQ ID NO:6, a Marburg marburgvirus—Musoke cluster consensus (MARV-MUS CON) using (Musoke, Popp, and Leiden) and modified to include an IgE signal peptide at the N terminus of the consensus Marburg marburgvirus—Mus immunogen. The sixth plasmid comprises a nucleic acid sequence that encodes a Marburg marburgvirus Angola 2005 isolate glycoproteins immunogen which is based upon MARV ANG, SEQ ID NO:3, modified to include an IgE signal peptide at the N terminus of the Marburg marburgvirus Angola immunogen.

#### Example 7

**[0274]** Described herein is a DNA vaccine formulation expressing 3 synthetic Zaire Ebola virus (EBOV) glycopro-

teins (GP): 2 designed based on GP sequence alignments (1976-2014) and a 3rd construct matched to a 2014 outbreak strain. Plasmid IL-12 (pIL-12) was also included as an adjuvant to further enhance cellular immune responses. The multivalent GP DNA vaccine formulation was administered in macaques following a DNA-DNA prime-boost immunization regimen. Macaques (n=3 or 4/group) received the multivalent GP DNA formulation+pIL-12 by intramuscular delivery followed by electroporation. Differences in immunogenicity were assayed and protection between different doses, regimens (2, 3, 4, and 5 injections), and different spacing intervals between subsequent doses were monitored. Both antibody and T cell responses were observed in 83% of animals 2 weeks following the first injection and 100% of animals after the 2nd injection. The macaques were challenged with a lethal dose of the EBOV Guinea-Makona outbreak strain (1000 pfu, 7-U virus) and monitored for 28 days following infection. 100% of animals receiving at least 3 injections at 4 week intervals survived lethal challenge. Animals were fully protected against signs of disease and did not exhibit elevated blood chemistry. Interestingly, 50% of animals receiving 2 injections survived lethal challenge. The surviving animals exhibited minimal signs of disease, suggesting that with further optimization complete protection with 2 injections is potentially achievable. In additional optimization studies in mice, single injections were found to be 100% protective and long-term immune responses 8 months post vaccination were induced.

## Methods

### Developing an EBOV GP DNA Vaccine Formulation

**[0275]** Vaccines currently in clinical trials include rSVAG/ZEBOVGP, ChAd3 prime+MVA boost, and MVA pan-filovirus. While these vaccines are immunogenic, protective in non-human primates (NHPs), and provide single dose protection, they develop anti-vector immunity, have uncertain duration of memory response, give adverse reactions in human clinical trials and may not be suitable for all populations. Thus, an additional platform with a cleaner safety profile that can induce strong immune responses against heterologous Zaire Ebola viruses would be very beneficial (FIG. 9).

**[0276]** Three EBOV DNA constructs were designed: a consensus sequence of ZEBOV (1976-1996) (ConEBOVGP #1), ZEBOV (2002-2008) (ConEBOVGP #2), and a matched ZEBOV sequence from the 2014 Guinea outbreak. (Guinea-GP). Five vaccines were developed, monovalent vaccines which comprise only a single DNA construct, a bivalent vaccine formulation which comprise either ConEBOVGP #1 with Guinea-GP and a trivalent formulation which comprises all three of ConEBOVGP #1, ConEBOVGP #2, and Guinea-GP (FIG. 10).

## Results

### A Single Immunization of DNA Vaccine is Immunogenic in Mice

**[0277]** BALB/c mice received a single intramuscular (IM) immunization followed by electroporation (EP) of the vaccine formulation. On day 28, Total IgG antibody titer and ELISPOT-IFN $\gamma$  were determined. Each vaccine formulation produced a robust IgG response. Polyfunctional CD4+ and

CD8+ T cells secreting IFN $\gamma$ , IL2, and TNF $\alpha$  were similar for all vaccines and formulations. (FIG. 11).

### A Single Immunization is Fully Protective in Mice Against Lethal Mouse-Adapted Ebola Virus Challenge

**[0278]** BALB/c mice immunized with bivalent or trivalent vaccine formulations were lethal challenged with 1000LD $_{50}$  of heterologous Ebolavirus. The challenge strain was mouse adapted-Ebola Mayinga 1976. Mice vaccinated with the control plasmid, pVax1, quickly lost weight and did not survive past day 7. However, both the mice vaccinated with the bivalent and mice vaccinated with the trivalent vaccine formulations maintained their weight and had no deceased mice up to day 20 (FIG. 12).

### Individual GP DNA Vaccine Constructs Induce Robust Memory Responses in Mice.

**[0279]** BALB/c mice received a 3xIM 40 g immunization of a monovalent vaccine followed by electroporation on days 0, 28 and 84. IgG antibody titer, INF $\gamma$ , CD4+CD44+ memory T cells, and CD8+CD44+ memory T cells were measured. Robust immune responses were detectable months after last injection (FIG. 13).

### GP DNA Vaccine Formulations are Immunogenic in NHPs

**[0280]** Cynomolgus macaques were used as a NHP because they are a model for Ebola vaccine efficacy and lethal challenge. Macaques were administered either a bivalent formulation with a Rhesus pIL12 adjuvant or a trivalent formulation with a Rhesus pIL12 adjuvant I.M. followed by EP. Different injection regimens in order to understand immunogenicity. Group 1 received 2 IM-EP injections of the bivalent formulation at a 4 week interval. Group 2 received 2 IM-EP injections of the trivalent formulation at a 4 week interval. Group 3 received 3 IM-EP injections of the trivalent formulation. Samples for immunogenicity studies were taken monthly and for one additional month following the last dose. (FIG. 6). Each DNA vaccine formulation induced robust anti-Ebola GP antibody responses (GMT>10<sup>3</sup>) & anti-GP T-cell responses. The immune responses were boosted following each injection (FIG. 14).

### GP DNA Formulation Vaccines Protect Against Lethal Zaire Ebola Virus (Makona) Challenge

**[0281]** The Cynomolgus macaques from groups 1, 2 and 3 were challenged with a 1000 TCID50 Guinea-Makona 2014 C07 virus (7-U reference strain) dose 28 days post-final DNA immunization. Animals were monitored for 28 days post-challenge. While none of the control animals survived past day 10 post challenge, 4/4 group 3 animals survived 28 days post challenge, 4/8 group 2 animals survived 28 days post challenge and 3/4 group 1 animals survived 28 days post challenge (FIG. 15). Surviving animals did not have any significant signs of disease. They also maintained normal CBC and enzyme levels. Bivalent and Trivalent DNA vaccines delivered by IM-EP elicit long-term antibody and T cell responses that were detectable >3 months post final DNA injection (FIG. 43).

**[0282]** Three doses of a Trivalent EBOV GP DNA vaccine is 100% protective against lethal EBOV challenge. Two doses of a Bivalent EBOV GP DNA vaccine affords 75% protection. Overall, the data supports further study of DNA

vaccines, delivered by IM-EP, for possible administration against Ebola and other infectious pathogens

#### EBOV-001 Phase I Clinical

**[0283]** An Open-Label study of INO-4212 (with or without INO-9012 was conducted. INO-4212 was administered IM or ID followed by electroporation in healthy volunteers. Safety and immunological assessments were monitored. Intradermal delivery and intramuscular delivery were compared. There were 69 total subjects. ELISA analysis was performed before immunization (baseline), and at weeks 2, 6, and 14. Seropositive is defined as a positive IgG antibody response to Ebola Zaire glycoprotein.

**[0284]** INO-4201 is a DNA vaccine formulated with the consensus envelope glycoprotein of Zaire Ebolavirus (ConEBOVGP #1) generated by using the envelope glycoprotein sequences of the 1976, 1994, 1995, 1996, 2003, 2005, 2007 and 2008 outbreak strains, driven by a human CMV promoter (hCMV promoter) with the bovine growth hormone 3'end polyadenylation signal (bGH polyA). pGX4201 was made by cloning the synthetic consensus envelope glycoprotein gene of Zaire Ebolavirus into pGX0001 at the BamHI and XhoI sites.

**[0285]** The ConEBOVGP #1 (ConGP1) sequence was constructed by generating a consensus envelope glycoprotein sequence of Zaire Ebolavirus using the envelope glycoprotein sequences of the 1976, 1994, 1995, 1996, 2003, 2005, 2007 and 2008 outbreak strains. Briefly, a consensus GP sequence was first generated based on six envelope sequences of the 1976, 1994, 1995, 1996, 2003 and 2005 outbreak strains. Then three non-consensus residues at the positions 377, 430 and 440 were weighted towards the 2003, 2005, 2007 and 2008 strains since they were the most recent and lethal outbreaks with published sequence data. The GenBank accession numbers for selected outbreak strain GP sequences are: Q05320, P87671, AAC57989, AEK25495, ABW34743, P87666, AER59718, AER59712, ABW34742, AAL25818. Once the consensus GP1 sequence was obtained, an upstream Kozak sequence was added to the N-terminal. Furthermore, in order to have a higher level of expression, the codon usage of this gene was adapted to the codon bias of *Homo sapiens* genes. In addition, RNA optimization was also performed: regions of very high (>80%) or very low (<30%) GC content and the cis-acting sequence motifs such as internal TATA boxes, chi-sites and ribosomal entry sites were avoided. The synthesized ConGP1 was digested with BamHI and XhoI, and cloned into the expression vector.

**[0286]** INO-4202 is a DNA vaccine formulated with a DNA plasmid expressing the envelope glycoprotein of Zaire Ebolavirus isolated from the 2014 outbreak in Guinea (GuineaGP), driven by a human CMV promoter (hCMV promoter) with the bovine growth hormone 3'end polyadenylation signal (bGH polyA).

**[0287]** INO-4212 is a bivalent vaccine of INO-4201 and INO-4202.

**[0288]** FIG. 17 depicts the vaccine formulation schedule, route and dose for each cohort. After the first injection, 15% or less of the patients was seropositive. After the second injection, 50-100% of the patients were seropositive. After the third injection 79-100% of the patients were seropositive (FIG. 18). Two representative patients with a moderate IFN $\gamma$  ELISpot, or a high IFN $\gamma$  ELISpot showed specific T-cell responses (FIG. 19).

**[0289]** While other Ebola vaccines platforms, including NIAID VRC/GSK and rVSV/ZEBOVGP, are currently in clinical trials the present bivalent and trivalent vaccines described herein have advantages not observed in the other vaccine platforms. For example, the bi- or tri-valent vaccines can be administered IM or ID, while the other vaccine platforms are only administered IM. Importantly, NIAID VRC/GSK and rVSV/ZEBOVGP show side effects including fever, fatigue, arthralgia, and lymphopenia while the bi- and tri-valent vaccines do not show any side effects. It should be noted however, that some of the side effects of rVSV/ZEBOVGP and ChAd3/MVAGP overlap with symptoms of Ebola. Further the bi- and tri-valent vaccines give antibody titers one to two orders of magnitude larger than rVSV/ZEBOVGP and ChAd3/MVAGP (FIG. 20).

**[0290]** Subjects (n=15) were assigned to receive INO-4201 at a 2 mg DNA/dose given as two separate 1 mg (0.1 mL) ID (Mantoux) injections followed by EP with the CELLECTRA®-3P device. Subjects received a 3-dose series with immunizations at 0, 4 weeks, and 12 weeks (0-4-12 week schedule). Antibodies specific for EBOV glycoprotein (GP) were measured from the sera of vaccinated subjects with a binding ELISA. Reciprocal endpoint titers above Day 0 are shown two weeks post each immunization (FIG. 22). 100% of subjects vaccinated with INO-4201 seroconverted after 2 immunizations (FIG. 22, Cohort 3 and FIG. 24).

#### Example 8

**[0291]** Described herein is immune response data for the three EBOV DNA constructs described in Example 7: a consensus sequence of ZEBOV (1976-1996) (ConEBOVGP #1 or INO-4201), ZEBOV (2002-2008) (ConEBOVGP #2), and a matched ZEBOV sequence from the 2014 Guinea outbreak. (Guinea-GP). Five vaccines were developed, monovalent vaccines which comprise only a single DNA construct, a bivalent vaccine formulation which comprise either ConEBOVGP #1 with Guinea-GP and a trivalent formulation which comprises all three of ConEBOVGP #1, ConEBOVGP #2, and Guinea-GP. 69 Subjects from cohorts 1-5 were included in analysis of immune response by ELISA and 75 subjects from cohorts 1-5 were included in analysis of immune response by ELISpot (FIGS. 21, 25).

#### ELISA Titers by Cohort and Timepoint

**[0292]** Titers of anti-EBOV were determined for each cohort at weeks 2, 6 and 14. By week 6, each cohort saw an increase in antibody titer above Day 0 (FIGS. 22-23). There was little to no reactivity for the first dose in each cohort. Dose 2 begins to drive seroconversion, with Cohorts 3 and 5 seeing the largest frequency. Dose three drives >90% seroconversion in 4/5 cohorts. Cohorts 3 and 5 show 100% seroconversion at this time point (FIG. 24)

#### Subject Responses by Peptide Pool

**[0293]** Cohort responses were analyzed by peptide pool (FIGS. 26-33). To analyze ELISpot outliers, day 0 values for each pool and total EBOV responses were used to create an outlier threshold (Mean day 0 values+(3 $\times$ STDEV of day 0 values)). This threshold should encompass 99% of a normally distributed population. Any subject that displayed

baseline values greater than the outlier threshold was removed and a responder criteria was generated with the remaining subjects.

#### ICS Analysis

**[0294]** 47 subjects from all cohorts were included in the analysis, however cohort 5 is underrepresented (FIG. 35). ICS analysis performed at baseline and week 14. A single EBOV peptide pool composed of Pools 1-4 is used for stimulation. Analysis of T cell activity in the form of IFNg or TNF $\alpha$  production from both CD4 and CD8 compartments suggests significant elevation of TNF $\alpha$  in both CD4 and CD8 compartments as well as elevation of TNF $\alpha$  and/or IFNg in Cohort 3 only (Wilcoxon matched paired analysis, two-tailed)

#### Immunology Summary

**[0295]** 100% of Cohort 3 (ID) patients seroconverted after 2 doses. 92% of Cohort 5 (IM+IL12) patients seroconverted after 2 doses and 100% after 3 doses. Other cohorts showed 67% at best after 2 doses and ranged as high as 93% after 3 doses.

**[0296]** When analyzing all patients: the best response frequency were Cohorts 2 and 4 with 53% and 57% respectively. Cohort 3 showed 40% responders. Addition of IL-12 in Cohort 5 did not seem to influence response rates (47%). When analyzing patients with 8 outliers removed the response frequency were Cohorts 2 and 4 with 84.6% and 76.9% respectively. Cohort 3 showed 64.3% responders. Addition of IL-12 in Cohort 5 did not seem to influence response rates (53.3%).

**[0297]** Both CD4 and CD8 T cells showed high expression of TNF $\alpha$  and TNF $\beta$  and/or IFNg in Cohort 3 (statistically significant to baseline, Wilcoxon matched pairs test, 2 tailed).

**[0298]** Immunization with INO-4201 was well tolerated in healthy volunteers with no Grade 3 or Grade 4 SAEs noted. INO-4201 induced robust Ebola GP-specific antibody (GMT 46,968) and resulted in 100% seroconversion, as gauged by binding ELISA, after only two doses of INO-4201. Administration of INO-4201 generated EBOV GP

specific T cell responses as assessed by Interferon gamma (IFNg) ELISpot (295.3 SFU per 106 PBMCs) and significant increases in the production of IFNg or TNF $\alpha$  in both the CD8+ T and CD4+ T cell compartments. Intradermal administration of INO-4201 using the Cellectra device is both well tolerated and immunogenic as assessed by both humoral and cellular EBOV GP-specific immunoassays. These results indicate that INO-4201 is a strong candidate for further clinical development of a prophylactic Ebola vaccine.

#### Example 9—Lasting Humoral and Cellular Immune Responses in Cynomolgus Macaques Following Administration of a Zaire Ebola Virus (EBOV) GP DNA Vaccine Delivered by Intramuscular Electroporation

**[0299]** Presented herein are novel Ebola virus disease (EVD) DNA vaccines that have a clean safety profile and are serology independent, allowing for possible repeat vector administration. Three novel synthetic Zaire Ebola virus (EBOV) GP DNA vaccines were designed and Bivalent, or Trivalent formulations were developed. Both EBOV-GP DNA vaccines were highly protective (75-100%) against lethal EBOV Makona C07 challenge in cynomolgus macaques. Animals (n=4-5/group) with different regimens were followed to monitor long-term immunogenicity following DNA immunization. All NHPs rapidly seroconverted. NHPs have durable total IgG antibody titers and T cells responses to EBOV GP antigen, including polyfunctional CD4 and CD8 T cells expressing IFNg, IL2, and TNF $\alpha$  and responses in memory subset populations (FIGS. 47-59). Together, the data strongly support EBOV-GP DNA vaccine delivery for protection and the generation of robust memory immune responses.

**[0300]** The EBOV-GP Dan vaccines elicit long-term immune responses and have a strong recall response following a 1 year boost (FIGS. 49-50). The recall response was remarkably high in the group receiving a single IM injection (FIG. 50).

#### Example 10

**[0301]** Presented herein are the peptide sequences and the nucleic acid sequences for the peptides.

TABLE 1

Plasmid Vaccine pMARB GP sequence MARV ANG								
Peptide		SEQ		ELISPOT			FACS T cell	
Number	Sequence	ID NO:	Position	H-2	Ave	$\pm$ SEM	restr.	
3	IQGVKTLPILEIASN	7	13-27	d	62	34	4+	
5	ASNIQPQNVDVCSG	8	23-39	b	743	186	8+	
12	SKRWAFRAGVPPKNV	9	67-81	b	694	204	4+	
27	GKVFTEGNIAAMIVN	10	137-171	d	602	75	4+	
28	GNIAAMIVNKTVHKM	11	163-177	b/d	126	28	8+	
	GNIAAMIVNKTVHKM	12		d	30	10	4+	
29	IVNKTVHKMIFSRQG	13	169-183	d	92	17	4+	
30	HKMIFSRQGQGYRH	14	175-189	d	31	10	4+	

TABLE 1-continued

Plasmid Vaccine pMARV							
GP sequence MARV ANG							
Peptide		SEQ		ELISPOT		FACS	
Number	Sequence	ID NO:	Position	H-2	AVE	±SEM	restr.
31	RQGQQYRHMNLSTN	15	181-195	b	674	112	8+
32	RHMMNLSTSTNKWTSS	16	187-201	b	44	16	8+
65	LPTENPTTAKSTNST	17	385-399	b/d	398/16	107/2	4+
71	PNSTAQHLVYFRRKR	18	421-435	d	29	6	4+
72	HLVYFRRKRNLWRE	19	427-441	d	145	18	4+
89	GLSWIPFFGPGIEGL	20	529-543	b	26	8	4+
92	GLIKNQNNLVCRLLRR	21	547-561	d	29	10	4+
93	NNLVCRLLRLANQTA	22	553-567	d	34	13	4+
97	TTEERTFSLINRHAI	23	577-591	b	46	18	8+
99	HAIDFLLARWGGTCK	24	589-603	d	63	12	4+
101	TCKVLGPDCIGIED	25	601-615	b	97	37	4+

<sup>a</sup>Epitope-containing peptides were identified by IFN $\gamma$  ELISPOT ( $\geq 10$  SFC/ $10^6$  splenocytes AND  $\geq 80\%$  response rate) and then confirmed by FACS ( $\geq 3.5 \times 10^4$  CD3+ cells were acquired).

Responses for each were further characterized by FACS (expression of CD4 and/or CD8 by CD3+/CD44+/IFN $\gamma$  cells).

Predicted CD8+ epitopes are underlined (best consensus % rank by IEDB) and previously-described epitopes are referenced.

Immunodominant epitopes are displayed (\*).

TABLE 2

Plasmid Vaccine pEBOS							
GP sequence SUDV CON							
Peptide		SEQ		ELISPOT		FACS	
Number	Sequence	ID NO:	Position	H-2	AVE	±SEM	restr.
4	FFVW <u>VIIILFQKAF</u> SM	26	19-33	b	310	139	8+
15	RWGFRSGVPPKVVSY	27	85-99	b	108	59	4+
19	YNLEIKKPDGSECLP	28	109-123	b	55	25	4+
24	HKAQGTGPCPGDYAF	29	139-153	d	13	3	8+
27	GAFFLYDRLASTVIY	30	157-171	d	29	9	8+
30	NFAEGVIAFLILAKP	31	175-189	d	31	6	4+
36	SYYATSYLEYEIENF	32	211-225	b	60	16	4+
41	FVLLDRPHTPQFLFQ	33	241-255	d	338	55	8+
78	NITTAVKTVLQUEST	34	463-477	b/d	28/105	12/18	4+
82	TGILGSLGLRKRSRR	35	487-501	d	82	14	4+
83	LGLRKRSRRQVNTRA	36	493-507	d	69	12	4+
89	IAWIPYFGPGAEGIY	37	529-543	b	123	40	8+/4+
97	TELRTYTILNRKAID	38	577-591	d	12	5	4+
101	CRILGPDCICIEPHDW	39	601-615	b	80	41	4+

TABLE 2-continued

Plasmid Vaccine pEBOS GP sequence SUDV CON							
Peptide		SEQ		ELISPOT		FACS T cell	
Number	Sequence	ID NO:	Position	H-2	AVE	±SEM	restr.
105	<u>QIIHDFIDNPLPNQD</u>	40	625-639	b	28	23	4+
110	<u>GIGITGIIIAIALL</u>	41	655-669	b	27	19	8+

<sup>a</sup>Epitope-containing peptides were identified by IFN $\gamma$  ELISPOT ( $\geq 10$  SFC/ $10^6$  splenocytes AND  $\geq 80\%$  response rate) and then confirmed by FACS ( $\geq 3-5 \times 10^4$  CD3+ cells were acquired). Responses for each were further characterized by FACS (expression of CD4 and/or CD8 by CD3+/CD44+/IFN $\gamma$ + cells). Predicted CD8+ epitopes are underlined (best consensus % rank by IEDB) and previously-described epitopes are referenced. Immunodominant epitopes are displayed (\*).

TABLE 3

Plasmid Vaccine pEBOZ GP sequence ZEOBV CON							
Peptide		SEQ		ELISPOT		FACS T cell	
Number	Sequence	ID NO:	Position	H-2	AVE	±SEM	restr.
6	<u>FSIPLGVIHNSTLQV</u>	42	31-45	d	78	31	8+
15	RWGFRSGVPPKVNVY	43	85-99	b	44	12	4+
19	YNLEIKKPDGSECLP	44	109-123	b	29	12	4+
24	HKVSGTGPCAGDFAF	45	139-153	d	484	85	8+
27	GAFFLYDRLASTVIY	46	157-171	d	72	18	8+
30	TFAEGVVAAFLILPQA	47	175-189	d	581	85	4+
32	PQAKKDFFSSHPLRE	48	187-201	b	18	6	4+
33	FFSSHPLREPVNATE	49	193-207	b	21	8	4+
40	EVDNLTYVQLESRFT	50	235-249	d	32	17	4+
41	YVQLESRFTPQFLLQ	51	241-255	d	97	23	4+
48	TTIGEWAFWETKKNL	52	283-297	d	219	70	4+
49	AFWETKKNLTRKIRS	53	289-303	d	32	15	4+
50	KNLTRKIRSEELSFT	54	295-309	d	105	37	4+
60	SQGREAAVSHLTTLA	55	355-369	b	16	7	4+
65	DNSTHNTPVYKLDIS	56	385-399	d	29	18	4+
66	TPVYKLDISEATQVE	57	391-405	d	371	118	4+
71	PPATTAAGPPKAENT	58	421-435	b	21	8	4+
84	TRREAIVNAQPKCNP	59	499-513	b	12	5	8+
89	LAWIPYFGPAAEGIY	60	529-543	b	93	8	8+/4+
97	TELRTFSILNRKAID	61	577-591	b/d	14/82	4/42	8+
101	CHILGPDCCEPHDW	62	601-615	b	96	62	4+

<sup>a</sup>Epitope-containing peptides were identified by IFN $\gamma$  ELISPOT ( $\geq 10$  SFC/ $10^6$  splenocytes AND  $\geq 80\%$  response rate) and then confirmed by FACS ( $\geq 3-5 \times 10^4$  CD3+ cells were acquired). Responses for each were further characterized by FACS (expression of CD4 and/or CD8 by CD3+/CD44+/IFN $\gamma$ + cells). Predicted CD8+ epitopes are underlined (best consensus % rank by IEDB) and previously-described epitopes are referenced. Immunodominant epitopes are displayed (\*).

TABLE 4

Plasmid Vaccine pMARV GP sequence MARV ANG									
Peptide		SEQ	Best con % rank (IEDB)					Previously	
			CD8+ ( $\leq 0.5$ )		CD4+ (<25)			defined (80% Blast; Allele)	
Number	Sequence	ID NO:	D <sup>b</sup>	K <sup>b</sup>	D <sup>d</sup>	K <sup>d</sup>	L <sup>d</sup>	I-A <sup>b</sup>	I-A <sup>d</sup>
3	IQGVKTL <u>P</u> ILEIASN	7							12.1
5	ASNIQPQN VDSVCSG	8	0.4						
12	SKRWAFRA GVPPKNV	9						0.8	
27	GKVFTEGN IAAMIVN	10						12.9	
28	GNIAAMIV NKTVHKM GNIAAMIV NKTVHKM	11	0.2					3.9	H-2 <sup>d</sup> class I
		12	0.2					3.9	
29	IVNKTVHK MIFSRQG	13						17.2	
30	HKMIFSRQ GQGYRHM	14							
31	RQGQGYRH MNLTSTN	15		0.1				23.9	
32	RHMNLTST NKYWTSS	16							
65	LPTENPTT AKSTNST	17					24.0		
71	PNSTAQHL VYFRRKR	18						7.5	
72	HLVYFRK RNILWRE	19			0.3			8.3	
89	GLSWIPFF GPGIEGL	20				7.0			
92	GLIKNQNN LVCRLLR	21							
93	NNLVCRLLR RLANQTA	22					13.3		
97	TTEERTFS LINRHAI	23	0.1		0.4				
99	HAIDFLLA RWGGTCK	24						21.8	
101	TCKVLGPD CCIGIED	25		0.4					

<sup>a</sup>Epitope-containing peptides were identified by IFN $\gamma$  ELISPOT ( $\geq 10$  SFC/ $10^6$  splenocytes AND  $\geq 80\%$  response rate) and then confirmed by FACS ( $\geq 5 \times 10^4$  CD3+ cells were acquired). Responses for each were further characterized by FACS (expression of CD4 and/or CD8 by CD3+/CD44+/IFN $\gamma$  cells). Predicted CD8+ epitopes are underlined (best consensus % rank by IEDB) and previously-described epitopes are referenced. Immunodominant epitopes are displayed (\*).

TABLE 5

Plasmid Vaccine pEBOS GP sequence SUDV CON												
Peptide		SEQ	Best con % rank (IEDB)						Previously			
Number	Sequence		ID NO:	D <sup>b</sup>	K <sup>b</sup>	D <sup>d</sup>	K <sup>d</sup>	L <sup>d</sup>	I-A <sup>b</sup>	I-A <sup>d</sup>	I-E <sup>d</sup>	Blast; Allele
4	<u>FFVVVIILFQKAFSM</u>	26		0.4								
15	RWGFRSGVPPKVVSY	27							1.2			
19	YNLEIKKPDGSECLP	28										
24	HKAQGTGPCPGDYAF	29					0.3					
27	GAFFLYDRLASTVIY	30		0.3					21.1		23.4	H-2 <sup>b</sup> class I
30	NFAEGVIAFLILAKP	31			0.1							
36	SYYATSYLEYEIENF	32	0.4		0.3	0.1						
41	FVLLDRPHTPQFLFQ	33					0.1					
78	NITTAVKTVLQUEST	34							7.2			
82	TGILGSLGLRKRSRR	35								17.2		
83	LGLRKRSRRQVNTRA	36										
89	IAWIPYFGPGAEGIY	37		0.1				3.0				
97	TELRTYTILNRKAID	38	0.1						18.5	21.2		
101	CRILGPDCCIEPHDW	39										
105	QIIHDFIDNPLPNQD	40	0.3									
110	GIGITGIIIAIIALL	41										

<sup>a</sup>Epitope-containing peptides were identified by IFN $\gamma$  ELISPOT ( $\geq 10$  SFC/ $10^6$  splenocytes AND  $\geq 80\%$  response rate) and then confirmed by FACS ( $\geq 3.5 \times 10^4$  CD3+ cells were acquired). Responses for each were further characterized by FACS (expression of CD4 and/or CD8 by CD3+/CD44+/IFN $\gamma$ + cells). Predicted CD8+ epitopes are underlined (best consensus % rank by IEDB) and previously-described epitopes are referenced.

Immunodominant epitopes are displayed (\*).

TABLE 6

Plasmid Vaccine pEBOZ GP sequence ZEOBV CON												
Peptide		SEQ	Best con % rank (IEDB)						Previously			
Number	Sequence		ID NO:	D <sup>b</sup>	K <sup>b</sup>	D <sup>d</sup>	K <sup>d</sup>	L <sup>d</sup>	I-A <sup>b</sup>	I-A <sup>d</sup>	I-E <sup>d</sup>	Blast; Allele
6	<u>FSIPLGVIHNSTLQV</u>	42					0.2					H-2 <sup>d</sup> class I
15	RWGFRSGVPPKVVSY	43							1.2			H-2 <sup>d</sup> class I
19	YNLEIKKPDGSECLP	44										
24	HKVSGTGPCAGDFAF	45					0.1	14.9				
27	GAFFLYDRLASTVIY	46	0.3					21.1		23.4		
30	TFAEGVVAFLILPQA	47		0.2					21.6			
32	PQAKKDFSSHPLRE	48	0.1	0.4					16.4			
33	FFSSHPLREPVNATE	49						14.7				
40	EVDNLTYVQLESRFT	50			0.4			19.6				H-2 <sup>b</sup> class I

TABLE 6-continued

Plasmid Vaccine pEBOZ GP sequence ZEBOV CON											
		Best cons % rank (IEDB)								Previously	
Peptide		SEQ	CD8+ (<0.5)				CD4+ (<25)			defined (80%)	
Number	Sequence	ID NO:	D <sup>b</sup>	K <sup>b</sup>	D <sup>d</sup>	K <sup>d</sup>	L <sup>d</sup>	I-A <sup>b</sup>	I-A <sup>d</sup>	I-E <sup>d</sup>	Blast; Allele
41	YVQLESRFTPQFLLO	51									H-2 <sup>k</sup> class I
48	TTIGEWAFWETKKNL	52									12.9
49	AFWETKKNLTRKIRS	53									22.9
50	KNLTRKIRSEELSFT	54									22.7
60	SQGREA AVSHLTTLA	55	0.3					23.1	3.9		
65	DNSTHNTPVYKLDIS	56									
66	TPVYKLDISEATQVE	57						22.6	5.5		
71	PPATTAAGPPKAENT	58						2.1			
84	TRREAIYN AQP KCNP	59	0.3					14.6	7.9		
89	LAWIPYFGPAAE GIY	60			0.1			0.8			
97	TELRTFSILNRKAI D	61	0.1								22.2
101	CHILGPDC CIEPHDW	62									

<sup>a</sup>Epitope-containing peptides were identified by IFN $\gamma$  ELISPOT ( $\geq 10$  SFC/ $10^6$  splenocytes AND  $\geq 80\%$  response rate) and then confirmed by FACS ( $\geq 3-5 \times 10^4$  CD3+ cells were acquired). Responses for each were further characterized by FACS (expression of CD4 and/or CD8 by CD3+/CD44+/IFN $\gamma$ + cells). Predicted CD8+ epitopes are underlined (best consensus % rank by IEDB) and previously-described epitopes are referenced. Immunodominant epitopes are displayed (\*).

## SEQUENCE LISTING

Sequence total quantity: 74

SEQ ID NO: 1 moltype = AA length = 676  
 FEATURE Location/Qualifiers  
 REGION 1..676  
 note = synthetic consensus Zaire ebolavirus glycoprotein,  
 pGX4201  
 source 1..676  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 1

MGTGILQLP RDRFKRTSFF LWVIILFORT FSIPLGVIIHN STLQVSDVDK LVCRDKLSST 60  
 NQLRSVGLNL EGNGVATDVP SATKRWGFRS GVPVKVVNYE AGEWAENCYN LEIKKPDGSE 120  
 CLPAAPDGIR GFPRCRYVHK VSGTGPCAGD FAFHKEGAFD LYDRLASTVI YRGITFAEGV 180  
 VAFLILPQAK KDFFSSHPLR EPVNATEDPS SGYYSTTIRY QATGFGTNET EYLFEVDNL 240  
 YVQLESRFTP QFLQLQNETI YTSGKRSNTT GKLWIKVMP EIDTTIGEWAF WETKKNLTRK 300  
 IRSEELSFTA VSNRAKNISG QSPARTSSDP GTNTTTEDHK IMASENSSAM VQVHSQGRE 360  
 AVSHLTTLAT ISTSPQSPPTT KPGPDNSTHN TPVYKLDISE ATQVEQHRR TDNDSTASDT 420  
 PPATTAAGPP KAENTNTSKS TDLLDPATT SPQNHSSETAG NNNTHHQDTG EESASSGKLG 480  
 LITNTIAGVA GLITGRRTR REAIVNAQPK CNPNLHYWT QDEGAIGLA WIPYFGPAAE 540  
 GIYTEGLMHN QDGLICGLRQ LANETTQALQ LFLRATTELR TFSILNRKAI DFLLQRWGKT 600  
 CHILGPDCCI EPHDWTKNIT DKIDQIIHDF VDKTLPDQGD NDNNWWTGWRQ WIPAGIGVTG 660  
 VIIAVIALFC ICKFVF 676

SEQ ID NO: 2 moltype = AA length = 676  
 FEATURE Location/Qualifiers  
 REGION 1..676  
 note = synthetic consensus sequence Sudan ebolavirus  
 glycoprotein  
 source 1..676  
 mol\_type = protein  
 organism = synthetic construct

-continued

---

SEQUENCE: 2  
 MEGLSLQLQP RDKFRKSSFF VVVIILFQKA FSMPLGVVTN STLEVTEIDQ LVCKDHLAST 60  
 DQLKSVGLNL EGSGVSTDIP SATKRGFRS GVPPKVVSYE AGEWAENCYN LEIKKPDGSE 120  
 CLPFFFFDGVR GFPRCRYVHK AQQGTGCPGD YAFHKDGAFF LYDRLASTVI YRGVNFAEVG 180  
 IAFLILAKPK ETFLQSPPIR EAVNYTENTS SYYATSYLEY EIENFGAQHS TTLFKINNNNT 240  
 FVLLDRPHTP QFLFQLNDTTI HLHQQLSNTT GKLIWTLDAW INADIGEWAA WENKKNLSEQ 300  
 LRGEELSFTET LSLNNETEDDD ATSSRTTKGR ISDRATRKYS DLVPKDSPGM VSLHVPEGET 360  
 TLPSONSTEGR RRVDVNTQET ITETTATTIIG TNGNNM01ST ITGGLSSSQI LSSSPTMAPS 420  
 PETQTSTTYT PKLPVMTTEE PTTPPRNSPG STTEAPLT LT PENITTAVKT VLPQESTNSG 480  
 LTSTVTGIL GSLGLRKRSR RQVNTRATGK CNPNLHYWTA QEQQHNAAGIA WIPYFPGGAE 540  
 GIVTEGLMHN QNALVCLRLQ LANETTQALQ LFRLRATTELR TYTILNRKAI DFLLRRWGTT 600  
 CRILGPDCCI EPHDWTKNIT DKINQIIHDF IDNPLPNQDN DDNWWTGWRQ WIPAGIGITG 660  
 IIIAIIALLC VCKLLC 676

SEQ ID NO: 3 moltype = AA length = 681  
 FEATURE Location/Qualifiers  
 source 1..681  
 mol\_type = protein  
 organism = Marburg virus

SEQUENCE: 3  
 MKTTCLLISL ILLIQGVKTL PILEIASNIQP QNVDSVCSTG LQKTEDVHLM GFTLSGQKVA 60  
 DSPLEASKRW AFRTGVPPKN VEYTEGEEAK TCYNISVTDP SGKSLLLDPP TNIRDYPKCK 120  
 TIHHIQGQNP HAQGIALHLW GAFFLYDRIA STTMYRGKVF TEGNIAAMIV NKTVHKMIFS 180  
 RQGQGYRHMN LTSTNKYWTS SNGTQTNDTG CFGTLQEYNS TKNQTCAPSK KPLPLPTAHP 240  
 EVKLTSTSTD ATKLNTTDPN SDDEDLTTSG SGSGEQEPYT TSDAATKQGL SSTMPPTPSP 300  
 QPSTPQQQGN NTNHSGQVVT EPGKTNTTAAQ PSMMPHNITT ISTNNNTSKHN LSTPSVPIQN 360  
 ATNYNTQSTA PEPEQTSAPS KTTLLPTEQPN TTAKSTNSTK SPTTTVPTNT NKYSTSPSPPT 420  
 PNSTTAQHLVY FRRKRSNILWR EGDMFPFLDG LINAPIDFPD VPNTKTIFDE SSSSGASAAE 480  
 DQHASPNISL TLSYFPKVNE NTAHSGENEN DCDAELRIWS VQEDDLAAGL SWIPFFGPGI 540  
 EGLYTAGLIK NQNNLVCRRL RLANQTAKSL ELLLRVTTTE RTFSLINRHA IDFLLTRWGG 600  
 TCKVLGPDC CIGIEDLSRN1 SEQIDQIKKD EQKEETGWGL GGKWWTSWDW VLTNLGILL 660  
 LSIAVLIALS CICRIFTKYI G 681

SEQ ID NO: 4 moltype = AA length = 681  
 FEATURE Location/Qualifiers  
 REGION 1..681  
 note = synthetic consensus sequence 1 of Marburgvirus  
 glycoprotein  
 source 1..681  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 4  
 MRTIYFLISL ILLIQSITKTL PILEIASNSQP QDVDSVCSTG LQKTEDVHLM GFTLSGQKVA 60  
 DSPLEASKRW AFRTGVPPKN VEYTEGEEAK TCYNISVTDP SGKSLLLDPP SNIRDYPKCK 120  
 TVHHIQGQNP HAQGIALHLW GAFFLYDRVA STTMYRGKVF TEGNIAAMIV NKTVHKMIFS 180  
 RQGQGYRHMN LTSTNKYWTS SNETRNRNDTG CFGILQEYNS TNNQTCAPSL KPPSLPTVTP 240  
 SIHSTNTQIN TAKSGTMNPS SDDDELMISG SGSGEQGPHT TLNVVTEQKQ SSTILSTPSL 300  
 HPSTSQQHEQN STNPSRAHT EHNGTDPTTQ PATLNNNTNT TPTYNTLKYN LSTPSPTTRN 360  
 ITNNNDTQREL AESEQTNAQL NTTLDPTEQPN TTAQDTNSTT NIIMTTSDIT SKHPTNNSPD 420  
 SSPTTRPPIY PRKKRSIFWK EGDIFFPFLDG LINTEIDFPD IPNTETIFDE SPSFNTSTNE 480  
 EQHTPPNISL TFSYFPDKNG DTAYSGENEN DCDAELRIWS VQEDDLAAGL SWIPFFGPGI 540  
 EGLYTAGLIK NQNNLVCRRL RLANQTAKSL ELLLRVTTTE RTFSLINRHA IDFLLTRWGG 600  
 TCKVLGPDC CIGIEDLSRN1 SEQIDKIRKD EQKEETGWGL GGKWWTSWDW VLTNLGILL 660  
 LSIAVLIALS CICRIFTKYI G 681

SEQ ID NO: 5 moltype = AA length = 681  
 FEATURE Location/Qualifiers  
 REGION 1..681  
 note = synthetic consensus sequence 2 of Marburgvirus  
 glycoprotein  
 source 1..681  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 5  
 MRTTCFFISL ILLIQGIKTL PILEIASNDQP QNVDSVCSTG LQKTEDVHLM GFTLSGQKVA 60  
 DSPLEASKRW AFRTGVPPKN VEYTEGEEAK TCYNISVTDP SGKSLLLDPP TNVRDYPKCK 120  
 TIHHIQGQNP HAQGIALHLW GAFFLYDRIA STTMYRGKVF TEGNIAAMIV NKTVHKMIFS 180  
 RQGQGYRHMN LTSTNKYWTS SNGTQTNDTG CFGTLQEYNS TKNQTCAPSK TPPPPPTARP 240  
 EIKPTSTPTD ATRLNNTTNPN SDDEDLTTSG SGSGEQEPYT TSDAVTKQGL SSTMPPTPSP 300  
 QPGTPQQGGN NTNHSQDAAT ELDNTNTTAAQ PPPTPSHNTTT ISTNNNTSKHN LSTLSEPPQN 360  
 TTNPNTQMSA TEKEKTSAPP KTTLLPTEQPN TTAKSTNSTK SPTTMEPNTT NGHFTSPSST 420  
 PNSTTQHLIY FRRKRSILWR EGDMFPFLDG LINAPIDFPD VPNTKTIFDE SSSSGASAAE 480  
 DQHASSNISL TLSYLPHTSE NTAYSGENEN DCDAELRIWS VQEDDLAAGL SWIPFFGPGI 540  
 EGLYTAGLIK NQNNLVCRRL RLANQTAKSL ELLLRVTTTE RTFSLINRHA IDFLLTRWGG 600  
 TCKVLGPDC CIGIEDLSRN1 SEQIDQIKKD EQKEETGWGL GGKWWTSWDW VLTNLGILL 660  
 LSIAVLIALS CICRIFTKYI G 681

---

-continued

---

```

SEQ ID NO: 6          moltype = AA  length = 681
FEATURE
REGION
1..681
note = synthetic consensus sequence 3 of Marburgvirus
glycoprotein
1..681
source
mol_type = protein
organism = synthetic construct
SEQUENCE: 6
MKTTCLEFISL ILIQGIKTLPLILEIASNNQP QNVDSVCSGT LQKTEDVHLM GFTLSGQKVA 60
DPSLEASKRW AFRTGVPPKN VEYTEGEAK TCYNISVTPP SGKSLLDDPP TNIRDYPKCK 120
TIHHIQGQNP HAQGIALHLW GAFFLYDRIA STTMYRGRVF TEGNIAAMIV NKTVHKMIFS 180
RQCGQGYRHNM LTSTNKYWTN NNGQTNDTG CFGALQEYNS TKNQTCAPS K PSDAVTKQGL SSTMPPTPSP 240
EIKPTSTPTD ATKLNTDPN SDDEDLATSG SGSGEQEPT K PSDAVTKQGL SSTMPPTPSP 300
QPSTPQQEGN NTDHSQDAVN EPNKTNTTAQ PSMSPHNITA ISTNNNTSKHN FSTLsapLQN 360
TTNYDTQSTA TENEQTSAPS KTTLPPTGNL TTAKSTNNNT GPTTTAPNMT NGHLTSPSPT 420
PNPTTQHLVY FRKKRSILWE EGDMPPFLDG LINAPIDFP VPNTKTIFDE SSSSGASAE 480
DQHASPNISL TLSYFPVNINE NTAYSGENEN DCDAELRIWS VQEDDLAAGL SWIPFFGPGI 540
EGLYTAGLIK NQNNLVCRLR RLANQTAKS ELLLRVITEE RTFSLINRHA IDFLLTRWGG 600
TCKVLGPDC CIGIEDLSRNI SEQIDQIKKD EQKEGTGWGL GGKWWTSWDW VLTNLGILL 660
LSIAVLIALS CICRIFTKYI G 681

SEQ ID NO: 7          moltype = AA  length = 15
FEATURE
REGION
1..15
note = Marburg virus epitope fragment 1
source
mol_type = protein
organism = synthetic construct
SEQUENCE: 7
IQGVKTLPLIL EIASN 15

SEQ ID NO: 8          moltype = AA  length = 15
FEATURE
REGION
1..15
note = Marburg virus epitope fragment 2
source
mol_type = protein
organism = synthetic construct
SEQUENCE: 8
ASNIQPQNVSD SVCSSG 15

SEQ ID NO: 9          moltype = AA  length = 15
FEATURE
REGION
1..15
note = Marburg virus epitope fragment 3
source
mol_type = protein
organism = synthetic construct
SEQUENCE: 9
SKRWAFRAGV PPKNV 15

SEQ ID NO: 10         moltype = AA  length = 15
FEATURE
REGION
1..15
note = Marburg virus epitope fragment 4
source
mol_type = protein
organism = synthetic construct
SEQUENCE: 10
GKVFTEGNIA AMIVN 15

SEQ ID NO: 11         moltype = AA  length = 15
FEATURE
REGION
1..15
note = Marburg virus epitope fragment 5
source
mol_type = protein
organism = synthetic construct
SEQUENCE: 11
GNIAAMIVNK TVHKM 15

SEQ ID NO: 12         moltype = AA  length = 15
FEATURE
REGION
1..15

```

---

-continued

---

source	note = Marburg virus epitope fragment 6 1..15 mol_type = protein organism = synthetic construct	
SEQUENCE: 12		15
	GNIAAMIVNK TVHKM	
SEQ ID NO: 13	moltype = AA length = 15 Location/Qualifiers	
FEATURE	1..15	
REGION	note = Marburg virus epitope fragment 7 1..15 mol_type = protein organism = synthetic construct	
source		15
SEQUENCE: 13		
	VNKTIVHKMI FSRQG	
SEQ ID NO: 14	moltype = AA length = 15 Location/Qualifiers	
FEATURE	1..15	
REGION	note = Marburg virus epitope fragment 8 1..15 mol_type = protein organism = synthetic construct	
source		15
SEQUENCE: 14		
	HKMIFSRQGQ GYRHM	
SEQ ID NO: 15	moltype = AA length = 15 Location/Qualifiers	
FEATURE	1..15	
REGION	note = Marburg virus epitope fragment 9 1..15 mol_type = protein organism = synthetic construct	
source		15
SEQUENCE: 15		
	RQGQGYRHMN LTSTN	
SEQ ID NO: 16	moltype = AA length = 15 Location/Qualifiers	
FEATURE	1..15	
REGION	note = Marburg virus epitope fragment 10 1..15 mol_type = protein organism = synthetic construct	
source		15
SEQUENCE: 16		
	RHMNLTTSTNK YWTSS	
SEQ ID NO: 17	moltype = AA length = 15 Location/Qualifiers	
FEATURE	1..15	
REGION	note = Marburg virus epitope fragment 11 1..15 mol_type = protein organism = synthetic construct	
source		15
SEQUENCE: 17		
	LPTEENPTTAK STNST	
SEQ ID NO: 18	moltype = AA length = 15 Location/Qualifiers	
FEATURE	1..15	
REGION	note = Marburg virus epitope fragment 12 1..15 mol_type = protein organism = synthetic construct	
source		15
SEQUENCE: 18		
	PNSTAQHLVY PRRKR	
SEQ ID NO: 19	moltype = AA length = 15 Location/Qualifiers	
FEATURE	1..15	
REGION	note = Marburg virus epitope fragment 13 1..15 mol_type = protein organism = synthetic construct	
source		15
SEQUENCE: 19		
	HLVYFRRKRN ILWRE	

---

-continued

---

```

SEQ ID NO: 20      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Marburg virus epitope fragment 14
                  1..15
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 20      GLSWIPFFGP GIEGL
                                         15

SEQ ID NO: 21      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Marburg virus epitope fragment 15
                  1..15
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 21      GLIKNQNNLV CRLRR
                                         15

SEQ ID NO: 22      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Marburg virus epitope fragment 16
                  1..15
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 22      NNLVCRLLR ANQTA
                                         15

SEQ ID NO: 23      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Marburg virus epitope fragment 17
                  1..15
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 23      TTEERTFSLI NRHAI
                                         15

SEQ ID NO: 24      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Marburg virus epitope fragment 18
                  1..15
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 24      HAIDFLLARW GGTCK
                                         15

SEQ ID NO: 25      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Marburg virus epitope fragment 19
                  1..15
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 25      TCKVLGPDCC IGIED
                                         15

SEQ ID NO: 26      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Sudan ebolavirus peptide fragment 1
                  1..15
                  mol_type = protein
                  organism = synthetic construct
SEQUENCE: 26      FFVWVIIILFQ KAFSM
                                         15

SEQ ID NO: 27      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Sudan ebolavirus peptide fragment 2
                  1..15

```

---

-continued

---

	mol_type = protein
	organism = synthetic construct
SEQUENCE: 27	
RWGFRSGVPP KVVSY	15
SEQ ID NO: 28	moltype = AA length = 15
FEATURE	Location/Qualifiers
REGION	1..15
source	note = Sudan ebolavirus peptide fragment 3
	1..15
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 28	
YNLEIKKPDG SECLP	15
SEQ ID NO: 29	moltype = AA length = 15
FEATURE	Location/Qualifiers
REGION	1..15
source	note = Sudan ebolavirus peptide fragment 4
	1..15
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 29	
HKAQGTGPCP GDYAF	15
SEQ ID NO: 30	moltype = AA length = 15
FEATURE	Location/Qualifiers
REGION	1..15
source	note = Sudan ebolavirus peptide fragment 5
	1..15
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 30	
GAFFLYDRLA STVIY	15
SEQ ID NO: 31	moltype = AA length = 15
FEATURE	Location/Qualifiers
REGION	1..15
source	note = Sudan ebolavirus peptide fragment 6
	1..15
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 31	
NFAEGVIAFL ILAKP	15
SEQ ID NO: 32	moltype = AA length = 15
FEATURE	Location/Qualifiers
REGION	1..15
source	note = Sudan ebolavirus peptide fragment 7
	1..15
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 32	
SYYATSYLEY EIENF	15
SEQ ID NO: 33	moltype = AA length = 15
FEATURE	Location/Qualifiers
REGION	1..15
source	note = Sudan ebolavirus peptide fragment 8
	1..15
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 33	
FVLLDRPHTP QFLFQ	15
SEQ ID NO: 34	moltype = AA length = 15
FEATURE	Location/Qualifiers
REGION	1..15
source	note = Sudan ebolavirus peptide fragment 9
	1..15
	mol_type = protein
	organism = synthetic construct
SEQUENCE: 34	
NITTAVKTVL PQEST	15
SEQ ID NO: 35	moltype = AA length = 15

---

-continued

---

FEATURE REGION	Location/Qualifiers 1..15 note = Sudan ebolavirus peptide fragment 10
source	1..15 mol_type = protein organism = synthetic construct
SEQUENCE: 35 TGILGSLGLR KRSRR	
	15
SEQ ID NO: 36 FEATURE REGION	moltype = AA length = 15 Location/Qualifiers 1..15 note = Sudan ebolavirus peptide fragment 11
source	1..15 mol_type = protein organism = synthetic construct
SEQUENCE: 36 LGLRKRSRRQ VNTRA	
	15
SEQ ID NO: 37 FEATURE REGION	moltype = AA length = 15 Location/Qualifiers 1..15 note = Sudan ebolavirus peptide fragment 12
source	1..15 mol_type = protein organism = synthetic construct
SEQUENCE: 37 IAWIPYFGPG AEGIY	
	15
SEQ ID NO: 38 FEATURE REGION	moltype = AA length = 15 Location/Qualifiers 1..15 note = Sudan ebolavirus peptide fragment 13
source	1..15 mol_type = protein organism = synthetic construct
SEQUENCE: 38 TELRTTYILN RKAID	
	15
SEQ ID NO: 39 FEATURE REGION	moltype = AA length = 15 Location/Qualifiers 1..15 note = Sudan ebolavirus peptide fragment 14
source	1..15 mol_type = protein organism = synthetic construct
SEQUENCE: 39 CRILGPDCCI EPHDW	
	15
SEQ ID NO: 40 FEATURE REGION	moltype = AA length = 15 Location/Qualifiers 1..15 note = Sudan ebolavirus peptide fragment 15
source	1..15 mol_type = protein organism = synthetic construct
SEQUENCE: 40 QIIHDFIDNP LPNQD	
	15
SEQ ID NO: 41 FEATURE REGION	moltype = AA length = 15 Location/Qualifiers 1..15 note = Sudan ebolavirus peptide fragment 16
source	1..15 mol_type = protein organism = synthetic construct
SEQUENCE: 41 GIGITGIIIA IIALL	
	15
SEQ ID NO: 42 FEATURE REGION	moltype = AA length = 15 Location/Qualifiers 1..15 note = Zaire ebolavirus consensus fragment 1
source	1..15 mol_type = protein organism = synthetic construct

---

-continued

---

```

SEQUENCE: 42          moltype = AA  length = 15
FSIPLGVIGHN STLQV               15

SEQ ID NO: 43          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Zaire ebolavirus consensus fragment 2
1..15
mol_type = protein
organism = synthetic construct

SEQUENCE: 43          moltype = AA  length = 15
RWGFRSGVPP KVVNY               15

SEQ ID NO: 44          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Zaire ebolavirus consensus fragment 3
1..15
mol_type = protein
organism = synthetic construct

SEQUENCE: 44          moltype = AA  length = 15
YNLEIKKPDG SECLP               15

SEQ ID NO: 45          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Zaire ebolavirus consensus fragment 4
1..15
mol_type = protein
organism = synthetic construct

SEQUENCE: 45          moltype = AA  length = 15
GAFFLYDRLA STVIY               15

SEQ ID NO: 46          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Zaire ebolavirus consensus fragment 5
1..15
mol_type = protein
organism = synthetic construct

SEQUENCE: 46          moltype = AA  length = 15
GAFFLYDRLA STVIY               15

SEQ ID NO: 47          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Zaire ebolavirus consensus fragment 6
1..15
mol_type = protein
organism = synthetic construct

SEQUENCE: 47          moltype = AA  length = 15
TFAEGVVAFL ILPQA               15

SEQ ID NO: 48          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Zaire ebolavirus consensus fragment 7
1..15
mol_type = protein
organism = synthetic construct

SEQUENCE: 48          moltype = AA  length = 15
PQAKKDFFSS HPLRE               15

SEQ ID NO: 49          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15
source            note = Zaire ebolavirus consensus fragment 8
1..15
mol_type = protein
organism = synthetic construct

SEQUENCE: 49          moltype = AA  length = 15
FFSSHPLREP VNATE               15

SEQ ID NO: 50          moltype = AA  length = 15
FEATURE          Location/Qualifiers
REGION           1..15

```

---

-continued

---

```

source          note = Zaire ebolavirus consensus fragment 9
                1..15
                mol_type = protein
                organism = synthetic construct
SEQUENCE: 50      EVDNLTYVQL ESRFT
                                15

SEQ ID NO: 51      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
note = Zaire ebolavirus consensus fragment 10
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 51      YVQLESRFTP QFLLO
                                15

SEQ ID NO: 52      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
note = Zaire ebolavirus consensus fragment 11
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 52      TTIGEWFATW TKKNL
                                15

SEQ ID NO: 53      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
note = Zaire ebolavirus consensus fragment 12
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 53      AFWETKKNLT RKIRS
                                15

SEQ ID NO: 54      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
note = Zaire ebolavirus consensus fragment 13
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 54      KNLTRKIRSE ELSFT
                                15

SEQ ID NO: 55      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
note = Zaire ebolavirus consensus fragment 14
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 55      SQGREAAVSH LTTLA
                                15

SEQ ID NO: 56      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
note = Zaire ebolavirus consensus fragment 15
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 56      DNSTHNTPVY KLDIS
                                15

SEQ ID NO: 57      moltype = AA length = 15
FEATURE          Location/Qualifiers
REGION           1..15
note = Zaire ebolavirus consensus fragment 16
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 57      TPVYKLDISE ATQVE
                                15

```

---

-continued

---

```

SEQ ID NO: 58          moltype = AA length = 15
FEATURE
REGION
1..15
note = Zaire ebolavirus consensus fragment 17
source
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 58
PPATTAAGPP KAENT
15

SEQ ID NO: 59          moltype = AA length = 15
FEATURE
REGION
1..15
note = Zaire ebolavirus consensus fragment 18
source
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 59
TRREAIIVNAQ PKCNP
15

SEQ ID NO: 60          moltype = AA length = 15
FEATURE
REGION
1..15
note = Zaire ebolavirus consensus fragment 19
source
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 60
LAWIPYFGPA AEGIY
15

SEQ ID NO: 61          moltype = AA length = 15
FEATURE
REGION
1..15
note = Zaire ebolavirus consensus fragment 20
source
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 61
TELRTFSILN RKAID
15

SEQ ID NO: 62          moltype = AA length = 15
FEATURE
REGION
1..15
note = Zaire ebolavirus consensus fragment 21
source
1..15
mol_type = protein
organism = synthetic construct
SEQUENCE: 62
CHILGPDCCI EPHDW
15

SEQ ID NO: 63          moltype = AA length = 15
FEATURE
source
1..15
mol_type = protein
organism = Homo sapiens
SEQUENCE: 63
CHILGPDCCI EPHDW
15

SEQ ID NO: 64          moltype = DNA length = 2034
FEATURE
misc_feature
1..2034
note = synthetic Zaire ebolavirus glycoprotein consensus,
pGX4201
source
1..2034
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 64
atgggggtca ctgggattct gcagctgcgt agagatcgct tcaaggcgaac ctctttctt 60
ctgtgggtca tcattctgtt ccagaggact tttagtatcc ctctggcgct cattcaaat 120
tctaccctgc aggtgagtga cgtcgataag ctgtgtgtc gggacaact gagtcacc 180
aaccagctga gatctgtcggt cctgaatctg gaggggaacg gagtggtac cgatgtccca 240
agtgcaacaa agagatgggg gtttcgtca ggagtgcggcc cttaaagtgtt caattacgag 300
gccggggat gggctgagaa ttgtatataac ctggaaatca aqaaacccga cggatcagag 360
tgtctgcggcc cgctccccga tggtggatccata gatgcagata cgtgcacaag 420
gtcagcggca cccggccatg tgcaggagac ttgcgccttc ataaagaagg cgccttctt 480

```

-continued

ctgtacgata	gactggcttc	caccgtgatc	tatagggggta	ccacattcgc	cgagggagtg	540
gtcgcttttc	tgattctgcc	tcaggccaag	aaagacttct	tttctagtca	tcctctgcgg	600
gaacagtgc	acgcttacca	ggaccccacg	agcggctact	attccactac	catacagatc	660
caggccacag	gattccccgc	caatgagaca	gaatacttgc	ttgaatgtga	caacgtacca	720
tatgtccacg	tggagtcttag	gttcaactcc	cagtttctgc	tgcaactgaa	tgaactatc	780
tataccatgt	gcaaggcgtc	aaatacaact	gggaaagetga	tttggaaagt	gaacccttag	840
atcgatcacca	caattggcga	atggggccctt	ttgggagacca	agaaaaaacct	gacacggaa	900
atcagaagcg	aggaactgtc	cttcacccga	ttggagataa	ggggccaaaaaa	catttcaggc	960
caagccccac	caccaacttc	ctctgacccc	gggaccaacta	ctacccacaga	agatccacaa	1020
atcatggccca	gcgagaacag	ttcagctatg	gtgcagggtcc	actcccaagg	aaggggaggca	1080
ggccgtgtttt	atctgactac	cctggccaca	atctctacta	gtccccagag	ccccacacact	1140
aaggccccgg	ctgacaatag	caccctaaac	acacccgtgt	acaaactgg	tatcccgaa	1200
gcaccccaagg	tcgagcagca	ccatcgggaa	acagacaaatg	attccatgc	atctggacacc	1260
cctccagcaaa	ccacagctgc	aggacccccc	aagggtcgaga	atactaacaac	cagccaaaagg	1320
accgacccgtc	tggacccccc	aactaccaca	tcacccacaga	accacacgca	gacacccggg	1380
aaataatcaaa	cttcacccat	ggacacccgg	gaggaatccg	ccagctccgg	caagctgggg	1440
ctgatcaccaa	atactatttc	tggagtggca	ggactgtca	caggggggag	ggactactgca	1500
cgagaagctt	tttgtaaacgc	acagccccaa	tgcaatctta	acctggacta	ttggactacc	1560
caggacgagg	gagcagctat	cggacttgca	ttggattccat	actttttggcc	cgcagccgaa	1620
ggaatctata	cggaggccgt	gatcataat	caggatggac	tgatctgtgg	cctggccgeag	1680
ctggtaacgc	aaacaacttc	ggcactgcgg	ctgttctgc	gatcttacacc	agactgtcg	1740
acctttatcg	tcctgaaatcg	caaggcaatt	gacttctgc	tgacccgtat	ggggagggacaa	1800
tgccacatcc	tgggaccaga	ctgctgtatt	gagcctctatg	attggacaaa	gaacatcaact	1860
gacaaaaatgt	atcagatcat	tcacgacttc	gtggataaaa	cacttgcgc	tcagggggac	1920
aatgatataact	ggtggactgg	atggagacag	ttggatcccg	ccggatattgg	cgtccacccgc	1980
gtcattatgg	ccgtattatc	tctgttctgc	attttaatgt	tcgtttctgc	ataa	2034

-continued

```

SEQ ID NO: 67 moltype = AA length = 676
FEATURE Location/Qualifiers
REGION 1..676
note = ZEBOV GUI, pGX4202
source 1..676
mol_type = protein
organism = synthetic construct

SEQUENCE: 67
MGVTGILQLP RDRFKRTSFF LWVIIILFQRT FSIPLGVIHN STLQVSDVK LVCRDKLSST 60
NQLRSVGLNL EGGNVATDVP SATKRWGFGRS GVPVKVNYE AGEWAENCY LEIKHPDGSE 120
CLPAAPDGCIR GPPRCRYVHK VSGTGPCAGD FAFHKEGAFF LYDRLLASTVI YRGTTFAEGV 180
VAFLFLPQAK KDFFFSSHPLR EPVNATEDPS SGYVSTTIFY QATGFGTNET EYLFLFVDNLT 240
YVQLESRFTP QFLQLQNETI YASGKRSNTT GKLIWKVNPE IDTTIGEWAF RETKKNLTRK 300
IRSEELTSFTA VSNGPKNISG QSPARTSSDP ETNTTNEHDHK IMASENSSAM VQVHSQGRKA 360
AVSHLLTLAT ISTSPQPPTT KTGPDNSTHN PTVPYKLDISE ATQVGQHRR ADNDSTASDT 420
PPATTAAGPL KAENTNTKS ADSDLDDATT SPONYSETAG NNNTHHODTG ESEASSKGKL 480
LITNTIAGVA GLITGGRRTR REVIVNAQPK CNPNLHYWTQ DEGAAIGLA WIPYFGPAAE 540
GIYIEGLMHN QDGLICLGRQ LANETTQALQ LFLLRATTTEL TFSILNRKAI DFLLLQRWGGT 600
CHILGPDCII EPHDWTKNIT DKIDQIHFDF VDKTLPDQGD NDNWWTGWRQ WIPAGIVTG 660
VIIAVIAFLC ICKFVPR 676

```

```

SEQ ID NO: 68 moltype = AA length = 676
FEATURE Location/Qualifiers
REGION 1..676
note = ZEOBV CON2, pGX4203
source 1..676
mol_type = protein
organism = synthetic construct

SEQUENCE: 68
MGITGILQLP RDRFKRTSFF LWVIIILFQRT FSIPLGVVIHN STLQVSDVDK LVCRDKLSSST 60
NQLRSVGLNL EGNGVATDVP SATKRWGFRS GVPVKVVNY AGEWAENCYN LEIKKPDGSE 120
CLPAAPDGIR GFPRCRYVHK VSGTGTGCAAGD FAFHKEGAFF LYDRLASTVI YRGTTFAEVG 180
VAFLILPQAK KDFFSSSHPLR EPVNATEDPS SGYYSTTIRY QATGFGTNET EYLFEVDNL 240
YVQLESRFTP QFLLQLNETI YASGKRSNTT GKLIWKVNPET IDTTIGEWAF WETKKTSLGK 300
IRSEELSTSFA VSNGAKDISG QSPARTSSDP ETYTTEDEHK IMASENSSTM VQVHNQGRE 360
AVSHLTLAT ISTSPQSPPTT KPGDNSTNTN TPVYKLDDST ATQVEHQHRR TDNDSTASDT 420
PPATTAAQGPV KAENINTSKS ADSLDPATT SPONYSETAG NNNTHHDOTG EESAGSGKLG 480

```

-continued

---

LITNTIAGVA GLITGRRTR REAIVNAQPK CNPNLHYWTQ QDEGAAIGLA WIPYFGPAAE	540
GYYTEGLMHN QDGLICGLRQ LANETTQALQ LFLRATTELR TFSILNRKAI DFLLQRWGQT	600
CHILGPDCCI EPHDWTKNIT DKIDQIIHDF VDKTLPDQGD NDNWWTGWRQ WIPAGIGVTG	660
VIAVIALFC ICKFVF	676
 SEQ ID NO: 69	moltype = DNA length = 4991
FEATURE	Location/Qualifiers
misc_feature	1..4991
	note = plasmid pZEBOV-GUI, pGX4202
source	1..4991
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 69	
gtctgcttcgc gatgtacggg ccagatatac gcgttgcacat tgattattga ctgttatta	60
atagtaatca attacggggt cattaggta tagcccatat atggaggttcc gcgttacata	120
acttacggta aatggcccgc ctggctgacc gccccacgc ccccgcccat tgacgtcaat	180
aatgacgtat gtcccatag taacgccaat agggacttcc cattgacgtc aatgggtgga	240
gttattacgg taaaactgccc acctggcagt acatcaagtg tatctatgc caagtacgcc	300
ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatggccagt acatgacctt	360
atggactttt cttacttgcg agtacatcta cgttattgtc atcgcttata ccatggtgat	420
gccccgtttgg cagtagatca atggggcgtgg atagcgggtt gactcacggg gatttccaa	480
tcccccacccc attgacgtca atggggagt gttttggcac caaaatcaac gggactttcc	540
aaaatgtcgta aacaactccg ccccatgtac gcaaatggggc ggtaggcgtg tacgggtgg	600
ggcttatata agcagagctc tctggctaa tagagaacc cactgttact ggcttattcga	660
aattaatacgc actcactata gggagaccca agtggcttag egttttaact taagtttgt	720
accgagctcg gatccggccgc caccatgggg gtcacccggg ttctgcagct gccaagagat	780
agatctaaggc gcaaccttctt ttctctgtgg gtcatcatcc tgttttagag aaccctttct	840
atccccttggg agtggattca caatttcaaca ctgcaggta ggcgcgtcga taagcttgt	900
tgtcgacaca aactgagctc caccatcccg ctgcgcggcc tggggctgaa tctggaggga	960
aaaggagttgg caaccgtatg cccaaaggcga acaaagagat gggggctttag atccggagt	1020
cocccttaagg tggtaacta cggaggcggc gaatggggccg aagatgtcata taacctggaa	1080
atcaagaaac ctgcggatc agatgtctg cccggcgtctc ctgatggcat taggggattc	1140
ccaaagatgca gatacggtca caagggtcago ggcacaggac cctgtgttgc cgacttcgca	1200
tttcataaagg aaggagcttt ctttctgtac gatcgactgg caagcaccgt gatctatagg	1260
ggcaccacat tccggcgaggg agtgggtcgt tttctgttcc tggcccgaggc taagaaagac	1320
ttcttttctta gtcacccact gagggaaacc gtaacgcgcga cagaggaccc cagcggcgc	1380
tactatagatc ctaccatcatcg ataccaggcc actgggttgc gcaactaatga gaccgaat	1440
ctgttttggg gacatatgtc cagctggaga gccgggttccac tcctcagttt	1500
ctgtcgacgc tgaatgaaacg catctatgtc agcggaaagc gtcacaatac aactgggaag	1560
ctgattttggaa aagtgaacc accatcgatg cccaaatgggc ctttcgggag	1620
accaagaaaaa acctgacacgc caagatccgc tctggggaaac tgtagttcac cgccgtgcgc	1680
aatggggccaa aaaacatttc cggccagtc cctgcttaga ttccctctga cccagaaacc	1740
aataactatcca acggaggatc caagatcatg gttcccgaga acagttcagc aatgggtcag	1800
gtccacagtc agggcggaaa agcagccgtg teacatctgc caactctggc cacaatctt	1860
actagtcttc accaccatccac cacaagaca gggcccgacca attctaccca taacacac	1920
gtgtacaaac tggatatcgatcggccacc caggctggcc agcaccatag gagagccgac	1980
aatgtatgta ctgtcttcga cacccttcga gcaactatcc ctgcggccc actgaaggcc	2040
gaaaatatacaa acacttcggaa aagcggccgac tccctggatc tggttacaaat tacccccc	2100
cagaactatt ctggggccgc tgggaaaat aacactcacc atcaggacac cggggaggaa	2160
tctgcaagct cggggaaagct gggccctgatc accaataacaa ttgtgttgc ggcaggactg	2220
atcacaggag gacgacggacatcgaagagaa gtgattgtca acgctcggcc taaatgcata	2280
ccaaacatcgcc actactggac aactcaggac gagggaggac ctatcgatg ggcattggatt	2340
cctacttcg cgcctgcgcgc cgaaggaaatcattatggatcggatgtcataatcaggat	2400
ggactgtatc gtgggtgcgc gcaactatcc tggggatcggatcggatcggatcggatcggat	2460
ctggggccaa atccatcgatg ggcacatccatccatctgtca atagaaaggc cattgtactt	2520
ctgtcgacgc gatggggagg aacctcgatcgc tccctggggc caggactgtcgt tattggccc	2580
catgatgttgc caaaggaaatcatcactgtatcggatcggatcggatcggatcggatcggatcggat	2640
aagactctgc ctgtatcgatcggggatcggatcggatcggatcggatcggatcggatcggatcggat	2700
ccggcggggaa ttgggtgcgc cggccgtatcgttgc tgcgtctgtt ctgcattttgt	2760
aagtgcgttcttgcattatccatctgtca cggatgttgc gggcccggtt aaacccgtcg atcgcctcg	2820
actgtgcctt ctatgttgcgc gccatctgttgc gtttgccttcc cccctgtcc ttccctgtacc	2880
ctggaaatgttgc cactatccatccatctgtca tataaaaatgc agggaaatgtc atcgcattgt	2940
ctgatgtatcgttgc tctggggggatcggatcggatcggatcggatcggatcggatcggatcggat	3000
tggggaaatgcatacgatcggatcggatcggatcggatcggatcggatcggatcggatcggatcggat	3060
ttttatggac acgaacggaa cccggatgttgc ggttgccttgc atgggtggatcggatcggatcggat	3120
agccctgtcaaa atggatgttgc gatgttgcgc gatgttgcgc gatgttgcgc gatgttgcgc	3180
caagctctgc tcaagatgc gatgttgcgc gatgttgcgc gatgttgcgc gatgttgcgc	3240
acgcaggatcc tccggccgc tgggtggatcggatcggatcggatcggatcggatcggatcggatcggat	3300
caatcggtcgatc ctctgtatccatctgtca ggcgtgttgc gcaaggccgcgc cccgttctt	3360
ttgtcaagatc cggccgttgc ggttgccttgc atgggtggatcggatcggatcggatcggatcggat	3420
cgtggctgcgc caccacgggc gtttgcgtgc cggatgttgc gatgttgcgc gatgttgcgc	3480
gaaggggactg gctgttgcgc ggcgtgtgc cggggccggatcggatcggatcggatcggatcggat	3540
cttcctgcgcgaa gaaatgtatccatctgtca atcatggatcggatcggatcggatcggatcggat	3600
cggttacccatc cccatcgatcgc caccatcgatcgc gatgttgcgc gatgttgcgc gatgttgcgc	3660
tggaaatgcgc tcttgcgtatcgc cggatgttgc gatgttgcgc gatgttgcgc gatgttgcgc	3720
ccgaactgttgc cggccaggatccatctgtca aacatcgatcgc gatgttgcgc gatgttgcgc gatgttgcgc	3780

---

-continued

---

atggcgtgc	ctgcttgcg	aatatcatgg	tggaaaatgg	ccgttttct	ggattcatcg	3840
actgtggcg	gttgggtgt	gcggaccgt	atcaggacat	agcggttgt	acccgtgata	3900
ttgtcaaga	gttggcgcc	gaatgggtc	acgcttcct	cgtgtttac	ggtagtcgg	3960
ctccccattc	gaagcgcatc	gccttctatc	gccttctga	cgagtttctc	tgaattatta	4020
acgcttacaa	tttctgtat	cggtattttc	tccttacgca	tctgtgcgtt	atttcacacc	4080
gcatcagggt	gacttttgcg	ggggaaatgt	cgcgaaaccc	ctatgtttt	atttttctaa	4140
atacattcaa	atatgtatcc	gctcatgaga	caataaccct	gataaatgt	tcaataatag	4200
cacgtgttaa	aacttcattt	ttaataaaa	aggatctagg	tgaagatct	ttttgataat	4260
ctcatgacca	aaatccctta	acgtgagtt	tcgttccact	gagcgtcaga	ccccgtagaa	4320
aagatcaag	gtatcttgc	agatctttt	tttctgcgtc	taatctgcgt	cttgcacaca	4380
aaaacccac	cgcttacagg	gggtgttgc	ttggccggatc	aagagctacc	aactctttt	4440
cggaaaggtaa	ctgggttcag	cgagcgcag	ataccaaaa	ctgttcttct	agtgttagcc	4500
tagtttagcc	accactcaa	gaactctgt	gcaccgccta	cataccctgc	tctgttaatc	4560
ctgttaccag	ttggctgtgc	cagtgcgt	aagtcgtgtc	ttaccgggtt	ggactcaaga	4620
cgtatgttac	cggtatggc	cgagcgtc	ggctgaacgg	gggttgcgt	cacacggcc	4680
agcttggagc	gaacgaccta	cacccaaatc	agataacctc	agcgtgactt	atgagaagac	4740
gccacgttcc	ccgaaggggag	aaaggcggac	aggtatccgg	taagcggcag	ggtcggaaaca	4800
ggagagccca	cgaggaggt	tccaggggga	aacgcctgt	atcttata	tcctgtcggg	4860
tttcgcacc	tctgacttg	gctgtcgat	ttgtgtatgt	cgtcaggggg	ggcgagct	4920
tggaaaaacc	ccagcaacgc	ggcctttta	cggttcttg	ccttttgct	gccttttgct	4980
catatgttct	t					4991

SEQ ID NO: 70	moltype = DNA length = 2034					
FEATURE	Location/Qualifiers					
misc_feature	1..2034					
source	note = pEBOZ CON2 DNA Coding Sequence, pGX4203 1..2034					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 70						
atggggatta	ctgggattct	gcagctgccc	cgagatagg	tcaagegcac	ttcatttttc	60
ctgtgggtca	ttattctgtt	tcagagaacc	tttagcatcc	ccctgggagt	gattcacaat	120
taaacactgc	aggtgagcga	cgtcgataag	ctgtgtgt	gagacaaact	gagctccacc	180
aaccagctgc	gatccgtcgg	cctgaatctg	gagggaaacg	gggtggccac	agatgtccca	240
agtgtctacta	acgcgttgc	cttgcata	ggagtgcctt	ctaaagtgtt	caactacag	300
gcaggcgaat	ggggcggagaa	ttgtcttac	tcggaaatca	agaaacctga	cgccagcgg	360
tgtctggcc	cagctctgt	ttggatttgcg	ggattcccc	gatgcagata	tgtgcacaa	420
gtctctggca	caggacatttgc	tgctggcgac	ttcgatttc	ataaagaagg	agcattttt	480
ctgtacgtac	gtctggccag	caccatgtac	tatccggcc	ccacattcgc	agagggagt	540
gtcgcccttc	ttgtctgtcc	tcaggaaat	aaagacttct	tttctgtca	ccctctgcgc	600
gaaccagtgt	atgctacaga	ggaccccag	agggctact	atagactac	catccgatac	660
caggccactt	gttctggc	taatgagacc	gaataccctgt	ttgaagtgg	caaccgtact	720
atgtccacgc	ttggagacg	gttcacccc	caigttctgc	tgcaagtcgaa	cgaaaccatc	780
atgtccacgc	ttggagacg	caataact	ggaaagctgt	tttggaaatg	gaaccctgt	840
atcgacacca	caatttgg	atggcttt	ttggagacaa	agaaaacttc	tctggggaa	900
atccggctgt	aggaacttg	tttccatgt	gtggatgt	gggaaaaga	tatctcgaa	960
caagccggcc	cacgaaatcc	ctctgacc	aaacataca	ctaccacaga	ggatcacaag	1020
atcatgggtt	cagaaaaatag	ttcaatccat	gtgcagg	ttttttttt	ttttttttt	1080
gcgcgtggcc	atctgtatc	cctggccaca	atttgcattt	ccccacag	ccccactacc	1140
aaggcctggcc	aggacaattt	cacccataac	acaccgtgt	ataaaactgt	tatctctgaa	1200
gcacacccagg	tcggcggac	ccataggaa	actgacaat	tttccatgtc	atctgacacc	1260
ccaccagccaa	caactgtgc	aggacctca	aaaggccg	atataccac	ttctaaatgt	1320
gtgtacacgc	ttggacccgc	ttcccaact	actacttgc	gaccggccg	ttttttttt	1380
aacaataaca	cccacccatca	ggacacagg	gaagaaatgg	ctggatcagg	gaagctggc	1440
ctgtatccca	atacaatttgc	ttggatggca	ggactgtat	ctgggggg	acgaaccgc	1500
agggaaaggcc	ttgtgtac	ttggatggca	ttggatggca	ttggatggca	ttggatggca	1560
caggacgagg	gaggcgtat	ttggatccat	tttccatgtc	ttttttttt	ttttttttt	1620
ggaatctata	cagggggct	ttttttttt	ttttttttt	ttttttttt	ttttttttt	1680
ctggccaaacgc	aaactatccca	ttttttttt	ttttttttt	ttttttttt	ttttttttt	1740
accttttcc	ttctgtatcg	ttttttttt	ttttttttt	ttttttttt	ttttttttt	1800
tgccatcc	ttggggcc	ttttttttt	ttttttttt	ttttttttt	ttttttttt	1860
gacaaaattt	atcagatcat	ttttttttt	ttttttttt	ttttttttt	ttttttttt	1920
aatgataact	ttggggcc	ttttttttt	ttttttttt	ttttttttt	ttttttttt	1980
gtcatcatttgc	ttgtgtatcg	ttttttttt	ttttttttt	ttttttttt	ttttttttt	2034

SEQ ID NO: 71	moltype = DNA length = 4991					
FEATURE	Location/Qualifiers					
misc_feature	1..4991					
source	note = plasmid pEBOZ CON2, pGX4203 1..4991					
	mol_type = other DNA					
	organism = synthetic construct					
SEQUENCE: 71						
gtgtcttcgc	gatgtacgg	ccagatatac	cggttgacat	tgattatgt	ctgttatta	60
atagtaatca	attacgggtt	cattagttca	tagccat	atggagtcc	gcgttacata	120
acttacggta	aatggccgc	ctggctgacc	ccccaaacgc	cccccccat	tgacgtcaat	180

-continued

aatgacgtat	gttcccatag	taacgcata	agggactt	cattgacgtc	aatgggtgga	240
gtattttacgg	taaaactgccc	acttggcagt	acatcaactg	tatcatatgc	caagtacgccc	300
cccttattgg	gtcaatacg	gtaaaatggcc	cgccgtgc	tatgcggc	atcatgc	360
atggggactt	cctacttgcc	agatacatca	cgtttagtc	atgcattt	ccatgggtat	420
gcccctttgg	cagtacatca	atggggotgg	atagcgtt	gactcacggg	gattccaag	480
tctccacccc	attgacgtca	atggggagtt	gttttggcac	caaatacAAC	gggactttcc	540
aaaatgtcgc	aacaactc	ccccatggac	gcaaaatgggg	ggtaggcgt	tacgggtgg	600
ggctataata	agcagagc	tctggataca	tagagaacc	actgttact	ggcttatcga	660
aattaatacg	actcaacta	ggggacacca	agctggct	cgtttaact	taacttgg	720
accgagctcg	gatccggcc	caccatgggg	attactgg	tttgcagct	gccccagat	780
agggttcaagc	gcaactt	cattttgtgg	gtcattatt	tggttcag	aaactttagc	840
atccccctgg	gagtgattc	caatcaaca	ctgcaggta	cgacgtcg	taatgtgg	900
ttgttagagaca	aactgtgc	caccaaccc	ctgcgcate	tgcgtcg	tctgggggg	960
aacgggggtg	ccacagat	ccccatgtct	actaagcgt	ggggctt	atcaggagt	1020
cccccttaaa	tggtcaacta	cgaggccgg	gaatggcc	agaatgtca	taacttggaa	1080
atcaagaaaa	ctgacggc	cgatgttgc	ccacagtc	ctgtatggat	tcggggatt	1140
ccccatgtca	gatatgtca	caagggtct	ggcacaggac	cttgcgttgc	cgatctcg	1200
tttcataaag	aaggagcatt	cttttgtc	gatecggttgc	ccagcacccgt	gatctatcg	1260
ggcaccacat	tcgcagagg	agtgttgc	tttgcattt	tgccctcg	aaagaaagac	1320
tttcttttca	gtcacccct	cgcgacca	gtgaatgtca	cagagaccc	cagcagccg	1380
tactatagta	cttacatcc	ataccaggc	actgggttc	gactatgt	gaccgaaatc	1440
ctgtttaag	tggtacaact	gactttagt	cagctggaga	gcagggttac	ccccca	1500
ctgctgcagc	tgaacgaa	catctatgc	agcgaaaga	gatccaaatac	aacttggaa	1560
ctgatgttgc	aagtgtaccc	tgagatcg	accacaaat	gagaatgggg	ttttgggg	1620
acaaagaaaa	cttctctgg	gagatccgg	tctgaggaa	tgatgttac	agctgtgt	1680
acagggggca	agatgtatc	aggagacag	ccagacgg	ccttcctcg	ccccaaaca	1740
tacactatcca	cagaggatca	caagatcat	gttcagaaa	atagttcaac	catggtgc	1800
gtccacaacc	agggacgaga	ggcagcgt	agccatctg	tcaccc	ccccggc	1860
acttccccca	agagccccac	taccaagg	ggcaggaca	attccaccc	taacacac	1920
ttgtataaac	tggatatc	tgagocaca	caggctcg	acgcattag	gagaatgtac	1980
aatgattcca	ctgcatctg	cacccacca	gcaacaact	ctgcaggacc	tccaaaggcc	2040
gagaatatca	acacttctaa	aagtgtgc	agctggacc	ccgcacacc	aacttcccc	2100
cagaactact	ctgacggc	cggaaacaa	aaacccacc	atcaggacac	aggggaagaa	2160
atgtgttgc	caggaaatgt	cgccgtc	accaataca	tttgcgttgc	ggcaggact	2220
atcaacttgc	actactgg	gacgacgaa	ccgaggaa	gcatttgt	acgcttgc	2280
ccataacttc	ccatccgg	cacacaggac	gaggaggc	ctatccgt	ggcatggatt	2340
ccatcttc	ccccccgc	cgaaggaa	tatacagg	ggctgtatgc	taatcaggat	2400
ggactgtt	gtgggtgc	gcacgtgc	aaacaaata	ccccatgt	gcacgttgc	2460
ctggggct	caactcgat	gagaac	ttccatctcg	atcggaaagg	atttgc	2520
ctgctgcaga	gatggggagg	aacatgc	atcttgg	cagactgt	tatttgcct	2580
catgttgc	caaagaaat	cattgtc	attgttgc	tcattc	catttgc	2640
aaagacttgc	cagatcagg	ggcaatgt	aactgttgc	ccggctgg	acatgttgc	2700
cccgccggca	tttgggtgc	cggcgtc	attgcgttgc	tcgcgttgc	ctgcatttgc	2760
aagtgcgt	tttgcataact	cgagtct	gggccc	tttgcgttgc	aaacc	2820
actgtgtt	ctagttgc	gccatcttgc	tttgcgttgc	ccccccgt	tttgcgttgc	2880
ctggaaatgt	ccatcc	tgcatttgc	taataaaat	aggaaatgt	atcgcatttgc	2940
ctgatgttgc	gtcattatc	tgttgc	gggggttgc	ggggatgg	ggggatggat	3000
ttggaaagaca	atagcagg	tgctgggg	gcccgttgc	ctatggctt	tacttgggg	3060
ttttatggac	agcaagc	ccggaaat	cgatgttgc	ggccct	tttgcgttgc	3120
agccccctgc	agtaaaatgt	atgttgc	tcgcgc	atgcgtatgc	ggcagggg	3180
caagctgtca	tcaagagaca	ggatggat	cgatgttgc	atgcgtatgc	ggatggat	3240
acgcagggtt	tccggccgt	ttgggtgg	ggctatt	ctatgtact	gcacaaacaga	3300
caatcggtc	ctctgtat	ggccgtt	ggctgtc	gcacggcgc	ccgggttctt	3360
tttgcacca	cgacgttgc	gggtt	ggctgtc	gcacggcgc	ccgggttctt	3420
cgtggctgc	cacgcacgg	gttcc	cgatgttgc	ggccct	tttgcgttgc	3480
aaaggggact	gtctgttgc	gggttgc	cgatgttgc	gcacgttgc	actgaagcgg	3540
ctccctgcga	gaaagtatc	atcatgttgc	atcggacat	agctgttgc	accctgtat	3600
cggctactt	ccatcc	caccaacgg	aaacatcgat	cgacgttgc	atcgttgc	3660
tggaaacgg	tcttgc	cattgt	tggttgc	ggatgggt	ttttgtat	3720
ccgaacttgc	cgccatgt	ggatgttgc	tggttgc	ggatgggt	ttttgtat	3780
atggcgtatc	ctgttgc	aatatcat	ttggaaaat	ccgtt	ttttgtat	3840
actgtgttgc	ctgggttgc	ggcgttgc	atcggacat	agctgttgc	accctgtat	3900
ttgtgttgc	gttgcgttgc	gaatgggt	accgttct	ctgttgc	ttttgtat	3960
ctcccgatc	cgacgtatc	ggctt	ggctt	ggatgggt	ttttgtat	4020
acgcttacaa	tttgcgtat	cggtt	ggctt	ggatgggt	ttttgtat	4080
geatcgtat	cgatgttgc	tattt	tcctt	ggatgggt	ttttgtat	4140
atacattca	atatgtatcc	gtctat	ggatggat	gtataatgt	ttttgtat	4200
cacgtgtat	aacttccat	ttaattt	aaatggat	ttttgtat	ttttgtat	4260
ctcatgacca	aaatcc	actgttgc	ttgttcc	actgacgt	ccccatggaa	4320
aaagatcaag	gatcttgc	tttgc	tttgc	tttgc	tttgc	4380
aaaaaaacc	cgatcacc	gggttgc	tttgc	tttgc	tttgc	4440
ccgaaggat	ctggcttgc	cattgt	tttgc	tttgc	tttgc	4500
tagttaggc	accatcc	gaaatgt	tttgc	tttgc	tttgc	4560
ctgttacc	tggctgc	cattgt	tttgc	tttgc	tttgc	4620
cgatgttac	cgatgttgc	tttgc	tttgc	tttgc	tttgc	4680
agcttggac	gaacgac	cattgt	tttgc	tttgc	tttgc	4740

-continued

gcccacgttc ccgaaggggag aaagggggac aggtatccgg taagccgcg ggtcgaaaca 4800  
 ggagagcgcg cggggagact tccaggggg aacgccttgg atctttatag tcctgtcggg 4860  
 tttcgcacc tctgacttga gctgtatgtc cgtcaggggg gcgagcccta 4920  
 tggaaaaaac cgacaaacgc ggcctttta cggttctgg cctttgtc gccttttgct 4980  
 cacatgttct t 4991

**SEQ ID NO: 72** moltype = DNA length = 2036  
**FEATURE** Location/Qualifiers  
**misc\_feature**  
**source** 1..2036  
**note** = pZEOBOV-GUI DNA Coding Sequence, pGX4202  
**mol\_type** = other DNA  
**organism** = synthetic construct

**SEQUENCE: 72**  
 atgggggtca cgggattct gcagctgcc agagatagat tcaagcgcac ctcttttc 60  
 ctgggggtca tcatcttgg tcaagagata ttcttatcc ccctggggat gattcaaat 120  
 tcaacatgcg aggtgagcga cgtcgatag ctgggtgtc ggcacaaact gagtccacc 180  
 aaccagtcg gaagcgctgg gctgaatctg gaggaaacg gagtggcaac cgatgtccca 240  
 agcgcaacaa agagatggg cttagatcc ggagtggcccc ctaaaatggt caatacagag 300  
 gcggcgaat gggccggaaa ttgtcttaac ctggaaatca agaaaacctga cggatcagag 360  
 tgctgtccgg cggctcttga tggcatttgg ggatcccaa gtatcgatata cgtgcacaa 420  
 gtcaagcggca caggaccctg tgctggcgc ttcgcatttc ataaaagg agtttctt 480  
 ctgtacgatc gactggcaag caccgtgtc tataggggca ccacattcgc cgaggggagt 540  
 gtgcgtttt tgatcttgc ccaggctaaq aaagactt tttctagtca cccactgagg 600  
 gaacccgtga acggccacaga ggaccccgac agccgtact atagtaact catcagata 660  
 caggccactg ggttcggcac taatgagac gataacctgt ttgaatgttca caacccgtaca 720  
 tatgtccagc tggagggccg gttcacttctc cagtttctgc tgcaatgttca tggaaaccatc 780  
 tatgtcaatcg gaaaggcgtc caataactt gggaaactgtt tttggaaatg gaaaccaggag 840  
 atcgataccatca caattggcga atggccctt cgggagatca agaaaaacactt gacacgcga 900  
 atccgatctt aggaacttgcg tttcaccggc gtggaaatgg ccggccaaaaa cattttccggc 960  
 cagtcctctg cttaggactc ctctgaccca gaaaccataa ctaccaacgcg ggatcacaag 1020  
 atatggctt cggagaaacg ttcagaaatg gtgcagggtc acatcgaggc cagaaaaacgca 1080  
 gccgtgtcata atctgacaaatc ttggccaca atcttacta gtcctcgc accaccacca 1140  
 aagacggggc cggacaaatc taccatatac acacccgtgt cacaatgttca tttatgttgc 1200  
 gccacccaggc tggccagca ccataggaga ggcgacaaatg atagtaacttgc ttcaagacacc 1260  
 cttccagcaat ctaccgttc aggccccactt aaggccggaa atacaaacacttccaaaaaaacg 1320  
 gccggccatc tggatcttgc tacaactat tccccccaga actatctgttca gaccgttgc 1380  
 aacaataaca ctaccatca ggacccccc gggaaatctg caatgtccgg gaaatgtggc 1440  
 ctgtatccca atacaatttc tggatgttgc ggactgtatca caggaggacg acgaaacttgc 1500  
 agagaatgtt ttgtcaatgc tcagctttaa tgcaatccaa acctgttcaatctggacaaact 1560  
 cggacggggc gggcgtatcg tggatgttgc tggatgttgc acttctggcc tggccggaa 1620  
 ggaatcttca ttgggggtt gatgtatcaat caggatggc tgatgttgc tggccggac 1680  
 ctggccaaacg aaaccacaca gggccctgcg ctgttcttc gggcaactac cgagctgcgc 1740  
 acattttccca ttctgtatcg aaaggccatt gacttcttc tggccggatc gggagggaaacc 1800  
 tggccacatcc tggggccaga ctgtgttattt gggcccccattt attggacaaa gaaatcatct 1860  
 gacaaaaattt atcagatcat tcacgactt gttgttcaaga ctctgccttgc tcaggggggac 1920  
 aatgataact ggtggacccg atggcgcac gttgttcccg caggttattgg ggtgacccggc 1980  
 gtcatcatgg cgggtatgc tctgttctgc atttgttactt tcgttttttataact 2036

**SEQ ID NO: 73** moltype = AA length = 25  
**FEATURE** Location/Qualifiers  
**REGION** 1..25  
**source** note = Chemically synthesized  
**1..25**  
**mol\_type** = protein  
**organism** = synthetic construct

**SEQUENCE: 73**  
 ETIYTSGKRS NTTGKLIWKV NPEID 25

**SEQ ID NO: 74** moltype = AA length = 25  
**FEATURE** Location/Qualifiers  
**REGION** 1..25  
**source** note = Chemically synthesized  
**1..25**  
**mol\_type** = protein  
**organism** = synthetic construct

**SEQUENCE: 74**  
 ETIYASGKRS NTTGKLIWKV NPEID

**1.-28. (canceled)**

29. An isolated nucleic acid molecule comprising a nucleic acid encoding a ZEBOV Guinea 2014 Outbreak envelope glycoprotein immunogen (ZEBOVGUI), wherein the ZEBOVGUI comprises an amino acid sequence that is at

least 95% identical to SEQ ID NO:67, or a fragment of an amino acid sequence that is at least 95% identical to SEQ ID NO:67.

**30.** The isolated nucleic acid molecule of claim 29, wherein the ZEBOVGUI comprises an amino acid sequence

that is at least 99% identical to SEQ ID NO: 67, or a fragment of an amino acid sequence that is at least 99% identical to SEQ ID NO: 67.

**31.** The isolated nucleic acid molecule of claim **29**, wherein the ZEBOVGUI is linked to an IgE signal peptide.

**32.** The isolated nucleic acid molecule of claim **29**, wherein the nucleic acid encoding ZEBOVGUI comprises a nucleic acid sequence at least 95% homologous SEQ ID NO:72, or a fragment thereof.

**33.** The isolated nucleic acid molecule of claim **29**, wherein the nucleic acid molecule is a plasmid.

**34.** The isolated nucleic acid molecule of claim **29**, formulated for delivery to an individual using electroporation.

**35.** A composition comprising a nucleic acid molecule of claim **29**.

**36.** The composition of claim **35**, wherein the fragment of an amino acid sequence that is at least 95% homologous to SEQ ID NO:67 comprises at least 600 amino acids, at least 630 amino acids, or at least 660 amino acids.

**37.** The composition of claim **35**, wherein the ZEBOVGUI is linked to an IgE signal peptide.

**38.** The composition of claim **35**, wherein the nucleic acid encoding ZEBOVGUI comprises a nucleic acid sequence at least 95% homologous SEQ ID NO:72, or a fragment thereof.

**39.** The composition of claim **35**, wherein the nucleic acid molecule is a plasmid.

**40.** The composition of claim **35**, formulated for delivery to an individual using electroporation.

**41.** The composition of claim **35** further comprising nucleic acid sequences that encode one or more proteins selected from the group consisting of: IL-12, IL-15 and IL-28.

**42.** A method of inducing an immune response against a filovirus comprising administering the nucleic acid molecule of claim **29** to an individual in an amount effective to induce an immune response in said individual.

**43.** The method of claim **42**, wherein the method induces an immune response against an Ebolavirus.

**44.** A method of inducing an immune response against a filovirus comprising administering the composition of claim **35** to an individual in an amount effective to induce an immune response in said individual.

**45.** The method of claim **44**, wherein the method induces an immune response against an Ebolavirus.

**46.** A method of treating an individual who has been diagnosed with Ebolavirus comprising administering a therapeutically effective amount of the nucleic acid molecule of claim **29** to an individual.

**47.** A method of treating an individual who has been diagnosed with Ebolavirus, the method comprising administering a therapeutically effective amount of the composition of claim **35** to an individual.

\* \* \* \* \*